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Thesis abstract  
Severe gastrointestinal (GI) toxicity symptoms such as diarrhoea, mucositis, nausea and vomiting 
are adverse side effects following 5-fluorouracil (5-FU)-based therapy. Current supportive care 
measures for the treatment of severe GI toxicity are limited, with many patients requiring treatment 
intervention or hospitalisation to help manage and relieve symptoms. The presence of severe GI 
toxicity not only compromises patient clinical outcomes but, is also a financial burden on the health 
care system. Most importantly, the presence of severe GI toxicity symptoms decreases a patients’ 
quality of life whilst receiving 5-FU-based therapy.  
A predictive marker for severe GI toxicity risk is urgently required to identify patients at most risk of 
developing severe GI toxicity prior to receiving 5-FU-based therapy. This would not only allow at 
risk patients to be closely monitored whilst receiving 5-FU-based therapy but, improve resource 
utilisation and patient education, reducing the severity of GI toxicity experienced by at risk patients. 
Current predictive markers for severe GI toxicity, such as single nucleotide polymorphisms (SNPs) 
in 5-FU drug biotransformation genes, lack clinical utility, sensitivity and specificity.  
As such, the gap in the knowledge is a new predictive marker(s) for severe GI toxicity risk needs 
to be identified. A clinical pilot study conducted in my laboratory highlighted the potential of the 
Toll-like Receptor/Interleukin-1 (TIR) domain innate immune signalling pathway to be predictive for 
severe GI toxicity risk. The TIR domain pathway is one of the key mediating pathways in the 
development of GI toxicity and consists of membrane bound Toll-like Receptors (TLRs), adapter 
proteins, transcription factors and proinflammatory cytokines such as interleukin 1 beta (IL-1β) and 
tumour necrosis factor alpha (TNF-⍺).  
Based on the results of the pilot study, I firstly investigated the association of 21 SNPs within the 





received 5-FU-based therapy. Secondly, in a subset of 34 participants, I also examined TLR2- and 
TLR4-stimulated IL-1β and TNF-⍺ secretion from isolated peripheral blood mononuclear cells to 
determine a phenotypic marker for severe GI toxicity risk. Both these studies were retrospective. 
Lastly, I considered whether administration of 5-FU could induce DNA methylation within the TIR 
domain innate immune signalling pathway in vitro, to identify a potential epigenetic predictive 
marker for severe GI toxicity risk.  
The results of my thesis point to no concordant genetic, phenotypic or epigenetic predictive marker 
for severe GI toxicity risk within the TIR domain innate immune signalling pathway. However, 
observations made throughout my thesis highlight the importance of using risk prediction modelling 
to encompass all potential predictive factors, such as demographic, clinical, genetic, phenotypic 
and epigenetic, to create a truly personalised risk prediction strategy for patients receiving 










5-FU-based therapy refers to chemotherapy regimens where 5-FU or capecitabine were 
administered as the principal chemotherapeutic agent.  
GI toxicity  
Throughout my thesis, GI toxicity is defined as symptoms diarrhoea, oral mucositis, nausea and 
vomiting.  
Mild to moderate GI toxicity  
Mild to moderate GI toxicity is classified as symptoms graded 1 or 2 on the National Cancer’s 
Institute’s Common Terminology for Adverse Events (NCI CTCAE v4.03 and 5.0).  
NCI CTCAE 
The National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI CTCAE) 
was the grading criteria used by clinical oncology staff to grade GI toxicity symptoms in participants. 
The NCI CTCAE was updated from version 4.03 to version 5.0 throughout my PhD and both 
versions will be referred to accordingly.  
Non-toxic participants  
Participants recruited to the study cohort who developed no or mild to moderate GI toxicity were 
categorised as non-toxic to 5-FU. 
Predictive marker  






Severe GI toxicity  
Severe GI toxicity is classified as GI toxicity symptoms graded ≥ 3 on the NCI CTCAE v4.03 and 
5.0. Additionally, GI toxicity symptoms that led to a dose reduction, treatment interruption, 
hospitalisation or early treatment cessation were also classified as severe.  
Toxic participants  
Participants recruited to the study cohort who developed severe GI toxicity were categorised as 
toxic to 5-FU.  
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Chapter 1: Thesis introduction  
Chapter 1 is an introductory chapter and sets the premise of my thesis.  
1.1 5-FU-based therapies induce GI toxicity  
5-fluorouracil (5-FU) and its prodrug, capecitabine, are staple chemotherapy agents used for the 
treatment of cancers of the breast, colon and upper gastrointestinal (GI) tract [1]. They are 
associated with improved overall survival and prognosis however, induce a range of ‘off target’ and 
dose-limiting adverse effects offsetting these benefits [1, 2]. These adverse effects are due to the 
non-selective nature of these chemotherapy agents targeting highly proliferative cells throughout 
the body [2]. One of the key dose-limiting adverse effects of 5-FU-based therapy is GI toxicity, 
which occurs in 20 – 50 % of patients [3]. Throughout the GI tract, 5-FU initiates DNA and non-DNA 
injury and death in cells of the basal epithelium and cells of the underlying tissue [1, 2]. This 
damage leads to the manifestation of GI toxicity symptoms including, but not limited to, mucositis, 
diarrhoea, nausea and vomiting [4]. Anti-metabolites such as 5-FU cause a higher degree of GI 
toxicity than other classes of chemotherapy agents such as taxanes or platinum-based [5]. The 
presence of GI toxicities at any grade throughout therapy are costly and may lead to sub-optimal 
therapy outcomes and decreased patient quality of life [6, 7]. Supportive care measures are 
recommended for the management of GI toxicity although, to date, these can only attempt to 
control symptoms and do not target the underlying pathology [8, 9]. 
1.2 Who is at risk of GI toxicity?  
Not all patients are at equal risk of GI toxicity. Some patients will develop mild to moderate GI 
toxicity, graded as 1 or 2 on the National Cancer’s Institute’s Common Terminology for Adverse 
Events (NCI CTCAE v 4.03 and v 5.0) [10]. However, a proportion of patients will develop severe 
GI toxicity, graded as  3 on the NCI CTCAE, in which supportive care is inadequate at controlling 
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symptoms [2, 10]. Patients with severe GI toxicity will need treatment delays, dose reductions, 
early treatment cessation and/or hospitalisation to help manage and relieve symptoms [2, 10]. Due 
to the extreme interventions required to manage severe GI toxicity, which can compromise patient 
therapy outcomes and quality of life, is a major concern for patients receiving 5-FU-based therapy. 
It is unclear which factors determine the development of GI toxicity and why some patients are 
more susceptible to tissue injury and severe GI toxicity than others. Consequently, there is currently 
no way to identify patients at most risk of developing severe GI toxicity prior to receiving 
5-FU-based therapy. A predictive maker would allow these ‘at risk’ patients to be identified prior to 
receiving 5-FU-based therapy. In turn, this may lead to improved resource utilisation, reducing the 
severity of GI toxicity experienced by ‘at risk’ patients and possibly minimising dose-limiting 
adverse effects.  
1.3 Current predictive markers for severe GI toxicity risk lack clinical sensitivity and 
specificity  
There are many controversies in the literature surrounding the identification of predictive markers 
for severe GI toxicity risk following 5-FU-based therapy. Research has identified traditionally-used 
risk prediction variables such as sex, age and 5-FU dosage to be unreliable, with many 
contradictory and inconsistent findings surrounding their use as predictive markers [11-15]. 
Candidate gene approaches, with specific interest in single nucleotide polymorphisms (SNPs) in 
the 5-FU rate determining enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the gene 
DPYD), have been more successful in identifying consistent and reliable predictive risk markers 
for severe GI toxicity risk [14, 16-18]. However, these too have their own limitations, as the DPYD 
SNPs identified as predictive for severe GI toxicity risk following 5-FU-based therapy cannot 
account for majority of incidences due to their low minor allele frequencies, particularly amongst 
the Caucasian population (< 5 %) [16, 18]. The use of genome-wide association studies (GWAS) 
is also divisive. As GWAS analyses a genome-wide set of SNPs, the relationship between severe 
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GI toxicity and SNPs is broader and less restrictive, with many SNPs identified as predictive for 
severe GI toxicity risk found in genes with no previous underlying relationship with the development 
of GI toxicity [19, 20]. As such, a new approach is required to identify predictive markers for severe 
GI toxicity risk following 5-FU-based therapy that are not only reliable and predictive but, are also 
clinically sensitive and specific.  
1.4 Potential predictors for severe GI toxicity risk may lie within the TIR domain innate 
immune signalling pathway  
One of the key signalling pathways implicated in the development of severe GI toxicity is the 
Toll-Like Receptor/Interleukin-1 (TIR) domain innate immune signalling pathway. Therefore, 
predictive makers for severe GI toxicity risk may lie within this pathway. The TIR domain signalling 
pathway consists of membrane-bound Toll-like Receptors (TLRs), adapter proteins and 
transcription factors. Activation of the TIR pathway mediates the secretion of proinflammatory 
cytokines such as tumour necrosis factor alpha (TNF-) and interleukin 1 beta (IL-1) [21, 22]. 
Both preclinical and clinical studies of mucosal injury have identified an increase in tissue and 
circulating proinflammatory cytokine levels following 5-FU administration [5, 23, 24]. These levels 
correlated with cell injury, cell death and GI toxicity severity in Dark Agouti (DA) rats [5, 23]. 
Increased proinflammatory cytokine levels were also associated with the severity of GI toxicity 
experienced in patients receiving 5-FU-based therapies [24].  
With preclinical and clinical studies highlighting the importance of the TIR domain innate immune 
signalling pathway in the development of severe GI toxicity, a small pilot study was conducted in 
my laboratory [25]. In 34 patients whom received 5-FU-based therapy, a general linear model of 
multivariate logistic regression created a risk prediction model which identified TLR2 rs384100 and 
TNF rs1800629 SNPs in conjunction with colorectal and upper GI cancer types as predictive of 
severe GI toxicity risk [25]. Importantly, TLR2 and TNF are key genes within the TIR domain 
signalling pathway.  
Chapter 1 
 4 
1.5 Thesis Rationale  
The risk prediction model produced in the pilot study [25] was one of the first risk prediction models 
to use a signalling pathway-directed approach to identify predictive markers for severe GI toxicity 
risk. It not only highlighted the potential of the TIR domain innate immune signalling pathway to be 
predictive for severe GI toxicity risk but, it also highlighted using multivariate logistic regression to 
build risk prediction models may be a desirable approach to accurately identify patients at most 
risk of severe GI toxicity. As the development of GI toxicity is multifaceted, multivariate logistic 
regression enables the simultaneously analysis of participant demographics, clinical data and 
SNPs of interest to produce a more accurate, sensitive and specific risk prediction model for severe 
GI toxicity. This approach was advantageous over candidate gene approach and GWAS, which 
focus on genetics alone and allows additional potential predictors, such as phenotypic markers and 
epigenetic modifications, to also be included in risk prediction modelling.  
The gap in the knowledge is there were no clinically sensitive and specific predictive markers to 
accurately identify patients at most risk of developing severe GI toxicity prior to receiving 
5-FU-based therapy. To address this gap, my thesis not only endeavoured to validate the results 
of the pilot study in a new, larger and independent cohort of participants but, also investigate 
potential phenotypic markers and epigenetic modifications within the TIR domain innate immune 
signalling pathway that may also be predictive for severe GI toxicity.  
1.6 Thesis Hypotheses and Aims  
Each research chapter is independent and was not reliant on the results of another therefore, each 
research chapter has its own hypotheses and aims. A timeline of study completion is provided in 




1.6.1 Chapter 3 
Hypotheses  
1. A general linear model of multivariate logistic regression would generate a risk prediction 
model with similar sensitivity and specificity to the pilot study risk prediction model, 
identifying TLR2 rs384100 and TNF rs1800629 SNPs in conjunction with colorectal and 
upper GI cancer types to be predictive for severe GI toxicity risk.  
Aims 
1. To identify which participant demographic and clinical data (5-FU-based regimen, cancer 
type, sex, age and number of treatment cycles) were significantly associated with severe 
GI toxicity using logistic regression. 
2. To identify which SNPs in TIR domain pathway genes TLR2, TLR4, IL1B, IL6, IL6R, IL10, 
TGFB, TNF, MYD88, CASP1 and CASP5, as well as OPRM1 and CRP, were significantly 
associated with severe GI toxicity using logistic regression.  
3. To determine the combined impact of clinical and genetic factors on severe GI toxicity risk 
using models of multivariate logistic regression.  
Chapter 3 is my first research chapter and details the main clinical study of my thesis, the Salivary 
Predictors in Treatment Validation (SPiT-V) study. The SPiT-V study was formed on the basis of 
the pilot study [25]. I recruited a new, larger and independent cohort of participants who had 
received 5-FU-based therapy and built multiple risk prediction models for severe GI toxicity 
incorporating participant demographics, clinical data and SNPs within TIR domain innate immune 




1.6.2 Chapter 4 
Hypotheses  
1. Participants who reported severe GI toxicity throughout their 5-FU-based therapy would 
secrete decreased IL-1β and TNF-⍺ pre- and post-stimulation with TLR2 and TLR4 
agonists compared to participants who reported no or mild to moderate GI toxicity.  
2. Any differences in IL-1β and TNF-⍺ secretion identified between the two participant groups 
would be associated with SNPs within TLR2, TLR4, IL1B, TNF, CASP1 and/or CASP5 
genes.  
Aims  
1. To determine pre-stimulation IL-1β and TNF-⍺ secretion in participants classified as 
non-toxic (participants who reported no or mild to moderate GI toxicity) and toxic 
(participants who reported severe GI toxicity) throughout their 5-FU-based therapy.  
2. To determine if TLR2- and TLR4-stimulated IL-1β and TNF-⍺ secretion was significantly 
different between participants classified as non-toxic and toxic throughout their 
5-FU-based therapy.  
3. To identify if any significant differences in post-stimulation IL-1β and TNF-⍺ secretion 
between the two participant groups were associated with TLR2, TLR4, IL1B, TNF, CASP1 
and/or CASP5 genotypes.  
Chapter 4 was an extension of the SPiT-V study. In a subset of participants recruited from the 
SPiT-V participant cohort, I investigated the association between pre- and post-stimulated IL-1 
and TNF- secretion, GI toxicity and SNPs within the TIR domain innate immune signalling 
pathway post-5-FU-based therapy.  
Chapter 1 
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1.6.3 Chapter 5 
Hypothesis  
1. 5-FU reduces mRNA expression of DNA methyltransferase (DNMT)1 and DNMT3A 
therefore, inhibits DNA methylation at CpG sites -244, -238, -169, -163, -161, -149, -119, 
-72, -49 and -38 upstream of the TNF transcription start site in U937 cells in vitro.  
Aims  
1. To optimise 5-FU and 5-Aza-2’-deoxycytidine (5-Aza-dc) concentration in the U937 cell 
line to determine a treatment dose that would not only induce cell injury and death but, 
result in a viable cell count that would allow adequate DNA and RNA extraction.  
2. To determine changes in mRNA expression of TNF, DNMT1 and DNMT3A following 
treatment with 5-FU and/or methylation inhibitor 5-Aza-dc in U937 cells in vitro using 
real-time polymerase chain reaction (RT-PCR). 
3. To determine changes in DNA methylation across CpG sites -244, -238, -169, -163, -161, 
-149, -119, -72, -49 and -38 upstream of the TNF transcription start site following treatment 
with 5-FU and/or methylation inhibitor 5-Aza-dc in U937 cells in vitro using methylation 
specific high-resolution melt (MS-HRM). 
Chapter 5 was my final research chapter and investigated the novel idea that 5-FU reduces DNA 
methylation within the TNF gene and therefore, increases expression of TNF in vitro. As such, 
increased expression of TNF could potentially increase TNF-⍺ secretion and be predictive for 
severe GI toxicity risk. As this study used experimental techniques not previously established in 




Figure 1.1 Timeline of research completion. Blue indicates participant recruitment, orange 
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Chapter 2: Toll-like receptor/Interleukin-1 domain innate immune 
signalling pathway genetic variants are candidate predictors for 
severe gastrointestinal toxicity risk  
Chapter two is my literature review and aims to provide an in-depth summary of 5-FU-based 
therapy and detailed overview of the pathophysiology and clinical management of GI toxicity. The 
review also discusses previous literature on the influence and function of SNPs within the TIR 
domain innate immune signalling pathway. This chapter was published in Cancer Chemotherapy 
and Pharmacology. Korver SK, Gibson RJ, Bowen JM and Coller JK (2019) Toll-like 
receptor/Interleukin-1 domain innate immune signalling pathway genetic variants are candidate 
predictors for severe gastrointestinal toxicity risk. Cancer Chemother Pharmacol 83: 217 - 236. 
This chapter is presented in its original publication format. The referencing style and spelling have 
been modified to maintain consistency throughout this thesis.  
2.1 Abstract 
Purpose: Severe gastrointestinal (GI) toxicity is a common adverse effect following 5-fluorouracil 
(5-FU)-based therapy. The presence of severe GI toxicity leads to treatment revisions, sub-optimal 
therapy outcomes, and decreases to patients’ quality of life. There are no adequate predictors for 
5-FU-induced severe GI toxicity risk. The Toll-like Receptor/Interleukin-1 (TIR) domain innate 
immune signalling pathway is known to be a mediating pathway in the development of GI toxicity. 
Hence, genetic variability in this signalling pathway may alter the pathophysiology of GI toxicity and 
therefore, be predictive of risk. However, little research has investigated the effects of TIR domain 
innate immune signalling pathway single nucleotide polymorphism (SNPs) on the risk and 




Methods: This critical review surveyed the literature and reported on the in vitro, ex vivo and in vivo 
effects, as well as the genetic association, of selected TIR domain innate immune signalling 
pathway SNPs on disease susceptibility and gene functioning.  
Results: Of the TIR domain innate immune signalling pathway SNPs reviewed, evidence suggests 
interleukin-1 beta (IL1B) and tumour necrosis factor alpha (TNF) SNPs have the greatest potential 
as predictors for severe GI toxicity risk. These results warrant further research into the effect of 
IL1B and TNF SNPs on the risk and development of severe GI toxicity.  
Conclusions: SNPs of the TIR domain innate immune signalling pathway have profound effects on 
disease susceptibility and gene functioning, making them candidate predictors for severe GI toxicity 
risk. The identification of a predictor for 5-FU-induced severe GI toxicity will allow the 




2.2 List of commonly used abbreviations 
5-FU 5-fluorouracil 
DAMPs Damage associated molecular patterns 
DPD Dihydropyrimidine dehydrogenase enzyme  
DPYD Dihydropyrimidine dehydrogenase gene 
GI Gastrointestinal  
HSCT Haematopoietic stem cell transplantation  
IKK Inhibitor of NF-κB-kinase complex 
IRAK1 Interleukin-1 receptor-associated kinases 1 
IRAK4 Interleukin-1 receptor-associated kinases 4 
MYD88 Myeloid differentiation primary response protein 88 
NCI CTCAE v5.0 The National Cancer Institute Common Terminology Criteria for Adverse Events 
version 5.0 
PAMPs Pathogen associated molecular patterns  
PBMCs Peripheral blood mononuclear cells  
SNPs Single nucleotide polymorphisms 
TAB1 Tak-1 binding protein 1 
TAB2 Tak-1 binding protein 2 
TAK1 transforming growth factor beta factor-β activated kinase 1 




TLR Toll-like receptor  




2.3 Introduction  
5-fluorouracil (5-FU) is a commonly administered chemotherapy drug used for the treatment of 
breast, colorectal and upper gastrointestinal (GI) tract solid tumours [1, 26]. Although highly 
effective, with response rates for 5-FU-based regimens between 40 – 50 % in patients with 
advanced colorectal cancer [27, 28], 5-FU causes severe damage to mucosal membranes of the 
GI tract [2, 5, 29]. This damage results in apoptosis, altered histopathology and an increase in 
proinflammatory cytokine expression giving rise to inflammation [2, 5, 29]. This in turn leads to the 
clinical manifestation of GI toxicities including but not limited to, mucositis, diarrhoea, nausea and 
vomiting [4].  
The development of GI toxicity is variable amongst patients, making it difficult to predict which 
patients will develop severe toxicity. Although supportive care measures are recommended and 
suggested, these are limited and are for use in highly specific patient cohorts [8]. Additionally, 
supportive care is often administered therapeutically not prophylactically, which in some patients 
is too late for the management and relief of severe GI toxicity symptoms [8, 9]. In these patients, 
further interventions are required to improve symptom management and relieve severe GI toxicity 
symptoms [30]. 
Currently, there are no adequate predictors for 5-FU-induced severe GI toxicity risk. It is imperative 
predictors are identified and translated to clinical practice to identify ‘at risk’ patients prior to 5-FU 
treatment. This will facilitate proactive delivery and personalisation of supportive care measures 
aimed at reducing the severity of GI toxicity experienced. 
Following administration of 5-FU, an innate immune inflammatory response is initiated, mediated 
by the Toll-like Receptor/Interleukin-1 domain innate immune signalling pathway. Toll-like 
Receptor/Interleukin-1 is commonly abbreviated to TIR. Activation of the TIR domain innate 




of proinflammatory cytokines [2, 31, 32]. Increased levels of these proinflammatory cytokines, in 
particular tumour necrosis factor alpha (TNF-⍺) and interleukin 1 beta (IL-1β), have been 
significantly associated with severe GI toxicity in both preclinical and clinical studies [2, 5, 24]. Due 
to the importance of the TIR domain innate immune signalling pathway in inflammatory signalling 
and subsequent severe GI toxicity development, single nucleotide polymorphisms (SNPs) in this 
pathway may be potential predictors for severe GI toxicity risk. However, these SNPs are largely 
understudied in the context of GI toxicity.  
This critical literature review will firstly provide an overview of 5-FU-based chemotherapy and the 
pathophysiology of GI toxicity; then outline and summarise previous research on the influence and 
function of TIR domain innate immune signalling pathway SNPs and how this can be applied to GI 
toxicity risk.  
2.4 Background  
2.4.1  5-FU Mechanism of action  
5-FU is an antimetabolite drug that inhibits DNA and RNA synthesis [1]. The uracil analogue was 
developed in the 1950’s following identification of uracil metabolism as a potential target for therapy 
due to the rapid use of uracil by rat hepatomas compared to normal tissues [33]. In the liver, 5-FU 
is metabolised to three active metabolites, fluorodeoxyuridine monophosphate (FdUMP), 
fluoro-deoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP) [34, 35]. The oral 
prodrug of 5-FU, capecitabine, travels unaltered through the gut wall where it is converted to 5-FU 
by liver carboxylesterase (CES) 1 and CES2, and cytidine deaminase [36, 37]. The principal 
mechanism of action of 5-FU is inhibition of thymidylate synthase (TS, encoded by the gene 
TYMS), a critical enzyme necessary for conversion of precursor deoxyribonucleotides required for 
purine and pyrimidine synthesis. Its principal active metabolite, FdUMP, inhibits TS, whilst 




synthesis, RNA processing and protein synthesis [34, 38, 39]. 5-FU catabolism is governed by the 
rate determining enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), 
catabolising 80 % of administered 5-FU to dihydroflurouracil, which is then excreted in the urine 
[34, 40]. 
2.4.2  Current 5-FU regimens  
5-FU is administered intravenously as either a bolus dose or continuous infusion over a 24 - 48 
hour period to treat solid tumours of the breast, colon and upper GI tract [41]. In breast cancer 
regimens, 5-FU is generally administered in conjunction with epirubicin and cyclophosphamide 
[41]. For colorectal and upper GI tract cancers, 5-FU is administered as either a monotherapy in 
synergistic combination with leucovorin or in combination with other chemotherapeutics such as 
irinotecan, oxaliplatin, and cisplatin [41]. 5-FU is used in both a curative and palliative care setting. 
Additional therapies including radiation therapy, monoclonal antibodies (bevacizumab, cetuximab), 
taxanes (docetaxel and paclitaxel) and tyrosine kinase inhibitors (lapatinib) may also be 
administered in conjunction with or following 5-FU treatment in an attempt to further reduce tumour 
activity [41]. Capecitabine, the oral and more selective prodrug of 5-FU, may also be substituted in 
replacement of 5-FU in the before-mentioned regimens [42]. 
2.4.3  5-FU administration induces GI toxicity 
Of all patients receiving 5-FU-based therapies, 25 – 50 % will experience GI toxicity [3]. Recording 
the prevalence and incidence of GI toxicity is vital for symptom management. However, this is often 
difficult and inconsistent due to a lack of standardised scoring criteria [43]. A number of toxicity 
grading scales exist, each with their own toxicity grading criteria. Among the most commonly used 
toxicity grading scale is The National Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI CTCAE v 5.0) [10]. The NCI CTCAE was developed during the late 1980’s and uses 




graded as 1 or 2 is classified as mild to moderate toxicity whilst GI toxicity graded ≥ 3 is classified 
as severe toxicity [10]. Additionally, patients can also be categorised as suffering from a grade 3 
GI toxicity on the NCI CTCAE v 5.0 if they receive a dose reduction, treatment delay, cease 
treatment prematurely and/or are hospitalised as a direct result of GI toxicity [10, 44]. 
There is currently no effective approach to prevent GI toxicity [2]. The Multinational Association of 
Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) provide 
worldwide clinical practice guidelines for management of GI toxicity secondary to cancer therapy 
[8, 45, 46]. Table 2.1 lists the current MASCC/ISOO recommendations and suggestions for the 




Table 2.1 MASCC/ISOO clinical practice guidelines for the management of GI toxicity. 
Oral Mucositis [8] 
Recommended  
 Thirty minutes of oral cryotherapy (sucking on ice chips) to prevent mucositis in 
patients receiving 5-FU bolus regimens. 
Suggested  
 Good oral hygiene (regular tooth brushing, flossing and mouth rinsing) to prevent 
mucositis across all treatment modalities.  
Diarrhoea [8] 
Recommended  
 Loperamide use to treat moderate diarrhoea induced by standard or high-dose 
chemotherapy. 
 Octreotide use to treat diarrhoea induced by standard or high-dose chemotherapy if 
loperamide is ineffective.  
Suggested  
 Probiotics such as Lactobacillus use prior to and during chemotherapy treatment to 
maintain gut homeostasis and reduce diarrhoea occurrence. 
Nausea and vomiting [9, 47] 
Recommended 
 Prophylactic administration of antiemetics such as aprepitant (substance 
P antagonist), ondansetron (5-HT3 receptor antagonist), dexamethasone 
(corticosteroid) or metoclopramide (dopamine-receptor antagonist) for patients 
receiving low emetogenic or high-dose chemotherapy. 
 No prophylactic administration of antiemetics for patients receiving minimal 
emetogenic chemotherapy.  
 Patients whom suffer vomiting should be treated as if they were receiving low 
emetogenic chemotherapy. 
 Breakthrough nausea and vomiting (categorised as nausea or vomiting that occurs 
within 5 days of chemotherapy administration following the use of antiemetic agents) 




In addition to GI toxicity, 5-FU can also induce hand and foot syndrome, peripheral neuropathy and 
haematological toxicities including leukopenia, thrombocytopenia and neutropenia [34]. This is due 
to ‘off-target’ effects of 5-FU; 5-FU metabolites non-specifically target highly proliferative basal 
epithelium and haematopoietic progenitor cells, as well as highly proliferative cancer cells [2, 17]. 
Bolus administration of 5-FU increases the risk of haematological toxicities whilst continuous 
infusion of 5-FU increases the likelihood of hand and foot syndrome [34, 48]. In contrast, treatment 
modality does not affect the risk of GI toxicity [48]. Furthermore, patients with GI toxicity may also 
develop additional toxicities and experience ‘toxicity clusters’ [49]. In a cohort of patients with 
colorectal cancer receiving 5-FU-based therapy, diarrhoea was strongly linked with the presence 
of bloating, constipation and cystitis, whilst vomiting was strongly linked with the presence of 
nausea, dehydration and chills [49]. No links were identified between GI toxicities and 
haematological or neurological toxicities [49]. Although research is still in its infancy, symptoms 
grouped in clusters may share a common biological mechanism meaning that, a predictive marker 
for severe GI toxicity risk may also have the ability to predict the risk of additional toxicities.  
2.4.4  The issue at hand – Severe GI toxicity  
Of the 20 – 25 % of patients who experience GI toxicity, a subset of these patients will develop 
severe GI toxicity, graded as ≥ 3 on the NCI CTCAE [10]. Supportive care measures are ineffective 
for patients with severe GI toxicity and treatment delays, dose reductions or premature treatment 
cessation will be required to manage and relieve symptoms [2]. Furthermore, severe GI toxicities 
can induce secondary symptoms such as pain, dehydration and malnutrition requiring opioid 
analgesics, intravenous fluids and parenteral nutrition [2, 4]. Treatment interruption may negatively 
influence prognosis and potentially impact long-term survival. In addition, the presence of severe 
GI toxicity can decrease patient quality of life whilst receiving treatment and increase health costs, 




care system US $15,500 per episode [6]. Currently, there is no way to identify patients at most risk 
of severe GI toxicity prior to treatment.  
2.5 How does 5-FU induce GI toxicity?  
2.5.1  Inhibition of DNA and RNA synthesis by 5-FU results in significant cell injury and death  
Following inhibition of DNA and RNA synthesis by 5-FU, base-excision repair is initiated to remove 
precursor deoxyribonucleotides and misincorporated 5-FU metabolites, leading to excessive DNA 
fragmentation resulting in mucosal injury and cell apoptosis [1, 50]. Consequently, injured and 
apoptotic cells release damage associated molecular patterns (DAMPs) including DNA, heat shock 
proteins and intracellular components [2, 51]. The injury and death of intestinal epithelial cells leads 
to the breakdown of the mucosal barrier, allowing entry of microorganisms and the colonisation of 
bacteria [2]. Microorganisms and bacteria release their own endogenous danger signals such as 
lipopolysaccharide, lipoteichoic acid and single stranded mRNA, termed pathogen-associated 
molecular patterns (PAMPs) [2, 51].  
The release of DAMPs and PAMPs initiates a signalling cascade mediated by Toll-like receptors 
(TLRs) of the TIR domain innate immune signalling pathway. Activation of the TIR domain innate 
immune signalling pathway leads to the recruitment of leukocytes and subsequent secretion of 
proinflammatory cytokines such as TNF-α and IL-1β. These molecular events, particularly TLR 
signalling, underlie the pathophysiology of GI toxicity [2, 23, 51-53].  
2.5.2  The TIR domain innate immune signalling pathway underpins the pathophysiology of GI 
toxicity  
TLRs are a family of highly conserved type 1 integral membrane glycoproteins containing an 
extracellular motif of leucine-rich repeats and cytoplasmic TIR domain (Figure 2.1) [21, 54, 55]. To 
date, ten TLRs have been identified in humans and are present on either the cell surface of innate 




bodies and endosomes (TLR3, 7, 8 and 9) [56, 57]. TLRs respond to a variety of PAMPs, DAMPs 
or synthetic compounds [22]. TLR2 and TLR4 are key TLRs which mediate mucosal destruction 
and protection against GI chemotoxicity [57, 58]. They are also abundantly present on a variety of 
cells throughout the GI tract including goblet cells, cells of the lamina propria and enterocytes [57, 
58]. Activation of TLR2 and TLR4 initiates the innate immune signalling pathway via the TIR domain 
and leads to the subsequent activation and translocation of NF-κB [22]. The TIR domain innate 









Figure 2.1 The TIR domain innate immune signalling pathway: a) Following 5-FU administration, 
DAMPs are released from injured and apoptotic cells whilst PAMPs are produced from colonised 
bacteria and microorganisms. DAMPs and PAMPs are recognised by TLR2 and TLR4 and on 
binding, stimulate the homodimerisation of TLR4, and heterodimerisation of TLR2 with either TLR1 
or TLR6; b) Dimerisation prompts the recruitment and binding of MyD88, which in turn recruits 
IRAK1 and IRAK4. Phosphorylation of IRAK1 and IRAK4 enables binding of TRAF6; c) TRAF6 
disengages from the newly formed IRAK complex and forms a new complex with TAK1, TAB1 and 
TAB2. Phosphorylation of TAK1 and TAB2 occurs, stimulating ubiquination of TRAF6 and 
subsequent activation of TAK1; d) Activated TAK1 disengages and phosphorylates the IKK 
complex; e) Phosphorylated IKK complex disengages from TAK1 and phosphorylates the Iκβ 
subunit of NF-κB; f) Following phosphorylation, Iκβ is ubiquinated and degraded from NF-κB by the 
26S proteosome. Activated NF-κB translocates to the nucleus; g) In the nucleus, NF-κB 
upregulates gene transcription and subsequent production and secretion of proinflammatory 





Following recognition and binding of DAMPs and PAMPs, TLR2 dimerises with TLR1 or 6, whilst 
TLR4 homodimerises [22]. TLR dimerisation prompts recruitment and binding of adapter protein 
myeloid differentiation primary response protein 88 (MyD88) to the TIR domain [22]. Binding of 
MyD88 in turn recruits interleukin-1 receptor-associated kinases (IRAK) 1 and IRAK4, resulting in 
phosphorylation of IRAK4 and subsequent activation and auto-phosphorylation of IRAK1 [22]. 
Phosphorylation of IRAK1 and IRAK4 enables binding of TNF receptor associated factor (TRAF) 6 
to the TLR/MyD88/IRAK complex. Once bound, TRAF6 disengages from the TLR/MyD88/IRAK 
complex and associates with transforming growth factor beta factor-β activated kinase (TAK) 1, 
TAK1-binding protein (TAB) 1 and TAB2 to form a new complex in the cytosol [22]. TAB1 enhances 
TAK1 kinase activity whilst TAB2 is an adapter protein responsible for linking TAK1 with TRAF6. 
Phosphorylation of TAB2 and TAK1 then occurs and the remaining complex associates with 
ubiquitin enzymes leading to the ubiquitylation of TRAF6 and activation of TAK1 [22]. TAK1 then 
phosphorylates the IKK complex (inhibitor of NF-κβ-kinase complex).  
Transcription factor NF-κB exists as a heterodimer of three subunits, NF-κβ1 (p50/p105), NF-κβ2 
(p52/p100) and p65 (Rel A) bound to the inhibitor kappa beta (Iκβ) subunit, responsible for 
maintaining NF-κB in an inactive state [22, 59, 60]. Once phosphorylated, the IKK complex 
phosphorylates the Iκβ subunit of NF-κβ, leading to its ubiquitination and subsequent degradation 
from the NF-κB complex by the 26S proteasome. Degradation of Iκβ permits the translocation of 
activated NF-κB to the nucleus (Figure 2.1) [59]. 
In the nucleus, NF-κB regulates nearly 200 target genes, many of which are implicated in mucosal 
injury and cell death [61]. Of particular importance are the upregulation of genes including 
interleukin-1 beta (IL1B) and tumour necrosis factor alpha (TNF) encoding the proinflammatory 
cytokines IL-1β and TNF-⍺, respectively [31]. Inactive precursor IL-1β is cleaved by 
caspase1/IL-1β-converting enzyme (ICE) to its active form and is released from peripheral blood 




tissue macrophages, natural killer cells and T lymphocytes [63, 64]. The production of IL-1β and 
TNF-⍺ mediates an inflammatory response reducing epithelial oxygenation, initiating 
mesenchymal-epithelial signalling and stimulating further injury and death in cells of the epithelium 
and submucosa [2, 32, 52]. In addition, these cytokines can amplify primary damage by degrading 
Iκβ, further activating NF-κB and instigating its translocation to the nucleus [2, 32, 52]. 
These changes have been reported in both preclinical and clinical studies following 5-FU 
administration. For example, in Dark Agouti rats given 5-FU, TNF-⍺ levels were highly elevated in 
the oral mucosa, jejunum and colon whilst IL-1β levels were highly elevated in the oral mucosa [5]. 
Additionally, TNF-⍺ and IL-1β levels were associated with severe GI damage including reduced 
epithelial thickness, blunting and fusion of villi and obliteration of crypts [5]. Elevated TNF-α and 
IL-1β are also observed in the peripheral blood of patients whom experience GI toxicity following 
chemotherapy [2, 24].  
To summarise, following damage instigated by 5-FU administration, the TIR domain innate immune 
signalling pathway is activated initiating a signalling cascade leading to the activation of 
proinflammatory cytokines such as IL-1β and TNF-⍺. These proinflammatory cytokines are 
consistently elevated in severely damaged mucosal tissue and associated with GI toxicity 
symptoms such as diarrhoea and mucositis.  
2.6 Have any predictors for severe GI toxicity risk been identified?  
2.6.1  Sex and age 
Patient characteristics such as sex and age are important facets that must be considered when 
identifying patients at risk of severe GI toxicity [15]. However, evidence defining the relationship 
between sex, age and severe GI toxicity is highly contradictory, with sex and age more adequately 
serving as co-contributors rather than predictors for severe GI toxicity risk. In patients receiving 




at being of higher risk for developing mucositis (P = 0.04) [14]. No significant relationship was 
identified between patients of advanced age and GI toxicity risk in the cohort [14]. Likewise, in 
patients receiving 5-FU and leucovorin for colorectal cancer, females developed higher counts of 
severe diarrhoea (P < 0.01) and vomiting (P = 0.03) compared to their male counterparts [11]. 
Univariate analysis identified sex (P < 0.0001) as an independent predictor for severe GI toxicity in 
addition to advanced age (P = 0.001) [14], contradictory to the findings by Schwab et al [14]. In 
similar studies, no significant relationship between the development of GI toxicity and sex was 
identified in patients receiving 5-FU-based therapy [13], whilst advanced age was identified as 
protective against severe GI toxicity, with decreases in diarrhoea and nausea/vomiting episodes in 
advanced age patients (P = 0.01) [12]. Although sex and age cannot solely predict severe GI 
toxicity risk and the utility of these associations is not understood [15], it is known that certain SNPs, 
such as those found in dihydropyrimidine dehydrogenase (DPYD), are more commonly identified 
in one sex than the other [14] and, this may be true for other SNPs that are identified as predictors 
for severe GI toxicity risk. Therefore, factors such as sex and age are important co-contributors for 
severe GI toxicity risk prediction.  
2.6.2  SNPs in the 5-FU rate determining enzyme  
SNPs in DPYD, responsible for encoding the 5-FU rate determining enzyme DPD, have been 
thoroughly investigated for their role in the development of severe GI toxicity. During 5-FU-based 
therapies, 60 – 100 % of patients carrying one or multiple DPYD SNPs develop grade 3 to 4 
toxicities (non-haematological and haematological) compared to 10 – 20 % of patients carrying no 
DPYD SNPs [14, 30, 65, 66]. In particular, two recent meta-analyses identified the presence of 
DPYD SNPs, IVS14+1 G > A, 2846 A > T, 1679 T > G, and 1236 G > A, increased the risk of grade 
3 GI toxicities such as mucositis and diarrhoea (P ≤ 0.05) [16, 18]. In addition, a clinical study of 
patients with colorectal cancer receiving FOLFOX (fluorouracil and oxaliplatin) or FOLFIRI 




(P = 0.003) and nausea/vomiting (P = 0.007), respectively [17]. However, all of these 
aforementioned SNPs occurred in less than 5 % of the populations studied and did not account for 
the majority of severe GI toxicity events [16-18]. Consequently, the clinical usefulness of routine 
genotyping in Caucasians for these DPYD SNPs prior to 5-FU treatment hasn’t been established 
and current literature regarding the clinical sensitivity and specificity of diagnostic testing of the 
DPYD gene in this population is yet to be demonstrated [16]. This is further complicated by 
inconsistencies in the literature regarding the association of particular DPYD variants and GI 
toxicity between different ethnic populations [67, 68], such that there is the possibility that a rare 
variant in one ethnicity may be more frequent in another ethnicity and therefore, have a greater 
impact on GI toxicity prevalence. Nevertheless, the US Food and Drug Administration (FDA) and 
the European Medicines Agency (EMA) warns about the increased risk of severe toxicity in patients 
carrying at least one decreased function DPYD allele on 5-FU and capecitabine drug labels [69-
71] and, the Clinical Pharmacogenomics Implementation Consortium recommends altered 5-FU 
and capecitabine dosing based on DPYD genotype and the resulting phenotype [15]. Interestingly 
though, neither agency requires genetic testing for DPYD SNPs prior to treatment [17, 72]. As a 
result, new genetic predictors for severe GI toxicity risk need to be identified.  
2.7 Candidate predictors for severe GI toxicity may lie within the TIR domain innate 
immune signalling pathway  
2.7.1  SNPs in key TIR domain innate immune signalling pathway genes are uniquely 
positioned to influence gene functioning  
The TIR domain innate immune signalling pathway is known to play a pivotal role in the 
development of GI toxicity, therefore, SNPs in key TIR domain innate immune signalling pathway 
genes may alter the pathophysiology and subsequent severity of GI toxicity. Hence, these 




innate immune signalling pathway genes TLR2, TLR4, MYD88, IRAK1, IRAK4, TRAF6, NFKB, 




Table 2.2 Summary information about TIR domain innate immune signalling pathway SNPs [73]a.  
ID Type of variant 
Base pair 
change 
Amino acid change MAF 
TLR2 
rs11938228 intronic C > A - 
CEU: 0.30, HCB: 0.35,  
JPT: 0.48, YRI: 0.10 
rs1898830 intronic A > G - 
CEU: 0.31, HCB: 0.36,  
JPT: 0.49, YRI: 0.08 
rs3804099 cds-synon T > C - 
CEU: 0.45, HCB: 0.37,  
JPT: 0.27, YRI: 0.63 
rs3804100 cds-synon T > C - 
CEU: 0.08, HCB: 0.33,  
JPT 0.22, YRI: 0.06 
rs4696480 intronic T > A - 
CEU: 0.00, HCB: 0.00,  
JPT 0.00, YRI: 0.00 
rs5743708 missense G > A arginine > glutamine 
CEU: 0.05, HCB:0.00,  
JPT:0.00, YRI:0.00 
TLR4 
rs10759930 upstream C > T - 
CEU: 0.37, HCB: 0.62,  
JPT: 0.65, YRI: 0.05 
rs10759932 upstream  T > C - 
CEU: 0.14, HCB: 0.26,  
JPT: 0.25, YRI: 0.25 
rs4986790 missense A > G aspartate > glycine 
CEU: 0.04, HCB: 0.00,  
JPT: 0.00, YRI: 0.04 
rs4986791 missense C > T threonine > isoleucine 
CEU: 0.05, HCB: 0.01,  
JPT: 0.00, YRI: 0.00 
rs5030710 cds-synon T > C - 
CEU: 0.00, HCB: 0.00,  
JPT: 0.00, YRI: 0.18 
rs7044464 upstream T > A - 
CEU: 0.14, HCB: 0.07,  
JPT: 0.07, YRI: 0.29 
rs7856729 upstream G > T - 
CEU: 0.15, HCB: 0.05, 





rs6853 3’-UTR A > G - 
CEU: 0.12, HCB: 0.03,  
JPT: 0.01, YRI: 0.33  
rs7744 3’-UTR A > G - 
CEU: 0.15, HCB: 0.41,  
JPT: 0.28, YRI: 0.01  
IRAK1 
rs1059701 cds-synon C > T - 
HCB: 0.14, JPT: 0.18, 
YRI: 0.15 
rs1059702 missense T > C 
phenylalanine > 
serine 
CEU: 0.79, HCB: 0.15,  
JPT: 0.24, YRI: 0.98  
rs1059703 missense C > T serine > leucine 
CEU: 0.77, HCB: 0.17,  
JPT: 0.20, YRI: 0.62  
rs2239673 intronic C > T - GMAF: 0.48 
rs3027898 downstream C > A - 
CEU: 0.74, HCB: 0.12,  
JPT: 0.22, YRI: 0.52  
rs5945174 intronic G > A - GMAF: 0.48 
rs7061789 intronic G > A - GMAF: 0.48 
rs731642 intronic G > A - GMAF: 0.44 
IRAK4 
rs1141168 3’-UTR A > G - 
CEU: 0.53, HCB: 0.47,  
JPT: 0.63  
rs1461567 intronic C > T - 
CEU: 0.03, HCB: 0.41,  
JPT: 0.54, YRI: 0.02  
rs3794262 intronic T > A - 
CEU: 0.93, HCB: 0.83,  
JPT: 0.91, YRI: 0.38  
rs4251429 intronic G > C - 
CEU: 0.02, HCB: 0.07,  
JPT: 0.06, YRI: 0.35  
rs4251431 intronic G > T - 
CEU: 0.05, HCB: 0.14,  
JPT: 0.14, YRI: 0.16  
rs4251466 intronic C > T - 
CEU: 0.08, HCB: 0.09, 
 JPT: 0.06, YRI:0.22  
rs4251513 intronic C > G - 
CEU: 0.50, HCB: 0.42,  




rs4251532 intronic C > T - 
CEU: 0.07, HCB: 0.16,  
JPT: 0.09, YRI: 0.62 
rs4251545 missense G > A alanine > threonine 
CEU: 0.08, HCB: 0.09,  
JPT: 0.06, YRI: 0.31 
rs4251569 5’-UTR C > T - 
CEU: 0.09, HCB: 0.17,  
JPT: 0.12, YRI: 0.00 
TRAF6 
rs16928973 intronic C > T - 
CEU: 0.19, HCB: 0.01,  
JPT: 0.12, YRI: 0.00 
rs331449 intronic T > C  
CEU: 0.00, HCB: 0.00, 
 JPT: 0.00, YRI: 0.20 
rs3740961 3’-UTR A > G - 
CEU: 0.11, HCB: 0.51,  
JPT: 0.55, YRI: 0.01  
rs5030411 intronic C > T - 
CEU: 0.60, HCB: 0.71,  
JPT: 0.72, YRI: 0.06  
rs5030416 intronic A > C - 
CEU: 0.17, HCB: 0.10,  
JPT: 0.14, YRI: 0.16 







delete codon GMAF: 0.42 
IL1B 
rs1143623 upstream C > G - 
CEU: 0.67, HCB: 0.61,  
JPT: 0.67, YRI: 0.94 
rs1143627 promoter T > C - 
CEU: 0.37, HCB: 0.47, 
 JPT: 0.46, YRI: 0.64 
rs1143634 cds-synon T > C - 
CEU: 0.02, HCB: 0.01,  
JPT: 0.05, YRI: 0.09 
rs16944 promoter C > T - 
CEU: 0.35, HCB: 0.45,  
JPT: 0.47, YRI: 0.58  
rs4848306 promoter G > A - 
CEU: 0.46, HCB: 0.52,  





rs1799964 downstream T > C - 
CEU: 0.21, HCB: 0.23,  
JPT: 0.14, YRI: 0.12 
rs1800629 promoter G > A - 
CEU: 0.17, HCB: 0.03,  
JPT: 0.02, YRI: 0.09 
rs1800750 promoter G > A - 
CEU: 0.01, HCB:0.00,  
JPT: 0.00, YRI: 0.01  
rs361525 promoter  G > A - GMAF: 0.06 
rs4248158 downstream  C > T - GMAF: 0.02 
a >: change; cds-synon: coding synonymous mutation; CEU: Caucasian population Utah, USA; GMAF: global minor allele 
frequency; HCB: Asian population Beijing, China; JPT: Asian population Tokyo, Japan; MAF: minor allele frequency; 




The TLR2 and TLR4 genes are located on chromosomes 4q31.3 and 9q33.1, respectively, with 
many TLR SNPs resulting in either synonymous or missense mutations [73]. Synonymous 
mutations do not alter the primary amino acid sequence. However, they may have indirect effects 
on gene functioning by influencing mRNA splicing and subsequent mRNA translation [74]. The 
MYD88, IRAK1, IRAK4 and TRAF6 genes are located on chromosomes 3q22.2, Xq28, 12q12, and 
11p12, respectively [73]. Many of the MYD88, IRAK1, IRAK4 and TRAF6 mutations are located 
within the intronic regions of their respective genes. It is currently thought intronic mutations 
influence mRNA stability and translation, and may cause alternative splicing sites [21, 75, 76].  
The NFKB gene is located on chromosome 4q24, with the NFKB mutation rs38362491 resulting in 
a premature stop codon [73]. Dependent on location in the gene, premature stop codons can lead 
to early termination of gene transcription and subsequent changes in protein function [77, 78]. The 
IL1B and TNF genes are located on chromosomes 2q14.1 and 6q21.33, respectively [73]. Key 
IL1B and TNF mutations lie within the promoter region therefore, are in prime location to alter 
transcription factor binding and subsequent gene transcription [73].  
2.7.2  Evidence suggests TIR domain innate immune signalling pathway SNPs alter gene 
functioning and influence disease susceptibility  
The in vitro, ex vivo and in vivo effects of key TIR domain innate immune signalling pathway SNPs 
as well as their association with disease susceptibility, is summarised in Table 2.3. It should be 
noted that for some SNPs, there is a lack of knowledge regarding functional impacts; a current 




Table 2.3 In vitro, ex vivo, in vivo and genetic association studies investigating the effects of TIR domain innate immune signalling pathway SNPs on disease 
susceptibility, gene transcription, protein binding and cytokine secretionb.  
Gene SNPs Study details  
Number of 
Participants 




Stimulated TNF-⍺, IL-6 and 
IL-10 secretion from isolated 
PMNs in patients with 
cirrhosis 
n = 114 
  ↓ stimulated TNF-α secretion in HE and HM vs WT (P < 0.01) 
  ↓ stimulated IL-6 secretion in HE and HM vs WT (P < 0.01) 





Association of SNPs with 
measles vaccine-induced 
immune responses  
n = 745 
Changes in antibody titer: 
  rs3804100 ↓ HE and HM vs WT (P = 0.002) 
Changes in cytokine secretion: 
  rs3804099 ↓ IFNλ-1 HE (P = 0.002) and HM (P = 0.009) vs WT 
[80] 
rs4696480 
Circulating LTA, LPS, TNF-α 
and IL-6 levels; stimulated 
secretion of TNF-⍺, IL-16 and 
IL-10 from cultured PMNs 
from patients with cirrhosis 
n = 114 
  ↓ circulating TNF-α in HM vs WT (P < 0.05) 







Association of SNPs with 
severe CIGT incidence 
following 5-FU-based 
treatment 
n = 34 
Predictive of severe CIGT incidence in conjunction with TNF 
rs1800629 and colorectal and gastric cancer types (P = 0.033, 
ROC AUC = 87.3 %) 
[25] 
rs5743708 
Association of SNPs with the 
severity and course of sepsis 
in critically ill patients 
n = 145 
  ↑ sepsis HE vs WT (P = 0.03)  
  ↑ number of infections HE vs WT (P = 0.012) 
  ↑ difficult-to-treat pathogens HE patients vs WT (P = 0.045) 
[81] 
rs5743708 
Association of SNPs with 
sepsis and pneumonia in 
patients with AML following 
induction chemotherapy 





Association of SNPs with 
HCC susceptibility 
n = 443 
rs3804099 and rs3804100: 
  in LD (R2 > 0.9) 
  ↓ HCC rs3804099 HE vs WT 
(P < 0.001, OR = 0.49, 95 % CI = 0.3-0.7)  
  rs3804100 HE vs WT (P < 0.001, OR = 0.509, 95 % CI = 0.3 - 0.8) 
rs11938228 & rs1898830: 





Gene SNPs Study details  
Number of 
Participants 





FEV1 decline following 
inhalation of LPS 
n = 83 
  SNPs were in LD (data not provided) 
  Dose-response decline in FEV1: WT 1.86 % vs HE 0.59 % 




Stimulated TNF-α, IL-6 and 
IL-10 secretion from isolated 
PMNs in patients with 
cirrhosis 
n = 114 
  ↓ stimulated IL-6 secretion in HE vs WT (P < 0.01)  




LPS-stimulated response in 
isolated airway epithelial cells 
n = 83 
  SNPs were in LD (data not provided) 
  ↓ IL-1⍺ secretion by airway epithelial cells of HE vs WT patients 








Association of SNPs with 
measles vaccine-induced 
immune responses 
n = 745 
Changes in antibody titer: 
rs5030710 and rs16906053 
  ↑ HE (P = 0.001) and HM (P = 0.005) vs WT 
rs16906053 





rs7856729 rs7044464 and rs7856729 
  ↓ IL-10 HE and HM vs WT (P = 0.001) 
rs10759932 
  ↑ IFN-α HE and HM vs WT (P = 0.001) 
rs10759930 
  ↓ IFN-γ HE and HM vs WT (P = 0.001) 
  ↑ IFNλ-1 HE and HM vs WT (P = 0.006) 
rs4986790 
Circulating LTA, LPS, TNF-α 
and IL-6 levels; stimulated 
secretion of TNF-α, IL-16 and 
IL-10 from cultured PMNs 
from patients with cirrhosis  
n = 114 
  ↓ stimulated IL-6 secretion in HE vs WT (P < 0.01)  
  ↑ stimulated IL-10 secretion in HE vs WT (P < 0.01) 
  No significant differences in circulating TNF-α, IL-6 and IL-10 levels 




LPS-stimulated response in 
THP-1 cells 
- 
↓ NF-κB activation by THP-1 cells with rs4986790 allele vs WT 




Association of SNPs with the 
severity and course of sepsis 
in critically ill patients 
n = 145 
  ↑ endocarditis HE vs WT (P < 0.05) 
  ↑ bloodstream infections HE vs WT (P < 0.05)  







Association of SNPs with 
severe CIGT incidence 
following 5-FU-based 
treatment 
n = 34 No significant associations [25] 
rs4986790  
rs4986791 
Association of SNPs with 
sepsis and pneumonia in 
patients with AML following 
induction chemotherapy 
n = 155 
  SNPs were in LD (data not provided) 
  ↑ sepsis development (P = 0.021, OR: 3.6, 95 % CI = 1.2 - 10.4) 
  ↑ pneumonia HE vs WT (P = 0.014, OR: 3.6, 95 % CI = 1.3 - 9.9) 
[82] 
Gene SNPs Study details  
Number of 
Participants 








TRAF6 expression and 
stimulated TNF-α and IL-6 
secretion from PBMCs of 
patients with sepsis-induced 
ALI 
n = 90 No significant associations [76] 
Genetic association 
rs6853 
Association of SNPs with 
severe CIGT incidence 








Association of SNPs with 
T2DM and its vascular 
complications 
n = 1106 
rs6853: 




Association of SNPs with 
sepsis-induced ALI 
susceptibility 
n = 548 No significant associations [76] 
rs6853  
rs7744 
Association of SNPs with 
SIPD risk and 2o SIPD 
symptoms 
n = 200 
rs6853 genotype analysis: 
  ↑ SIPD WT vs HE and HM 
(P < 0.0001, OR = 2.1, 95 % CI = 1.8 - 2.5) 
  ↑ death from SIPD HE and HM vs WT 
(P = 0.005, OR = 16.1, 95 % CI = 3.3 - 77.6) 
rs6853 allele analysis: 
  ↑ SIPD in patients carrying variant allele 
(P < 0.0001, OR = 1.9, 95 % CI = 1.5-2.6) 
  ↑ association of death in patients carrying variant allele 
(P = 0.0064, OR = 8.4, 95 % CI = 2.5-28.5) 





  No significant associations 
Gene SNPs Study details  
Number of 
Participants 




TRAF6 expression and 
stimulated TNF-α and IL-6 
secretion from PBMCs of 
patients with sepsis-induced 
ALI 










Association of IRAK-1 
haplotype with stimulated NF-
κB activation from peripheral 
blood neutrophils 
n = 30 
↑ NF-κB nuclear accumulation post-LPS in HE and HM vs WT 







Association of SNPs with 
sepsis-induced ALI 
susceptibility 
n = 548 No significant associations [76] 
rs1059702 
rs1059703 
Association of SNPs with 
SIPD risk and 2o SIPD 
symptoms 
n = 200 
rs1059701: 
 ↑ SIPD WT vs HE and HM 
(P = 0.0067, OR = 1.4, 95 % CI = 1.1 - 1.8) 
rs1059702: 
  ↑ leucocytosis HE and HM vs WT 











Association of IRAK-1 
haplotype with 2o symptoms 
in patients with sepsis 
n = 30 
  ↑ likelihood of developing septic shock in HE and HM vs WT 
(P = 0.047) 
  2.6 ↑ likelihood of death from sepsis in HE and HM vs WT 









Susceptibility of ADs in 




  ↑ ADs WT vs HE, HM (P = 0.000, OR = 0.8, 95 % CI = 0.7 - 0.8) 
  ↑ SLE WT vs HE (P = 0.000, OR = 0.7, 95 % CI = 0.6 - 0.7) 
  ↑ SSc WT vs HE and HM (P = 0.032, OR = 0.8, 95 % CI = 0.6 - 0.9) 
rs1079703: 
  ↑ SLE variant vs WT (P = 0.000, OR = 1.5, 95 % CI = 1.3 - 1.6) 
rs3027898: 
  ↑ ADs WT vs HE, HM (P = 0.034, OR = 0.7, 95 % CI = 0.6 - 0.9) 
  ↑ SLE WT vs HE (P = 0.001, OR = 0.8, 95 % CI = 0.6 - 0.9) 
  ↑ RA WT vs HE (P = 0.021, OR = 0.8, 95 % CI = 0.7 - 0.9) 
[88] 
Gene SNPs Study details  
Number of 
Participants 










TRAF6 expression and 
stimulated TNF-α and IL-6 
secretion from PBMCs of 
patients with sepsis-induced 
ALI 









Association of SNPs with 
SIPD risk and 2o SIPD 
symptoms 
n = 200 
rs4251513 genotype analysis: 
  ↑ SIPD WT vs HE and HM 
(P < 0.0001, OR = 2.2, 95 % CI = 1.6 - 3.0) 
  ↑ SIPD sequelae HE and HM vs WT 
(P = 0.001, OR = 7.1, 95 % CI = 2.6 - 18.9) 
rs4251513 allele analysis:  
  ↑ presence of SIPD in patients carrying variant allele 
(P < 0.0001, OR = 1.5, 95 % CI = 1.4 - 1.5) 
rs1461567: 
  ↑ SIPD variant allele vs WT 
(P = 0.016, OR = 1.5, 95 % CI = 1.1 - 1.9) 
rs1141168:  






Association of SNPs with 
T2DM and its vascular 
complications 
n = 1106 
1.66 ↑ T2DM HE vs WT and HM 













Association of SNPs with 
sepsis-induced ALI 
susceptibility 
n = 548 No significant associations [76] 
Gene SNPs Study details  
Number of 
Participants 






TRAF6 expression and 
stimulated TNF-α and IL-6 
secretion from PBMCs of 
patients with sepsis-induced 
ALI 
n = 90 
rs4755453: 
 ↑ TRAF6 baseline mRNA expression WT vs HE  
(P = 0.012) and vs HM (P = 0.003) 
 ↑ TRAF6 post-LPS mRNA expression WT vs HE  
(P = 0.009) and vs HM (P = 0.005) 
 ↑ TNF-α post-LPS secretion WT vs HE and HM  
(P = 0.015) 
 ↑ IL-6 post-LPS secretion WT vs HE and HM (P = 0.009) 





  no significant associations 
In vivo 
rs331449 
Association of SNPs with 
measles vaccine-induced 
immune responses 




Association of SNPs with 
T2DM and its vascular 
complications 




Association of SNPs with 
sepsis-induced ALI 
susceptibility 
n = 548 
↓ % variant allele in sepsis-induced ALI vs sepsis alone groups 






Association of SNPs with 
susceptibility and severity of 
sepsis  
n = 510 No significant associations [89] 
Gene SNPs Study details  
Number of 
Participants 
Impact of SNPs Ref 






luciferase reporter gene 
assay; and EMSA to 
determine protein binding in 
HeLA and HT-29 cells 
- 
  ↓ activity at baseline with variant vs WT allele in HeLA cells 
(P = 0.05)  
 ↓ activity following stimulation with variant vs WT allele in HeLA 
cells (P = 0.02)  
 ↓ activity following stimulation with variant vs WT allele in HT-29 




Association of SNP with IBD 
risk 
n = 822 No significant associations [90] 
rs28362491 
Association of SNPs with 
pathological response in 
patients with rectal cancer 
treated with PCRT 
n = 159 
↑ pathological response HE and HM vs WT  
(P = 0.03, OR = 6.4, 95 % CI = 0.8 - 52.7) 
[91] 
Gene SNPs Study details  
Number of 
Participants 




Association of SNP with IL-1β 
serum concentration following 
infliximab treatment 









reporter gene assay and gel 




  ↓ nuclear protein binding with variant vs WT allele (P < 0.01) 
rs1143623: 
  ↑ nuclear protein binding with variant vs WT allele (P < 0.01) 
  ↓ transcriptional activity variant vs WT allele (P < 0.01) 
rs1143627: 
  ↑ nuclear protein binding of complex 1 with variant vs WT allele 
(P < 0.01) 
  ↓ binding of complex 2 and 3 with variant vs WT allele (P < 0.01) 
  ↓ transcriptional activity with variant vs WT allele (P < 0.01) 
 
rs16944: 






Stimulation of isolated human 
monocytes and EMSA of 
nuclear extracts 
n = 442 
 
rs1143627: 
  rs1143627 and rs16944 in LD (no data given) 







Association of SNPs with 
toxicity in patients undergoing 
5-FU and cisplatin 
chemotherapy 
n = 100 
  ↑ thrombocytopenia HE and HM vs WT 
(P = 0.015, OR = 2.9, 95 % CI = 1.2-7.0)  
  Predictive of stomatitis (P < 0.01) and thrombocytopenia (P = 0.02) 




Association of SNPs with 
pathological response in 
patients with rectal cancer 
treated with PCRT 




Association of SNPs with risk 
of gastric cancer 
n = 442 
rs1143627: 
  rs1143627 and rs16944 in LD (0.99) 
  HE associated with gastric cancer risk 
(OR = 1.9, 95 % CI = 1.5 - 2.6) 
rs16944:  





Association of SNPs with 
severe CIGT incidence 
following 5-FU-based 
treatment 
n = 34 No significant associations [25] 
Gene SNPs Study details  
Number of 
Participants 






Functional analysis of SNP 
using CAT reporter gene in 
Jurkat and Raji cells 
- No significant associations [96] 
rs1800629 
Transient transfection 
luciferase reporter gene 
assay in Jurkat and U937 
cells 
- 
2-fold ↑ transcription with variant vs WT allele in both Jurkat and U937 






Association of SNPs with 
endotoxin-induced TNF-α 
secretion from PBMCs 




Stimulated TNF-α secretion 
from whole blood 





Association of SNPs with 
TNF-α serum concentration 
following infliximab treatment 
n = 47 No significant associations [92] 




Association of SNP with 
clinical outcome, incidence 
and severity of toxic 
complications and GvHD in 
HSCT patients  
n = 70 
↑ severe toxicity HE vs WT 
(P = 0.014, OR = 17.2, 95 % CI = 1.8 - 168.1) 
[77] 
rs1800629 
Association of SNPs with 
severe CIGT incidence 
following 5-FU-based 
treatment 
n = 34 
TLR2 and TNF SNPs were predictive of severe CIGT incidence in 
conjunction with colorectal and gastric cancer types 
(P = 0.033, ROC AUC = 87.3 %) 
[25] 
rs1799964 
Association of SNPs with 
toxicity in patients undergoing 
5-FU and cisplatin 
chemotherapy 
n = 100 
  ↑ stomatitis HE and HM vs WT 
(P = 0.02, OR = 3.1, 95 % CI = 1.2 - 8.3)  
  Predictive of stomatitis (P < 0.01) and thrombocytopenia (P = 0.02) 





Association of SNPs with MS n = 179 No significant associations [99] 
b ↑: increase; ↓: decrease; 2o: secondary; AD: autoimmune disease; ALI: acute lung injury; AML: acute myeloid leukaemia; CAT: chloramphenicol acetyltransferase; EMSA: electromobility shift 
assay; GvHD: graft vs. host disease; HCC: hepatocellular carcinoma; HE; heterozygous; HM: homozygous; HSCT: haemtopoietic stem cells; IBD: irritable bowel syndrome; LD: linkage 
disequilibrium; LPS: lipopolysaccharide; LTA: lipoteichoic acid; MS: multiple sclerosis; OR: odds ratio; PCRT: primary chemoradiation therapy; PBMCs: peripheral blood mononuclear cells; PMNs: 
peripheral polymorphonuclear cells; RA: rheumatoid arthritis; ROC AUC: receiver operator characteristic, area under the curve; SLE: systemic lupus erythaemtosus; SSC: systemic sclerosis; 
SIPD: invasive pneumococcal disease; T2DM: type 2 diabetes; WT: wild-type. 
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A pilot study conducted by Coller et al. was the first to investigate the association between innate 
immune receptor genetic variability and severe GI toxicity risk following 5-FU-based therapy [25]. 
TLR2 rs384100 and TNF rs1800629 SNPs (in conjunction with colorectal and gastric cancer types) 
were identified to be predictive of severe GI toxicity risk [25]. However, no relationship was 
identified with TLR4, MYD88 and IL1B SNPs [25].  
Other studies have focussed on association of SNPs with disease susceptibility and impact of the 
SNPs on protein expression. Patients with TLR2 and TLR4 SNPs were identified to have a higher 
risk of developing bloodstream infections and sepsis, and higher circulating levels of PAMPs such 
as lipoteichoic acid (as described in Table 2.3) [79, 81]. On a molecular level, TLR2 and TLR4 
SNPs have been linked to altered interferon gamma secretion, altered specific antibody responses 
and reduced NF-κB circulating serum levels and activation (as described in Table 2.3) [79, 80, 84]. 
No relationship was identified between MYD88 SNPs and TNF-⍺ and IL-6 concentrations 
post-stimulation of ex vivo PBMCs and the effect of MYD88 SNPs on MyD88 protein expression is 
variable (as described in Table 2.3) [76, 100]. IRAK1 and IRAK4 SNPs have been associated with 
an increased risk of autoimmune disease, with IRAK1 SNPs also identified to increase NF-κB 
activation (as described in Table 2.3) [87, 88]. TRAF6 SNPs were found to increase TNF-⍺ and 
IL-6 secretion at baseline and post-stimulation of ex vivo PBMCs, but no association was identified 
between TRAF6 SNPs with sepsis susceptibility and severity (as described in Table 2.3) [76, 89]. 
NFKB SNP rs28362491 was associated with severe toxic complications in haematopoietic stem 
cell transplantation (HSCT) patients and decreased NF-κB activity (as described in Table 2.3) [77, 
78]. 
2.7.3  IL1B and TNF SNPs show the greatest potential as predictors for severe GI toxicity risk 
Of the TIR domain innate immune signalling pathway SNPs discussed in Table 2.3, IL1B and TNF 
SNPs show the greatest potential as predictors for severe GI toxicity as they have been identified 
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to not only alter gene function but also increase cancer risk and predict toxic side effects following 
chemotherapy. The IL1B SNP rs16944 was shown to increase transcriptional activity of IL-1β and 
was identified as being predictive of stomatitis (in conjunction with TNF 1799964) in patients 
receiving 5-FU and cisplatin chemotherapy treatment [93, 95] (Table 2.3). IL1B rs1143634 was 
identified to increase the risk of gastric cancer, with an increase in nuclear protein binding identified 
in reporter gene assays [93, 94] (Table 2.3). This, in addition to further evidence presented in Table 
2.3, demonstrates IL1B SNPs are candidate predictors for severe GI toxicity risk. However, using 
individual IL1B SNPs as predictors for severe GI toxicity risk may be complicated, as many SNPs 
in IL1B are in linkage disequilibrium therefore, SNPs with opposing effects may ‘cancel’ one 
another out [94]. With regards to TNF SNPs, rs1800629 influences gene functioning, with a 2-fold 
increase in transcriptional activity identified in patients carrying the variant [97]. In addition, a small 
pilot study of patients receiving 5-FU-based therapy, TNF rs1800629 was found to be predictive of 
severe GI toxicity risk in a multivariate logistic regression model [25].  
2.8 Conclusion  
Severe GI toxicity is a debilitating side effect following 5-FU-based therapy. It is essential predictors 
for severe GI toxicity risk are identified to allow patients at most risk of severe GI toxicity to be 
identified prior to treatment, allowing the personalisation of supportive care measures to reduce 
the risk of developing severe GI toxicity. This would not only improve clinical outcomes and 
long-term prognosis, but also improve patient quality of life whilst on otherwise life-saving 
chemotherapy treatment. This critical review has provided evidence to suggest TIR domain innate 
immune signalling pathway SNPs are suitable candidate predictors for severe GI toxicity risk 
following 5-FU-based therapy.  
However, further investigation is required to thoroughly understand the effect of these TIR domain 
innate immune signalling pathway SNPs on the mechanisms underlying the development of GI 
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toxicity. To allow the ‘bench to beside’ translation of TIR domain innate immune signalling pathway 
SNPs as clinical predictors for severe GI toxicity risk, it is critical to not only associate, but identify 
mechanisms by which these SNPs influence the development of severe GI toxicity in addition to 
understanding the exact functional impact of the SNPs themselves.  
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Chapter 3: The Salivary Predictors in Treatment Validation (SPiT-V) 
Study 
Chapter 3 is my first research chapter and is presented as a traditional thesis chapter. This clinical 
study was named the Salivary Predictors in Treatment Validation (SPiT-V) Study and was 
undertaken over a four year period. The SPiT-V study built on previous research conducted in my 
laboratory.  
3.1 Introduction  
3.1.1 5-fluorouracil induces gastrointestinal toxicity  
5-fluorouracil (5-FU) and its prodrug, capecitabine, are highly prescribed antimetabolite 
chemotherapy agents used for the treatment of solid tumours of the breast, colon and upper 
gastrointestinal (GI) tract, among others [1]. Despite being highly effective, due to their 
non-selective nature, 5-FU and capecitabine may lead to severe damage to the mucosal 
membranes of the GI tract [2]. This damage may in turn lead to the manifestation of GI toxicities 
including, but not limited to, mucositis, diarrhoea, nausea and vomiting [4]. Of patients receiving 
5-FU-based therapy, 20 – 50 % will experience GI toxicity [3]. These patients will be administered 
supportive care measures, such as antiemetics and antidiarrhoeals, to help manage and relieve 
symptoms [8, 9]. However, a subset of these patients will develop severe GI toxicity graded as  
3 on the National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI CTCAE 
v 4.03 and v 5.0) [10]. Patients who require dose reductions, treatment delays, early treatment 
cessation and/or hospitalisation to relieve and manage GI toxicity symptoms are also reported as 
developing severe GI toxicity [2]. Current supportive care measures and practices are ineffective 
at managing and relieving severe GI toxicity symptoms [2], with as many as 14 – 25 % of patients 
receiving 5-FU-based therapy requiring a dose delay or reduction as a direct result of severe GI 
toxicity symptoms [14, 101, 102]. The incidence of all severe GI toxicity-related hospitalisations is 
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as high as 30 % in some instances [14, 101, 102]. In addition, secondary symptoms including, but 
not limited to, dehydration and malnutrition develop, requiring intravenous fluids and parenteral 
nutrition [2]. Treatment interruptions negatively influence prognosis and potentially impact 
long-term survival, leading to poorer clinical outcomes. The presence of any grade of GI toxicity 
can also decrease patient quality of life and increase health care costs [6, 7]. There is currently no 
effective approach to identify which patients will develop severe GI toxicity prior to receiving 
5-FU-based therapy.  
3.1.2 Current predictive markers for severe GI toxicity lack clinical sensitivity and specificity 
There is a lack of clinically sensitive and specific predictive markers available to predict the risk of 
severe GI toxicity following 5-FU-based therapy. Traditional variables such as sex, age and 5-FU 
dosage are unreliable, with many contradictory and inconsistent findings surrounding their use as 
predictive markers for severe GI toxicity risk in patients following 5-FU-based therapy [11-14]. 
Single nucleotide polymorphisms (SNPs) in the dihydropyrimidine dehydrogenase (DPYD) gene, 
responsible for encoding the rate determining 5-FU metabolic enzyme DPD, are also inadequate 
predictive markers for severe GI toxicity risk [14, 30, 65, 66]. Although the US Food and Drug 
Administration (FDA) warn of the increased likelihood of adverse effects for patients carrying one 
or multiple DPYD SNPs [71], these SNPs occur in < 5 % of the Caucasian population [70, 71, 73]. 
Therefore, they are not adequate, sensitive or specific predictive markers for severe GI toxicity risk. 
3.1.3 The Salivary Predictors in Treatment (SPiT) pilot study identified new potential predictive 
markers for severe GI toxicity risk  
In 2014, my laboratory conducted a pilot study investigating the association between SNPs in key 
mediating genes of the Toll-like receptor/interleukin-1 (TIR) domain innate immune signalling 
pathway with the risk of severe GI toxicity following 5-FU-based therapy [25]. The TIR domain 
pathway is a key mediating pathway in the development of GI toxicity [2, 22]. Its activation following 
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5-FU-induced mucosal injury mediates the transcription and secretion of proinflammatory cytokines 
tumour necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β) and IL-6 through TLR signalling 
[2, 22]. These proinflammatory cytokines further facilitate mucosal damage and subsequent GI 
toxicity development and have been consistently associated with the severity of GI toxicity in 
preclinical and clinical studies [5, 23, 24, 53]. Briefly, this small pilot study recruited 34 participants 
(10 with severe GI toxicity graded > 3 on the NCI CTCAE v 4.03 [10] or received a dose reduction, 
dose delay, ceased 5-FU-based therapy early or were hospitalised as a result of GI toxicity) from 
the Flinders Medical Centre in South Australia, Australia. A general linear model of multivariate 
logistic regression created a risk prediction model identified TLR2 rs384100 and TNF rs1800629 
SNPs, in conjunction with colorectal and upper GI cancer types, to be predictive for severe GI 
toxicity risk, with a receiver operator characteristic area under the curve (ROC AUC) of 87 % [25]. 
When colorectal and upper GI cancer types were removed from the risk prediction model, the 
predictive power of the model decreased, with a ROC AUC of 77 % [25]. This demonstrated the 
inclusion of cancer type gave a more informative, sensitive and specific risk prediction model for 
GI toxicity compared to using SNPs alone. This was one of the first studies associating genetic 
variability within innate immune signalling genes with the risk of severe GI toxicity [25]. These 
results suggest SNPs within the TIR domain innate immune signalling pathway may be potential 
predictive markers for severe GI toxicity risk. However, like any pilot study, the results need to be 
validated in a new, larger and independent cohort of participants.  
3.2 Hypothesis and aims  
The overall objective of this study was to validate the results of the pilot study in a larger  
independent cohort of participants.   
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This study hypothesised:  
1. A general linear model of multivariate logistic regression would generate a risk prediction 
model with similar sensitivity and specificity to the pilot study risk prediction model, 
identifying TLR2 rs384100 and TNF rs1800629 SNPs, in conjunction with colorectal and 
upper GI cancer types, to be predictive for severe GI toxicity risk.  
Aims 
1. To identify which participant clinical data (5-FU-based regimen, type of cancer, sex, age 
and number of treatment cycles) were significantly associated with severe GI toxicity using 
logistic regression (P < 0.05).  
2. To identify which SNPs in TIR domain pathway genes TLR2, TLR4, IL1B, IL2, IL6, IL6R, 
IL10, TGFB, TNF, MYD88, MD2, CASP1 and CASP5 as well as OPRM1 and CRP were 
significantly associated with severe GI toxicity using logistic regression (P < 0.05).  
3. To determine the combined impact of clinical and genetic factors on severe GI toxicity 
using models of multivariate logistic regression.  
A target sample size of 150 participants (45 who reported severe GI toxicity) was determined as 
providing 99 % power at alpha = 0.05 to predict severe GI toxicity risk. Participants for this study 
were recruited from the Flinders Medical Centre (FMC) in addition to a new recruitment site, the 
Royal Adelaide Hospital (RAH), both located in Adelaide, South Australia, Australia.  
3.3 Materials and Methods 
3.3.1 Reagents 
Ethanol (100 %) was obtained from Chem-Supply Pty Ltd (SA, Australia). Ethanol (75 %) was 
achieved by diluting ethanol (100 %) with Milli-Q® obtained from Merck (Darmstadt, Germany). 
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Sodium acetate was obtained from Merck (Darmstadt, Germany) and diluted to 3 M with Milli-Q®. 
Chloroform (stabilised with ethanol, Multisolvent® HPLC grade) was obtained from Scharlab 
(Barcelona, Spain).  
3.3.2 Ethics approval 
This study was approved by both the Southern Adelaide Clinical Human Research Ethics 
Committee (HREC/12/SAC/519) and the Royal Adelaide Hospital Human Ethics Committee 
(SSA/14/RAH/519). All participants provided informed written consent prior to participating in 
accordance with the Declaration of Helsinki. 
3.3.3 Participant recruitment 
This was a retrospective cohort study. 2185 potential participants who received 5-FU-based or 
capecitabine chemotherapy regimens between January 2012 and January 2018 were identified 
from pharmacy dispensary records obtained from FMC and RAH (Figure 3.1). 243 potential 
participants were mailed a letter of invitation to participate in the study. 170 responded to the 
invitation and were subsequently telephone screened to ensure they met eligibility criteria and fully 
understood the study. Exclusion criteria included; not fluent in the spoken English language, having 
a pre-existing medical condition associated with GI damage (i.e. Crohn’s Disease or Ulcerative 
Colitis), still receiving chemotherapy treatment, unwilling to consent to providing a saliva sample 
or having their clinical records reviewed. Following this check, 168 eligible participants were 
enrolled in the study and mailed a saliva collection kit (DNA Genotek Inc., Ontario, Canada) and 
study consent forms. 155 participants collected their own saliva and returned the sample and 
consent forms in a reply-paid envelope. Following receipt of the saliva sample, participants’ clinical 
medical records were reviewed to obtain clinical demographics, participant comorbidities, 
treatment and toxicity data. Participants were further screened for exclusion from the study if they 
were not Caucasian, had received concurrent radiation therapy or received a blood transfusion 
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throughout their 5-FU-based therapy. However, none were excluded on these criteria.  
  


















Figure 3.1 Flow diagram of the recruitment process. Grey text indicates the exclusion of 
participants. 
Deceased potential participants 
were removed from dispensary 
records 
Genotyping repeatedly failed 
for 4 participants 
Potential participants who did not 
meet eligibility criteria were 
excluded from the study 
170 potential participants responded to 
the letter of invitation and were 
telephone screened 
155 participants returned the saliva 
collection kit and consent forms. 
Participant medical records were 
reviewed and DNA was extracted from 
saliva sample 
       Toxic = 30 participants 
  ≥ 3 on the CTCAE v 4.03 or v 5.01  
  Hospitalised as a direct result of GI toxicity  
  5-FU or capecitabine dose reduction due to the 
presence of GI toxicity symptoms  
  Ceased treatment prematurely as a direct result 
of GI toxicity  
243 potential participants were mailed a 
letter of invitation to participate in the study 
 
Pharmacy dispensary records identified 
2185 potential participants who received 
5-FU-based therapy 
168 eligible participants were mailed a 
saliva collection kit and consent forms 
DNA samples for 155 participants were 
sent for genotyping 
       Non-toxic = 125 participants  
  ≤ 2 on the CTCAE v 4.03 or v 5.01 
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3.3.4 GI toxicity classification  
Clinical oncology staff at the FMC and RAH used the NCI CTCAE v 4.03 or v 5.0 to report and 
grade adverse events experienced by participants during chemotherapy treatment; this is recorded 
in participants’ clinical medical records (Table 3.1) [10]. Participants were classified into two GI 
toxicity groups for analysis. Participants classified as ‘non-toxic’ reported no GI toxicity (grade 0) 
or, mild to moderate GI toxicity (diarrhoea, mucositis, nausea and/or vomiting graded as 1 or 2 on 
the CTCAE v 4.03 or 5.0) (Table 3.1) [10]. Participants classified as ‘toxic’ reported severe GI 
toxicity (diarrhoea, mucositis, nausea and/or vomiting graded as ≥ 3 on the CTCAE v 4.03 or v 5.0) 
or, were hospitalised, received a 5-FU or capecitabine dose reduction or, ceased treatment 
prematurely as a direct result of GI toxicity. This classification of GI toxicity has previously been 




Table 3.1 NCI CTCAE v 4.03 and v 5.0 classification of GI toxicity during chemotherapy treatment [10]. Blue highlighted boxes indicate mild to moderate GI toxicity 
symptoms whereas red highlighted boxes indicate severe GI toxicity symptoms.  
 
Gastrointestinal Disorders 




Increase of < 4 stools per 
day over baseline. Mild 
increase in ostomy output 
compared to baseline. 
Increase of 4-6 stools per 
day over baseline. 
Moderate increase in 
ostomy output compared 
to baseline.  
Increase of ≥ 7 stools per 
day over baseline. 
Incontinence, 
hospitalisation indicated, 
severe increase in ostomy 




intervention indicated.  
Death 
Vomiting 
1-2 episodes (separated 
by 5 min) in 24 h.  
3-5 episodes (separated 
by 5 min) in 24 h.  
≥ 6 episodes (separated 
by 5 min) in 24 h. Tube 
feeding, hospitalisation.  
Life-threatening 
consequences: Urgent 
intervention indicated.  
Death 
Nausea 
Loss of appetite without 
alteration in eating habits. 
Oral intake decreased 
without significant weight 
loss, dehydration or 
malnutrition.  
Inadequate oral caloric or 




Oral Mucositis  
(Ulceration of the 
oral mucosa)  
Asymptomatic or mild 
symptoms. Intervention 
not indicated.  
Moderate pain. Not 
interfering with oral intake, 
modified diet indicated.  
Severe pain. Interfering 




intervention indicated.  
Death 
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3.3.5 DNA extraction from participant saliva samples  
Genomic DNA was isolated and purified from a 500 L sample of participants’ saliva using the 
prepIT-L2P DNA extraction kit according to manufacturer’s instructions (DNA Genotek Inc., ON 
Canada). Prior to extraction, saliva was incubated at 72°C for at least 2 h. Following incubation, 
500 L of saliva was added to 25 L of PT-L2P, mixed by vortex and incubated on ice for 10 min. 
Following incubation, the sample was centrifuged at room temperature for 15 min at 15,000 x g. 
Supernatant was collected in a new microcentrifuge tube and 600 L of 100 % ethanol was added. 
The sample was mixed by inversion 10 times and left to stand at room temperature for 10 min to 
allow DNA precipitation. The sample was centrifuged at room temperature for 2 min at 15,000 x g. 
Supernatant was carefully removed, leaving the DNA pellet, and a further 250 L of 75 % ethanol 
was added. The sample was left to stand at room temperature for 1 min prior to further 
centrifugation at room temperature for 2 min at 15,000 x g. Supernatant was carefully removed and 
the DNA pellet was left overnight at room temperature to allow the evaporation of any residual 
ethanol. The DNA pellet was resuspended in 100 L nuclease free water and DNA concentration 
and purity were quantified by spectrophotometry using the Synergy™️ Mx Microplate Reader 
(BioTek Instruments, VT USA).  
3.3.6 Genotyping  
Following spectrophotometry, DNA was diluted to a concentration of 10 ng.L-1 and sent to the 
Australian Genome Research Facility (AGRF) for genetic analysis. Genotyping for 21 SNPs was 
conducted by a previously established [25] customised Sequenom MassArray (iPLEX GOLD) 
assay. 19 SNPs in genes within TIR domain innate immune signalling pathway as well as, 2 SNPs 
in genes encoding the mu opioid receptor (OPRM1) and C-reactive protein (CRP) were 
also analysed (Table 3.2).  
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Table 3.2 SNPs analysed in the Sequenom MassArray assay [25, 73]a.  
Gene rs ID Type of variant Base pair change MAF 
IL1B 
rs16944 Upstream variant A > G 0.65 
rs1143627 5’-UTR  G > A 0.64 
rs1143634 Synonymous G > A 0.24 
IL2 rs2069762 Upstream variant A > C 0.29 
IL6 rs10499563 Not reported T > C 0.22 
IL10 
rs1800871 Upstream variant A > G 0.76 
rs1800896 Upstream variant T > C 0.45 
IL6R rs8192284 Missense A > C 0.36 
TGFB 
rs1800469 Upstream variant A > G 0.68 
rs11466314 Upstream variant C > T 0.00 
TNF rs1800629 Upstream variant G > A 0.13 
TLR2 rs3804100 Synonymous  T > C 0.06 
TLR4 
rs4986790 Missense A > G 0.05 
rs4986791 Missense C > T 0.05 
MYD88 rs6853 3’-UTR A > G 0.13 
MD2 rs11466004 Missense C > G 0.02 
CASP1 rs580253 Synonymous G > A 0.17 
CASP5 rs554344 Upstream variant G > C 0.17 
OPRM1 rs1799971 Missense A > G 0.16 
CRP rs2794521 Upstream Variant C > T 0.71 
BDNF rs6265 Missense C > T 0.19 
a >: change; 3’-UTR: 3’ untranslated region; 5’-UTR: 5’ untranslated region; MAF: MAF sourced from 1000 
genomes European Caucasian population as reported on dbSNP [73].  
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3.3.7 Chloroform clean-up of DNA that failed genotyping  
For DNA samples that failed genotyping due to low DNA quality (n = 20), DNA was re-extracted 
from participant saliva samples and chloroform cleaned to improve DNA quantity and quality. 
Following DNA extraction (as previously described), 5 L of chloroform was added to the 
resuspended DNA pellet, vortexed for 30 sec and centrifuged at room temperature for 15 min at 
15,000 x g. The aqueous layer was carefully transferred to a new microcentrifuge tube and, 2.1 
times the volume of 20:1 100 % ethanol: 3 M sodium acetate solution was added. The 
microcentrifuge tube was inverted 3 times, vortexed for 10 sec and centrifuged for 5 min at 15,000 
x g. Supernatant was removed without disturbing the DNA pellet and 250 L of 70 % ethanol was 
added. The sample was vortexed at 2/3 power for 30 sec and centrifuged for a further 5 min at 
15,000 x g. Supernatant was carefully removed and the DNA pellet was left overnight to allow the 
evaporation of any residual ethanol. The DNA pellet was resuspended in 100 L nuclease free 
water and DNA concentration and purity were quantified by spectrophotometry using the Synergy 
Mx Microplate Reader. DNA was diluted to a concentration of 10 ng.L-1 and sent to the AGRF for 
repeat genetic analysis.  
3.4 Statistical analysis  
3.4.1  Participant demographics and clinical data  
Chi-square or Fisher’s exact tests were used to examine differences in sex, type of cancer and 
5-FU-based regimen between participants classified as non-toxic or toxic within the pilot [25], 
interim and final participant cohorts. In addition, Mann-Whitney U tests examined differences in 
age and number of treatment cycles between the two participant groups for each cohort. 
Additionally, Chi-square and Mann-Whitney U tests also determined differences in the non-toxic 
and toxic groups between the pilot [25], interim and final participant cohorts.  
  Chapter 3 
67 
3.4.2 Genetic analysis  
Hardy-Weinberg equilibrium analysis was used to ascertain whether the observed allele 
frequencies in the participant cohorts differed from expected (P > 0.05). Chi-square tests compared 
the MAFs within the pilot [25], interim and final participant cohorts to the global Caucasian 
population [73]. Due to multiple comparisons, P-values were adjusted for false discovery rate (FDR) 
and considered significant if the FDR-corrected P-values was ≤ 0.05. The MAF for SNPs identified 
as predictive in the pilot [25], interim and final risk prediction models were also compared between 
non-toxic and toxic participants in the pilot [25], interim and final participant cohorts using Chi-
square tests (FDR-corrected P ≤ 0.05).  
3.4.3 Interim risk prediction model 
Due to the large amount of time taken to reach the target sample size of 150, an interim risk 
prediction model was produced with 105 participants. The interim risk prediction model was built 
using multivariate logistic regression on the statistical program R [104]. The model was built with 
step-wise addition of individual covariates (SNPs, 5-FU-based regimen, type of cancer, sex, 
hospital, age and number of treatment cycles) to the risk prediction model. If the covariate improved 
the model, determined by ANOVA analysis (P < 0.05), it remained in the model and was identified 
as predictive for severe GI toxicity risk.  
3.4.4 Final risk prediction models 
For the final risk prediction models, a more comprehensive statistical modelling method was used 
to build the risk prediction models in comparison to the interim risk prediction model. General linear 
models of multivariate logistic regression were used once again to build multiple risk prediction 
models for GI toxicity risk also using R [104].  
As well as building a model of multivariate logistic regression producing a final risk prediction model 
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for severe GI toxicity in the final participant cohort, several additional models were also investigated 
to further explore the data. These were:  
 Risk of severe GI toxicity in participants who received 5-FU-based therapy for either 
colorectal or upper GI cancer (83 participants were treated for colorectal and upper GI 
cancer, n = 83). As colorectal and upper GI cancer types were identified as predictive for 
severe GI toxicity risk in the pilot risk prediction model [25], this model was investigated to 
determine significant predictors for severe GI toxicity in participants who were treated for 
colorectal or upper GI cancer.  
 Risk of severe GI toxicity risk in the participant cohort with the exclusion of participants 
who reported grade 2 GI toxicity (155 participants minus 37 participants with grade 2 GI 
toxicity, n = 118). As grading of GI toxicity can be ambiguous and in some medical records 
the grade of GI toxicity reported was not clear, it was possible some participants were 
reported as developing grade 2 instead of grade 3 GI toxicity. This model was investigated 
excluding participants who developed grade 2 GI toxicity to determine if any potential 
ambiguity would lead to the production of a risk prediction model that is different to that 
produced in the final participant cohort.  
 Risk of severe GI toxicity between participants who received 5-FU-based therapy at FMC 
(n = 107) or the RAH (n = 48). As GI toxicity reporting procedures differed across both 
hospitals, it was investigated if these differences had any significant effect on identifying 
significant predictors for severe GI toxicity.  
Firstly, for each model, individual predictors (such as SNPs, treatment regimen, type of cancer, 
sex, age and number of treatment cycles) were identified using logistic regression. Due to multiple 
comparisons, P-values were corrected using the false discovery rate (FDR-corrected P < 0.05). 
Any significant predictors were included in the model of multivariate logistic regression, with 
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step-down removal of predictors that did not improve the model with the final risk prediction model 
having the lowest Akaike information criterion score. The ROC AUC assessed the ability of the risk 
prediction models to identify participants with different grades of toxicity in comparison to the 
observed number of participants with that grade of toxicity. A ROC curve is the plot of sensitivity 
(true positive rate) against 100-specifcity (false positive rate) for different cut-off points of a 
parameter [105]. The AUC measured the overall fit of the model [105]. If no significant predictors 
were identified in the first instance, then no model of multivariate logistic regression and risk 
prediction model was built.  
3.5 Participant results  
3.5.1 Diarrhoea was the most frequent severe GI toxicity symptom experienced in both interim 
and final participant cohorts 
A breakdown of GI toxicity symptoms experienced by participants in both interim and final 
participant cohorts are presented in Table 3.3. Some participants reported more than one GI 
toxicity symptom throughout their 5-FU-based therapy. Of the 105 participants in the interim cohort, 
24 (23 %) reported severe GI toxicity and were classified as toxic. With the addition of 50 
participants (44 non-toxic and 6 toxic) the final participant cohort was n = 155; the overall 
percentage of participants classified as toxic reducing by 4 % (Table 3.3). In both participant 
cohorts, diarrhoea was the most commonly experienced severe GI toxicity symptom (Table 3.3).  
 
   
 
Table 3.3 GI toxicity symptoms reported by participants in the interim (n = 105) and final (n = 155) cohorts throughout their 5-FU-based therapy. Data is presented 
as n (%). Some participants reported more than one GI toxicity symptom throughout their 5-FU-based therapy.  
 
Grade [10] 
Highest GI toxicity grade 













0 12 (11%) 22 (14%) 49 (47%) 74 (48%) 26 (25%) 44 (28%) 54 (51%) 81 (52%) 
1 48 (46%) 66 (43%) 40 (38%) 58 (37%) 46 (44%) 62 (40%) 30 (29%) 44 (28%) 





3 24 (23%) 30 (19%) 5 (5%) 7 (5%) 11 (10%) 13 (8%) 15 (14%) 19 (12%) 
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3.5.2 Clinical data was significantly different between non-toxic and toxic participants in the 
interim and final cohorts  
In both interim and final participant cohorts, cancer type (P = < 0.001 and P = 0.002, respectively) 
and 5-FU-based regimen (P = 0.002 and P < 0.001, respectively) were significantly different 
between non-toxic and toxic participants (Table 3.4). Toxic participants in both interim and final 
cohorts were more likely to have had colorectal cancer compared to non-toxic participants, who 
were more likely to have had breast cancer. The significant differences in 5-FU-based regimen 
between non-toxic and toxic participants in both participant cohorts was likely a direct result of 
cancer type.  
Sex was identified as significantly different between non-toxic and toxic participants in the interim 
cohort (P = 0.01) however, was not significantly different between the two participant groups in the 
final participant cohort (Table 3.4). In contrast, with the addition of 50 participants to the final 
participant cohort, significant differences were identified in age (P = 0.002) and number of treatment 
cycles (P = 0.032) between non-toxic and toxic participants (Table 3.4).  
 
   
 
Table 3.4 Participant demographics and clinical data from the pilot (n = 34), interim (n = 105) and final (n = 155) cohorts. Data is presented as n (%) or median 
(range)b. 
  
 Pilot cohort [25] Interim cohort Final cohort 
 Non-toxic 
(n = 24) 
Toxic 
(n = 10) 
P-value 
Non-toxic 
(n = 83) 
Toxic 
(n = 22) 
P-value 
Non-toxic 
(n = 125) 
Toxic 




 Female 18 (75%) 4 (40%) 
0.110 
61 (73%) 10 (45%) 
0.010* 
82 (66%) 16 (53%) 
0.061 






(39 – 80) 
66 
(48 – 78) 
0.780 
61 
(32 – 86) 
68 
(28 – 78) 
0.080 
61 
(32 – 78) 
68 








e Breast 12 (50%) 1 (10%) 
0.057 
53 (64%) 4 (18%) 
< 0.001* 
66 (52.8%) 6 (20%) 
< 0.001* Colorectal 11 (46%) 7 (70%) 28 (34%) 15 (68%) 52 (41.6%) 21 (70%) 











 5-FU monotherapy  4 (16.7%) 2 (20%) 
0.800 
10 (12%) 5 (23%) 
0.002* 
17 (14%) 6 (20%) 
< 0.001* 
Mayo  4 2 10 5 17 6 
5-FU combination 17 (70.8%) 6 (60%) 67 (81%) 10 (45%) 99 (79%) 15 (50%) 
DECO 0 0 0 0 1 0 
ECF 0 2 1 1 2 1 
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FOLFOX4  2 1 8 2 14 4 
FOLFOX 6 3 2 5 1 17 3 
Capecitabine 3 (12.5%) 2 (20%) 6 (7%) 7 (32%) 9 (7%) 9 (30%) 
Capecitabine 3 2 4 6 7 6 







(3 – 12) 
5 
(2 – 30) 
0.180 
5 
(2 – 30) 
8 
(2 - 30) 
0.076 
6 
(2 – 30) 
8 







 FMC 24 (100%) 10 (100%) 
- 
54 (65%) 15 (68%) 
> 0.999 
86 (69%) 21 (70%) 
> 0.999 
RAH - - 29 (35%) 7 (32%) 39 (31%) 9 (30%) 
b 5-FU monotherapy: 5-FU administered with folinic acid as part of the Mayo regimen; 5-FU combination: 5-FU administered as part of a regimen such as DECO (docetaxel, cisplatin, 
5-FU), ECF (epirubicin, cisplatin, 5-FU), EOF (epirubicin, oxaliplatin, 5-FU), FEC (5-FU, epirubicin, cyclophosphamide) or FOLFOX (5-FU, oxaliplatin, folinic acid); Capecitabine: 
Capecitabine monotherapy or XELOX (capecitabine and oxaliplatin); Cycles: Number of treatment cycles received; FMC: Flinders Medical Centre; RAH: Royal Adelaide Hospital. 
 
73 
  Chapter 3 
74 
3.5.3 Comparison of demographic and clinical characteristics of the non-toxic and toxic 
participant cohorts  
There were no significant differences in non-toxic participants between the pilot [25], interim and 
final cohorts (P > 0.05) (Table 3.5) [25]. However, there were significant differences in 5-FU-based 
regimen between toxic participants in the pilot, interim and final cohorts (P < 0.001) (Table 3.5). 
5-FU-based combination regimens were the most commonly administered in the toxic population 
across all three participant cohorts (Table 3.4). However, the percentage of toxic participants who 
received capecitabine regimens compared to 5-FU monotherapy was increased in the interim and 
final participant cohorts in comparison to the pilot participant cohort (Table 3.4).  
 
   
 
Table 3.5 Comparison of demographic and clinical data between non-toxic and toxic participants in the pilot (n = 34), interim (n = 105) and final (n = 155) 
cohorts. 
 Sex Age Cancer type 5-FU-based regimen Cycles 
 Chi-square P-value P-value Chi-square P-value Chi-square P-value P-value 
Non-toxic 
(Pilot vs Interim vs Final) 
2.240 0.326 0.411 5.061 0.281 3.534 0.473 0.310 
Toxic 
(Pilot vs Interim vs Final) 
3.406 0.182 0.303 6.794 0.142 55.350 < 0.001* 0.550 
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3.6 Genetic analysis  
Hardy-Weinberg equilibrium analysis revealed no deviation between observed and expected MAF 
in the interim or final participant cohorts therefore, the results of the SNP assays were reliable 
(P > 0.05). Hardy-Weinberg equilibrium was also not significant for SNP assays in the pilot 
participant cohort [25].  
3.6.1 The MAF for SNPs in IL1B, TGFB and CRP were not reflective of the general Caucasian 
population  
Chi-square tests identified the MAF for IL1B rs16944 and rs1143627, TGFB rs1800469 and CRP 
rs2794521 SNPs were lower in the pilot, interim and final participant cohorts in comparison to the 
general 1000 genomes and GnomAD European Caucasian population (FDR-corrected P < 0.001) 
(Table 3.6). The MAF of remaining SNPs was reflective of the general 1000 genomes and 
GnomAD European Caucasian population.  
 
   
 
Table 3.6 MAFs of investigated SNPs in the pilot (n = 34), interim (n = 105) and final (n = 155) cohorts compared to the European Caucasian population from 
1000 Genomes and GnomAD [73]c.  









Pilot cohort  
(n = 34) 
Interim cohort 
(n = 105) 
Final cohort 
(n = 155) 
IL1B 
rs16944 0.65 0.65 0.29 0.37 0.37 47.07 < 0.001* 
rs1143627 0.65 0.65 0.29 0.38 0.37 46.30 < 0.001* 
rs1143634 0.24 0.24 0.24 0.23 0.24 0.044 0.998 
IL2 rs2069762 0.29 0.30 0.34 0.30 0.28 0.987 0.998 
IL6 rs10499563 0.22 0.19 0.25 0.28 0.30 4.225 0.998 
IL10 
rs1800871 0.24 0.23 0.25 0.25 0.23 0.219 0.998 
rs1800896 0.45 0.47 0.46 0.49 0.49 0.513 0.998 
IL6R rs8192284 0.36 0.38 0.38 0.43 0.43 1.723 0.998 
TGFB 
rs1800469 0.68 0.70 0.34 0.28 0.29 73.190 < 0.001* 
rs11466314 0.00 0.00 0.00 0.00 0.00 - - 77 
   
 
TNF rs1800629 0.13 0.16 0.19 0.16 0.17 1.385 0.998 
TLR2 rs3804100 0.06 0.06 0.09 0.04 0.04 3.075 0.998 
TLR4 
rs4986790 0.06 0.06 0.01 0.06 0.05 3.493 0.998 
rs4986791 0.05 0.07 0.03 0.07 0.06 2.119 0.998 
MD2 11466004 0.02 0.02 0.01 0.02 0.01 0.762 0.998 
MYD88 rs6853 0.13 0.12 0.10 0.15 0.16 1.990 0.998 
CASP1 rs580253 0.17 0.17 0.21 0.20 0.17 1.012 0.998 
CASP5 rs554344 0.17 0.17 0.21 0.19 0.15 1.422 0.998 
OPRM1 rs1799971 0.16 0.14 0.14 0.12 0.12 0.953 0.998 
CRP rs2794521 0.71 0.74 0.35 0.34 0.36 68.74 < 0.001* 
BDNF rs6265 0.20 0.18 0.21 0.19 0.19 0.3326 0.998 
c - : no chi-square calculation possible. A single Chi-square test examined the difference between the MAFs reported by 1000 genomes, GnomAD and the pilot, interim and final cohorts for 
each SNP with the P-values obtained FDR-corrected to account for multiple comparisons.  
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3.6.2 MAFs for TNF rs1800629, TLR2 rs384100 and IL1B rs16944 were compared between 
the pilot, interim and final participant cohorts.  
SNPs in TNF rs1800629 and TLR2 rs384100 were identified as significantly predictive for severe 
GI toxicity risk in the pilot study risk prediction model [25] whilst, SNPs in IL1B rs1143634 and 
rs16944 SNPs were identified as significantly predictive for severe GI toxicity in the interim r isk 
prediction model. Therefore, the MAFs for these TNF, TLR2 and IL1B SNPs were compared 
between the pilot, interim and final participant cohorts. 
The MAF for TNF rs1800629 and TLR2 rs384100 was significantly increased in toxic participants 
of the pilot cohort compared to toxic participants of the interim and final cohort 
(FDR-corrected P = 0.016 and 0.004, respectively) (Table 3.7). Similarly, the MAF for IL1B rs16944 
was significantly increased in toxic participants of the interim cohort compared to the pilot and final 
cohorts (FDR-corrected P = 0.004) (Table 3.7).  
There were no significant differences in the MAF for TNF rs1800629, TLR2 rs384100 and IL1B 
rs16944 in non-toxic participants between the pilot, interim and final cohorts (Table 3.7).  
 
    
 
Table 3.7 Comparison of MAFs for SNPs identified as significantly predictive in the pilot study risk prediction model and the interim risk prediction model between 
the pilot, interim cohort and final cohorts. 
Gene rs ID 
MAF for Non-toxic participants 
Chi-square 
FDR-corrected 
P-value Pilot cohort 
(n = 24) 
Interim cohort 
(n = 83) 
Final cohort 
(n = 125) 
TNF rs1800629 0.15 0.16 0.17 0.149 0.928 
TLR2 rs3804100 0.04 0.05 0.04 0.1608 0.928 
IL1B 
rs16944 0.27 0.35 0.35 1.950 0.928 
rs1143634 0.25 0.19 0.24 1.179 0.928 
 
Gene rs ID 
MAF for Toxic participants 
Chi-square 
FDR-corrected 
P-value Pilot cohort 
(n = 10) 
Interim cohort 
(n = 22) 
Final cohort 
(n = 30) 
TNF rs1800629 0.30 0.13 0.20 8.800 0.016* 
TLR2 rs3804100 0.20 0.02 0.04 24.59 0.004* 
IL1B 
rs16944 0.25 0.47 0.45 3.386 0.004* 
rs1143634 0.20 0.34 0.27 1.365 0.078 
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3.7 Risk prediction models  
3.7.1 The interim risk prediction model identified IL1B SNPs in conjunction with cancer type to 
be predictive for severe GI toxicity 
In the interim cohort, a general linear model of multivariate logistic regression built a risk prediction 
model for severe GI toxicity identifying IL1B SNPs rs16944 and rs1143634 in conjunction with 
colorectal and upper GI cancer types as predictive for severe GI toxicity, with a ROC AUC of 82 % 
(P < 0.001) (Figure 3.2). Individually, cancer type had a ROC AUC of 73 % (P = 0.012) and IL1B 
SNPs rs16944 and 1143634 had a ROC AUC of 69 % (P = 0.016) (Figure 3.2). As seen, the 
inclusion of IL1B SNPs rs16944 and 1143634 and cancer type gave a more informative, sensitive 
and specific risk prediction model for severe GI toxicity compared to using SNPs alone or cancer 
type alone (Figure 3.2).  
  










Figure 3.2 The interim risk prediction model for severe GI toxicity. The model identified IL1B 
rs16944 and rs1143634 SNPs (blue) and colorectal and upper GI cancer types (green) to be 
predictive for severe GI toxicity. Using both genetics and cancer type as predictors improved the 
risk prediction model (red). 















1 - specificity 
ROC AUC 82% (P < 0.001)  
ROC AUC 73% (P = 0.012) 
ROC AUC 69% (P = 0.016) 
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3.7.2 The final risk prediction model identified 5-FU-based regimen to be predictive for severe 
GI toxicity 
At the end of the recruitment period, a final risk prediction model was completed encompassing all 
155 participants. Firstly, logistic regression identified individual predictors cancer type 
(FDR-corrected P = 0.047) and 5-FU-based regimen (FDR-corrected P = 0.047) to be associated 
with severe GI toxicity. No SNPs were identified as individual predictors. These significant 
predictors were then both included in the model of multivariate logistic regression. The inclusion of 
cancer type was not significant (FDR-corrected P > 0.05). Subsequently, this was removed from 
the risk prediction model, leaving 5-FU-based regimen with the lowest Akaike information criterion 
score. The final risk prediction model produced identified 5-FU-based regimen as predictive for 
severe GI toxicity, with a ROC AUC of 66 % (P = 0.028) (Figure 3.3).  
A separate risk prediction model including predictors identified to be associated with severe GI 
toxicity from the pilot study (cancer type, TLR2 rs3804100 and TNF rs1800629) was also built 
(Figure 3.3) [25]. The inclusion of TLR2 rs3804100 and TNF rs1800629 was not significant 
(FDR-corrected P > 0.05) in the final participant cohort and therefore, were removed from the risk 
prediction model, leaving cancer type with the lowest Akaike information criterion score. The risk 
prediction model produced identified cancer type as predictive for severe toxicity, with a ROC AUC 
of 66 % (P = 2.35 x 10-8) (Figure 3.3). Participants who had colorectal cancer were at a higher risk 
of developing severe GI toxicity compared to participants who had breast cancer (P = 0.003). No 
associations were determined with upper GI cancer.  
  









Figure 3.3 Risk prediction models for severe GI toxicity in the final participant cohort (n = 155). 
The validation risk prediction model (green) identified 5-FU-based regimen to be predictive for 
severe GI toxicity. A risk prediction model (red) including the significant predictors (TNF rs1800629, 
TLR2 384100 and cancer type) identified in the pilot study was also produced.  
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3.7.3 The risk prediction model excluding participants with grade 2 GI toxicity identified 
5-FU-based regimen and cancer type to be predictive for severe GI toxicity 
To determine if the ambiguity of GI toxicity grading was masking significant predictors for severe 
GI toxicity, another risk prediction model was produced excluding participants who reported grade 
2 GI toxicity form the analysis (n = 118). Similarly, logistic regression identified individual predictors 
cancer type (FDR-corrected P = 0.027) and 5-FU-based regimen (FDR-corrected P = 0.027) to be 
associated with severe GI toxicity. No SNPs were identified as individual predictors. These 
significant predictors were then included in the model of multivariate logistic regression and 
together, they produced the lowest Akaike information criterion score. The risk prediction model 
produced a ROC AUC of 74 % (P = 0.005) (Figure 3.4). Participants who had colorectal and upper 
GI cancer were at a higher risk of developing severe GI toxicity compared to participants who had 
breast cancer (P = 0.045 and P = 0.024, respectively). Likewise, participants who received a 
capecitabine regimen were at higher risk of developing severe GI toxicity compared to participants 
whom had received a 5-FU monotherapy regimen. No significant associations were determined 
with 5-FU-based combination regimens.  
Once again, a separate risk prediction model including the predictors identified to be associated 
with severe GI toxicity from the pilot study (cancer type, TLR2 rs3804100 and TNF 1800629) was 
also built with the exclusion of participants who reported grade 2 GI toxicity (Figure 3.4) [25]. The 
inclusion of TLR2 rs3804100 and TNF 1800629 was not significant (FDR-corrected P > 0.05) and 
therefore, was removed from the risk prediction model, leaving cancer type with the lowest Akaike 
information criterion score. The risk prediction model produced identified cancer type as predictive 
for severe GI toxicity, with a ROC AUC of 68 % (P = 1.2 x 10-6) (Figure 3.4). Participants whom 
had colorectal cancer were at a higher risk of developing severe GI toxicity compared to 
participants whom had breast cancer (P = 0.002).   











Figure 3.4 Risk prediction models for severe GI toxicity with the exclusion of participants who 
reported grade 2 GI toxicity (n = 118). The risk prediction model (green) identified 5-FU-based 
regimen and cancer type to be predictive for severe GI toxicity. A risk prediction model (red) 
including the significant predictors (TNF rs1800629, TLR2 384100 and cancer type) identified in 
the pilot study was also produced. 
 












1 - specificity 
ROC AUC 74% (P = 0.005)  
ROC AUC 68% (P = 1.2 x 10-6)  
Risk prediction 
model minus 
grade 2 GI toxicity 
Risk prediction 
model minus 
grade 2 GI toxicity 
with pilot 
predictors  
  Chapter 3 
 87 
3.7.4 No significant predictors were identified for severe GI toxicity in participants who were 
treated for colorectal or upper GI cancer  
To determine if there were any significant predictors for severe GI toxicity risk in participants with 
colorectal and upper GI cancer, another risk prediction model was investigated for participants who 
were treated for these cancer types (n = 83). Logistic regression did not identify individual 
predictors to be associated with severe GI toxicity (FDR-corrected P > 0.05). Therefore, no model 
of multivariate logistic regression and final risk prediction model was built. 
3.7.5 No significant predictors were identified for severe GI toxicity in participants treated at 
FMC or the RAH  
To determine if there were any significant predictors for each hospital site, another two risk 
prediction models were investigated in participants recruited from FMC (n = 107) or the RAH 
(n = 48). Logistic regression did not identify individual predictors to be associated with severe GI 
toxicity (FDR-corrected P > 0.05). Therefore, no model of multivariate logistic regression and final 
risk prediction model was built. 
3.8 Discussion  
Genetic variation within the TIR domain innate immune signalling pathway has previously been 
identified as predictive for severe GI toxicity risk following 5-FU-based therapy [25]. The objective 
of this study was to validate the results of a pilot study [25], that identified TLR2 rs384100 and TNF 
rs1800629 SNPs in conjunction with colorectal and upper GI cancer types to be predictive for 
severe GI toxicity risk in a larger independent cohort of participants. It is imperative a predictive 
marker for identifying patients at most risk of severe GI toxicity prior to receiving 5-FU-based 
therapy is identified. This would allow patients at most risk of severe GI toxicity to have their 
supportive care measures personalised, which may reduce the severity of GI toxicity experienced 
and may improve their quality of life throughout their 5-FU-based therapy.  
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This current study compared participant demographics, clinical data, genotype and, risk prediction 
models for severe GI toxicity within and between the interim and final participant cohorts, as well 
as, the participant cohort recruited in the pilot study [25]. Several significant differences exist 
between the pilot, interim and final participant cohorts, which may indicate reasons as to why the 
pilot, interim and final risk prediction models produced for severe GI toxicity were vastly different.  
Participant demographics and clinical data were identified to be either significantly different  
between toxic and non-toxic participants or, identified as predictive for severe GI toxicity risk in the 
pilot [25], interim or final participant cohorts. Cancer type, in particular colorectal and upper GI 
cancer types, were identified as predictive for severe GI toxicity risk in both the pilot and interim 
risk prediction models. Although, significant differences in cancer type between non-toxic and toxic 
participants were only identified in the interim and final participant cohorts. Likewise, 5-FU-based 
regimen was also significantly different between non-toxic and toxic participants in the interim and 
final participant cohorts yet, was only identified as predictive for severe GI toxicity risk in the final 
risk prediction model.  
The 5-FU-based regimen administered to participants in this study was specific to cancer type. 
Therefore, it was not surprising both cancer type and 5-FU-based regimen were consistently 
associated with severe GI toxicity risk in the pilot, interim and final participant cohorts. Due to the 
dosage and frequency of administration, 5-FU-based regimens administered to treat colorectal and 
upper GI cancers are known to increase the risk of severe GI toxicity [1, 41]. 5-FU monotherapy in 
addition to 5-FU combination regimens administered for colorectal and upper GI cancers include a 
single bolus dose as well as a continuous intravenous infusion (usually over a 24 - 48 h period) of 
5-FU with one cycle spanning either 7 or 14 days [41]. In comparison, 5-FU-based combination 
regimens administered for breast cancer include a single bolus dose of 5-FU with one cycle 
spanning 21 days [41]. The higher exposure to 5-FU in regimens administered for colorectal and 
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upper GI cancers is likely to increase the risk of severe GI toxicity [1, 41]. However, when 
participants who received treatment for colorectal or upper GI cancer from the final participant 
cohort were analysed in a separate risk prediction model, no significant predictors for severe GI 
toxicity risk were identified. This suggests predictors for severe GI toxicity risk are highly specific 
for patient cohorts, particularly across cancer types and 5-FU-based regimens.  
Additional participant demographics sex, age and number of treatment cycles were significantly 
different between non-toxic and toxic participants in the interim (sex) and final (age and number of 
treatment cycles) participant cohorts. However, sex, age and number of treatment cycles were not 
identified as predictive for severe GI toxicity risk in either the interim or final risk prediction models. 
Contradictory and inconsistent findings have previously surrounded the association of age and sex 
with severe GI toxicity risk [11-14]. In a large cohort of patients receiving 5-FU-based therapy for 
colorectal and upper GI cancer, no significant relationship was identified between severe GI toxicity 
symptoms and advanced age or sex [14]. In comparison, in a similar size cohort of patients 
receiving 5-FU-based therapy, increasing age was identified as an independent predictor for 
severe GI toxicity risk (P = 0.001) and, women developed higher counts of diarrhoea (P < 0.01) 
and vomiting (P = 0.03) than their male counterparts [11]. With regards to the impact of the number 
of treatment cycles in this current study, participants classified as toxic in the final participant cohort 
received significantly more treatment cycles compared to non-toxic participants. However, 
participants recruited in the final participant cohort reported GI toxicity symptoms within the first 
three cycles of treatment. Therefore, the relevance of this significant difference between the two 
toxicity groups is unclear. 
When comparing participant demographics and clinical data between the three participant cohorts, 
only a significant difference in 5-FU-based regimen between toxic participants was identified. Over 
the course of recruitment, some of the 5-FU-based regimens administered were discontinued 
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(i.e. Mayo) or superseded (i.e. FOLFOX4 to FOLFOX6) as it was consensus these regimens were 
‘too toxic’ for patients [41]. As a result, a shift towards prescribing other 5-FU-based regimens, 
such as those containing capecitabine, could possibly explain why capecitabine was the second 
most administered regimen amongst toxic participants in the interim and final participant cohorts 
whereas, only one toxic participant was administered capecitabine in the pilot participant cohort.  
When analysis shifted to genotype, significant differences in the MAF of TLR2 rs384100, TNF 
rs1800629, IL1B rs16944 and IL1B rs1143634 SNPs between toxic participants in the pilot, interim 
and final participant cohorts were identified. The in vitro and ex vivo effect of these TLR2, TNF and 
IL1B SNPs on gene expression and proinflammatory cytokine secretion has been discussed in 
Chapter 2 [106]. The interim risk prediction model was the first to associate IL1B rs16944 and 
rs1143436 SNPs with severe GI toxicity risk. However, following the addition of 50 participants 
(40 non-toxic and 10 toxic) to produce the final participant cohort, the MAF of IL1B rs16944 and 
rs1143436 SNPs decreased in the toxic population (0.47 vs 0.45 and 0.34 vs 0.27, respectively). 
This could be a possible explanation for why the predictive nature of individual SNPs for severe GI 
toxicity risk change between analyses. 
The genetic findings above demonstrate there was no consistent TIR domain SNP identified in the 
non-toxic or toxic groups across the three participant cohorts. Different SNPs were identified by 
the pilot and interim risk prediction models. It was observed as the genetic composition changed 
between studies or with the addition of new participants, the predictive nature of the SNPs also 
changed. Additionally, the MAF of IL1B rs16944, IL1B rs1143627, TGFB rs1800469 and CRP 
rs2794521 SNPs across all three participant cohorts was lower than what is observed in the 
Caucasian population [73]. This is especially relevant for IL1B rs16944, as the MAF in the interim 
participant cohort was almost half of what is observed in the Caucasian population.  
Aside from the pilot, interim and final risk prediction models identifying different predictors of severe 
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GI toxicity risk, their ROC AUCs were also different from one another. This indicates the pilot, 
interim and final risk prediction models were not equally sensitivity and specific. The closer the 
ROC AUC is to 100 %, the more sensitive and specific the risk prediction model is in determining 
which participants are at risk of severe GI toxicity [105]. The pilot risk prediction model reported 
the highest ROC AUC of 87 % [25], followed by the interim and final risk prediction models of 83 % 
and 66 %, respectively. As the number of participants included in the model increased, it became 
more difficult for the risk prediction model to accurately determine which participants were at risk 
of severe GI toxicity based on the predictors identified, signified by a lower ROC AUC. Although 
the pilot risk prediction model was more sensitive and specific compared to the interim and final 
risk prediction models, in a clinical setting, the pilot model may not be accurate in identifying 
patients at risk of severe GI toxicity as only 34 participants were included in the risk prediction 
model.  
Additional risk prediction models were also produced based on observations made throughout 
participant recruitment. As participants were recruited from two hospital sites, different medical 
oncologists were prescribing 5-FU-based regimens to participants. Therefore, it was possible bias 
was present if the prescribing medical oncologist preferred one 5-FU-based regimen over another. 
In addition, GI toxicity reporting procedures were different at both hospital sites. However, when 
participants in the final cohort were analysed based on hospital site, no significant predictors for 
severe GI toxicity risk at each hospital site were identified.  
Furthermore, a risk prediction model was built with the removal of participants who reported grade 
2 GI toxicity from the final participant cohort. As GI toxicity was graded by clinical oncology staff by 
comparing participant reported GI toxicity symptoms to the NCI CTCAE scale, GI toxicity grading 
may have been ambiguous. Potentially, some participants recruited to this study who were reported 
as developing severe GI toxicity (grade 3) may have been incorrectly reported as developing 
moderate GI toxicity (grade 2). These participants would have been wrongly classified as non-toxic 
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and analysed in the incorrect toxicity group. Additionally, some studies such as Wolff et al., 
classified grade 2 toxicity as severe due to the substantial impact grade 2 toxicity had on patient 
quality of life [107]. As my study was retrospective and toxicity data was collected from participant 
clinical medical records, it was difficult to determine if quality of life was substantially affected in 
participants who reported grade 2 GI toxicity. Therefore, grading classification was maintained with 
previous clinical work conducted in my laboratory [25, 103].  
The risk prediction model built with the exclusion of participants who reported grade 2 GI toxicity 
identified both cancer type and 5-FU-based regimen to be predictive for severe GI toxicity risk. It 
was further identified capecitabine and, colorectal and upper GI cancers, increased participants’ 
risk of severe GI toxicity. In comparison to the final risk prediction model, only 5-FU-based regimen 
was identified as significantly predictive for severe GI toxicity. No individual regimens or cancer 
types were determined to be more toxic than another. The ROC AUC was higher in this risk 
prediction model compared to the final risk prediction model (74 % vs 66 %), suggesting the 
removal of participants who reported grade 2 toxicity produces a more sensitive and specific 
predictive marker for accurately identifying participants at risk of severe GI toxicity.  
In this current study, there were a number of limitations which may have influenced the 
identification of a predictive marker for severe GI toxicity risk. Firstly, a sample size of 150 
participants (45 who reported severe GI toxicity) was initially determined as providing 99 % power 
at alpha = 0.05 to predict severe GI toxicity risk. Although the target sample size of 150 was 
exceeded, the breakdown between non-toxic (n = 125) and toxic (n = 30) participants did not 
adequately power the study. In addition, the calculated sample size of 150 participants was not 
adequate to ensure the MAF of all TIR domain SNPs of interest was reflective of the Caucasian 
population, with the MAF of some SNPs well below what is observed in the Caucasian population.  
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The clinical makeup of the participant cohort was also variable, with mixed cancer types and 
multiple 5-FU-based regimens included in analysis. This may have also influenced the identification 
of a predictive marker for severe GI toxicity risk as this risk is not equal across cancer types and 
5-FU-based regimens. This was evident when cancer type (colorectal and upper GI) was identified 
as predictive for severe GI toxicity risk in the pilot and interim risk prediction models yet, when 
participants with these cancer types were analysed separately, no predictors for severe GI toxicity 
risk were identified. This highlights the necessity for future research to investigate predictors for 
severe GI toxicity risk in individual cancer types. Participants were not able to be analysed based 
on cancer type or 5-FU-based regimen as to reach the target sample size and ensure the final risk 
prediction model was accurately powered, participants had to be analysed as a whole.  
The retrospective nature of this study was also a constraint and limits the clinical relevance of the 
predictive markers for severe GI toxicity identified in both the interim and final risk prediction 
models. In particular, some of the regimens administered to participants recruited to this study are 
no longer used in clinic today. Prospective recruitment and analysis would allow a clinically relevant 
and more accurate predictive marker to be identified for severe GI toxicity risk. A prospective study 
would also allow consistent grading of GI toxicity symptoms, eliminating any potential ambiguity in 
grading, as well as, enable participants to be screened for genotype prior to study enrolment, 
ensuring the MAF of the participant cohort is reflective of the Caucasian population. Additionally, 
participants could also be selected based on cancer type and the 5-FU-based regimens received 
in a prospective study would be currently used in clinic. A future study design for this research 
should be modelled off the QUASAR study [108], a prospective multi-site study recruiting 5,500 
patients receiving 5-FU and folinic acid for colorectal cancer to determine survival of patients 
following 5-FU-based therapy.  
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3.9 Conclusion  
To conclude, both the interim and final risk prediction models for severe GI toxicity produced in this 
validation study did not identify the same predictors for severe GI toxicity risk as the pilot risk 
prediction model [25]. The participant cohorts analysed in the pilot, interim and final risk prediction 
models were both clinically and genetically different to one another, which was reflected in the risk 
prediction models produced for each participant cohort. This confirms predictors for severe GI 
toxicity are reflective of the participant cohort analysed and emphasised predictive markers for 
severe GI toxicity risk are required for specific patient cohorts. 
As the development of severe GI toxicity is multifaceted, the results of the pilot, interim and final 
participant cohort analysis suggests using an approach combining clinical data and SNPs may be 
required to identify a predictive marker for severe GI toxicity risk. Additional data such as tumour 
genetics, participant comorbidities and other 5-FU-induced toxicities should also be included in risk 
prediction modelling to accurately reflect what a patient would look like in the consultation room.  
A major roadblock with identifying a predictive marker for severe GI toxicity risk is a poor 
classification of a phenotypic marker for severe GI toxicity. If a phenotypic marker for severe GI 
toxicity, such as increased proinflammatory cytokine secretion, was included in the risk prediction 
model, this would allow the model to identify either a clinical factor or SNP responsible for the 
change in phenotype observed. This is the focus of Chapter 4 of my thesis.  
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Chapter 4: Stimulated IL-1β secretion in participants 
post-5-FU-based therapy is predictive for severe GI toxicity risk  
Chapter 4 is my second research chapter and is unpublished and unsubmitted work written in 
manuscript style. It is intended to be submitted to the British Journal of Clinical Pharmacology. This 
chapter is presented in its intended publication format with referencing style modified to maintain 
consistency throughout this thesis.  
4.1 Abstract  
Aims: Severe gastrointestinal (GI) toxicity following 5-fluorouracil (5-FU)-based therapy is highly 
prevalent and negatively affects solid tumour therapy. The TIR domain innate immune signalling 
pathway mediates proinflammatory cytokine secretion following 5-FU-based therapy. Genetic 
variation within the TIR domain pathway has been identified as predictive for severe GI toxicity. 
However, a predictive phenotypic marker for severe GI toxicity risk is yet to be determined. 
Methods: Thirty-two participants were recruited to this study. Participant demographics, 
5-FU-based regimen, GI toxicity and genetic variation within TIR domain pathway genes were 
known. Ex vivo quantification of TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated IL-1 and 
TNF- secretion from isolated PBMCs was determined by ELISA. IL-1 and TNF- secretion was 
natural log-transformed and compared between participants with no or mild to moderate (grade 1 
and 2) GI toxicity and participants with severe (grade ≥ 3) GI toxicity and, between TLR2, TLR4, 
IL1B, TNF, CASP1 and CASP5 genotypes using t-tests and one-way ANOVA. In addition, 
ANCOVA modelling identified predictors significantly associated with log IL-1 and TNF- 
secretion.  
Results: ANCOVA determined increased log IL-1 secretion was associated with no or mild to 
moderate GI toxicity and, CASP1 rs580253 (G > A) and CASP5 rs554344 (G > C) SNPs following 
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stimulation with TLR2 (PAM3CSK4) and TLR4 (LPS) agonists (P < 0.05) post-5-FU-based therapy. 
No predictors were associated with log TNF- secretion.  
Conclusions: TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated IL-1β secretion was significantly 
different post-5-FU-based therapy between participants who reported no or mild to moderate GI 
toxicity and severe GI toxicity. Therefore, the IL-1β secretory response is a potential predictive 
phenotypic marker for severe GI toxicity risk.  
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4.2 Statement 1: What is already known on this subject 
 The TIR domain innate immune signalling pathway is a key mediating pathway in the 
development of severe GI toxicity. 
 Activation of the TIR domain pathway leads to increased proinflammatory cytokine 
secretion. 
 Genetic variation within the TIR domain pathway is predictive for severe GI toxicity 
following 5-FU-based therapy. 
4.3 Statement 2: What this study adds  
 TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated IL-1β secretion was significantly higher 
post-5-FU-based therapy in participants who reported no or mild to moderate GI toxicity.  
 CASP1 rs580253 (G > A) and CASP5 rs554344 (G > C) genotypes were associated with 
TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated IL-1β secretion post-5-FU-based therapy.  
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4.4 Introduction  
There are currently no clinically sensitive and specific predictive markers available for severe 
gastrointestinal (GI) toxicity risk following 5-fluorouracil (5-FU)-based therapy. GI toxicity symptoms 
develop in 25 – 50 % of patients receiving 5-FU-based therapy [3], with a subset of these patients 
developing severe GI toxicity, graded as  3 on the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events (NCI CTCAE v 4.03 and v 5.0) [3, 10]. Patients with severe 
GI toxicity require treatment delays, dose reductions, early treatment cessation and hospitalisation 
to help manage and relieve symptoms [2, 3]. This not only results in sub-optimal therapy outcomes 
and decreases patient quality of life whilst on treatment but, is also an economic burden on the 
health care system [2, 6, 7, 109]. The identification of a predictive marker for severe GI toxicity risk 
may allow the personalisation of supportive care measures for patients at most risk of developing 
severe GI toxicity prior to receiving 5-FU-based therapies. Not only will this decrease the severity 
of GI toxicity experienced by the patient but, will also decrease the likelihood of their 5-FU-based 
therapy being compromised by the presence of severe GI toxicity symptoms.  
Previous research has identified proinflammatory cytokine secretion contributes to the 
development of severe GI toxicity and, genetic variation within the Toll-like Receptor/Interleukin-1 
(TIR) domain innate immune signalling pathway is predictive for severe GI toxicity risk. 
Administration of 5-FU initiates an innate immune response mediated by the TIR domain signalling 
pathway [5, 22, 53, 58]. Activation of the TIR domain pathway is mediated by Toll-like Receptors 
(TLRs) and upregulates potent transcription factors and secretion of proinflammatory cytokines 
such as tumour necrosis factor alpha (TNF-) and interleukin 1 beta (IL-1) [2, 23, 110].  
Secretion of TNF- and IL-1 has been consistently associated with severe mucosal injury and 
cell death in the oral mucosa, jejunum and colon following 5-FU administration in preclinical models 
[5, 23]. Likewise, clinical studies have also demonstrated increased TNF- and IL-1 levels in 
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peripheral blood of patients with GI toxicity symptoms included, but not limited to, diarrhoea, 
mucositis, nausea and vomiting, following 5-FU-based therapy [2, 4, 24]. Genetic association 
identified the single nucleotide polymorphism (SNP) in tumour necrosis factor (TNF) -1031T/C 
(rs1799964) was predictive for stomatitis (also referred to as oral mucositis) in patients receiving 
5-FU-based therapy [95]. Similarly, my laboratory demonstrated in a small clinical study TLR2 
rs3804100 and TNF rs1800629 SNPs were predictive for severe GI toxicity risk following 
5-FU-based therapy in conjunction with colorectal and gastric cancer types (P = 0.033, 
ROC AUC = 87 %) [25].  
Although research consistently demonstrates the potential of the TIR domain innate immune 
signalling pathway to be predictive for severe GI toxicity risk, no phenotypic marker for severe GI 
toxicity has yet been identified. Furthermore, it has not yet been determined if IL-1 and TNF- 
secretion significantly differs between patients who develop no (grade 0), mild to moderate GI 
toxicity (graded as 1 or 2 on the NCI CTCAE v 5.0 [10]) or severe GI toxicity (graded as ≥ 3 on the 
NCI CTCAE v 5.0 [10], or patients that have a dose reduction, hospitalisation or cease treatment 
prematurely as a direct result of GI toxicity). If secretion of IL-1 and TNF- does differ between 
the two toxicity groups and, is associated with one of multiple SNPs within the TIR domain pathway, 
this would be a strong genotype-phenotype predictive marker for severe GI toxicity risk that could 
potentially be translated to clinic.  
This study is the first to my knowledge to investigate the innate immune response in participants 
post-chemotherapy. Changes in long-term proinflammatory cytokine secretion following exposure 
to either damage associated molecular patterns (DAMPs) or pathogen associated molecular 
patterns (PAMPs) is believed to occur as a result of innate immune memory [111]. On secondary 
challenge with either DAMPs or PAMPs, proinflammatory cytokine secretion may be diminished in 
comparison to secretion patterns that experienced pre-exposure (or pre-chemotherapy) [111]. 
DAMPs and PAMPs play a significant role in 5-FU-induced mucosal injury. Therefore, toxic 
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participants may be tolerant to a greater extent than non-toxic participants as a result of the high 
exposure to DAMPs and PAMPs that occurs during severe GI toxicity.  
This study firstly hypothesised participants who reported severe GI toxicity throughout their 
5-FU-based therapy would secrete decreased IL-1 and TNF- pre- and post-stimulation with 
TLR2 and TLR4 agonists compared to participants who reported no or mild to moderate GI toxicity. 
Secondly, it was hypothesised any differences in IL-1 and TNF- secretion identified between 
the two participant groups would be associated with SNPs within the TLR2, TLR4, IL1B, TNF, 
CASP1 and/or CASP5 genes. 
These hypotheses were investigated by the following aims:  
1. To determine pre-stimulation IL-1 and TNF- secretion in participants classified as 
non-toxic (participants who reported no or mild to moderate GI toxicity) and toxic 
(participants who reported severe GI toxicity) throughout their 5-FU-based therapy. 
2. To determine if TLR2- and TLR4-stimulated IL-1 and TNF- secretion was significantly 
different between participants classified as non-toxic and toxic throughout their 
5-FU-based therapy.  
3. To identify if any significant differences in post-stimulation IL-1 and TNF- secretion 
between the two participant groups was associated with TLR2, TLR4, IL1B, TNF, CASP1 
or CASP5 genotypes.  
4.5 Materials and Methods 
4.5.1 Ethics 
This study was approved by the Southern Adelaide Clinical Human Research Ethics Committee 
(HREC/15/SAC/231) and the Royal Adelaide Hospital Human Ethics Committee 
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(SSA/15/RAH/397). All participants provided informed written consent prior to participating in 
accordance with the Declaration of Helsinki. 
4.5.2 Study participants 
107 participants who had participated in previous [25] and current immune genetic studies were 
invited to further participate in this study. Briefly, participants had received 5-FU-based therapy 
from the Flinders Medical Centre or Royal Adelaide Hospital in South Australia, Australia between 
January 2012 and June 2018. In the first instance, invitation letters were mailed exclusively to 
participants who reported no, grade 1 or grade 3 GI toxicity. However, to meet the target sample 
size of 46 (to adequately power the study to detect a 2-fold change in IL-1β and TNF-α secretion 
between non-toxic and toxic participants), the invitations were extended to participants who 
developed grade 2 GI toxicity. 42 participants (39 %) responded to the letter of invitation and 32 
participants (30 %) were subsequently recruited to this study.  
Participant demographics, chemotherapy regimen, GI toxicity and SNPs within TIR domain 
pathway genes TLR2 (rs3804100), TLR4 (rs4986790 and rs4986791), IL1B (rs16944, rs1143634 
and rs1143627), TNF (rs1800629), CASP1 (rs580253) and CASP5 (rs554344) were collated from 
the immune genetic studies [25]. The SNPs had previously been determined using a customised 
Sequenom MassArray (iPLEX GOLD) assay [25].  
4.5.3 GI toxicity classification  
All study participants had previously been classified into two GI toxicity groups for analysis. 
Participants assigned as ‘non-toxic’ had reported either no GI toxicity (grade 0) or, mild to moderate 
GI toxicity (graded as 1 or 2 on the NCI CTCAE v 4.03 and v 5.0 [10]) throughout their 5-FU-based 
therapy. Participants assigned as ‘toxic’ had reported severe GI toxicity (graded as  3 on the NCI 
CTCAE v 4.03 [10]), or required a dose reduction, treatment break or hospitalisation due to GI 
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toxicity throughout their 5-FU-based therapy. This classification of GI toxicity has been previously 
used in clinical studies conducted in my laboratory [25, 103]. 
4.5.4 Whole blood collection and peripheral blood mononuclear cell (PBMC) isolation  
It was confirmed participants were not ill, had not recently received a vaccination or were not 
currently taking immunosuppressant medication prior to blood draw to limit outside influences on 
IL-1β and TNF-⍺ secretion. 27 mL of whole blood was collected from participants into EDTA tubes 
via venepuncture between 10 am and 11 am on the study day to ensure circadian rhythm did not 
influence secretion. PBMCs were immediately isolated to investigate proinflammatory cytokine 
secretion using the iodixanol mixer technique [112, 113]. Briefly, 2 mL of OptiprepTM (Sigma-
Aldrich, NSW, Australia) was added to whole blood and mixed by repeated inversion. Following 
inversion, 1 mL of enriched media containing RPMI 1640 + L-glutamine, 10% foetal bovine serum 
and 1 % penicillin/streptomycin (Thermo Fisher Scientific, MA, USA) was layered on top and the 
sample was centrifuged at 1500 x g for 30 min with no deceleration. Following centrifugation, 
PBMCs were collected from the mononuclear layer and washed with 5 mL of RPMI 1640 + 
L-glutamine. PBMCs were diluted to a working concentration of 1 x 106 cells.mL-1 using enriched 
media and plated into Costar® 96-well plates (Corning, NY, USA).  
4.5.5 TLR2 (PAM3CSK3) and TLR4 (LPS) stimulated IL-1 and TNF- secretion  
TLR2 agonist synthetic triacylated lipoprotein (PAM3CSK4) (Sigma Aldrich, NSW, Australia) was 
added to isolated PBMCs at concentrations of 0.00005, 0.01 and 1 g.mL-1. TLR4 agonist 
lipopolysaccharide (LPS, E.coli, Sigma Aldrich, NSW, Australia) was added to isolated PBMCs at 
concentrations 0.00005, 0.1 and 100 g.mL-1. Agonist treatments were performed in triplicate to 
stimulate an IL-1 and TNF- secretory response [112]. Appropriate negative controls minus TLR 
agonists were also included. Plates were incubated for 20 h at 37 °C with 5 % CO2. Following 
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incubation, supernatant from triplicate wells was collected, pooled and stored at -20 °C until further 
analysis.  
4.5.6 Quantification of IL-1 and TNF-α secretion 
IL-1β and TNF-⍺ concentrations from PBMC supernatants pre- and post-stimulation were 
determined by commercially available human ELISA kits (eBioscience, CA, USA). Manufacturer’s 
instructions were followed, including generation of standard curves from 2.34 to 150 pg.mL-1 
(IL-1) and 7.81 to 500 pg.mL-1 (TNF-). UV absorbance was quantified using the Synergy Mx 
Microplate ReaderTM (BioTek Instruments, VT, USA) at 450 nm. Individual ELISA assay results 
were accepted if the standard curve coefficient was R2 ≥ 0.99. When absorbance exceeded the 
standard curve, samples were diluted with ELISA diluent and repeated absorbance measurements 
taken.  
4.5.7 Statistical analysis 
Hardy-Weinberg equilibrium analysis was used to ascertain whether the observed allele 
frequencies in the participant cohort differed from expected (P > 0.05). Age, number of treatment 
cycles and number of months (between last treatment cycle and PBMC isolation) were tested for 
normality using the D’Agostino & Pearson test. Chi-square or Fisher’s exact tests and 
Mann-Whitney U tests compared clinical data between non-toxic and toxic participants as data was 
not normally distributed (D’Agostino & Pearson P < 0.05). As IL-1β and TNF-α secretion was highly 
skewed, secretion was natural log-transformed for each participant. Unpaired parametric t-tests 
compared log IL-1β and TNF-⍺ secretion between non-toxic and toxic participants at each TLR2 
(PAM3CSK4) and TLR4 (LPS) agonist concentration. Likewise, unpaired parametric t-tests and 
one-way ANOVA compared log IL-1β and TNF-α secretion between TLR2, TLR4, IL1B, TNF, 
CASP1 and CASP5 genotypes at each TLR2 (PAM3CSK4) and TLR4 (LPS) agonist concentration. 
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Due to multiple comparisons, P-values were adjusted for the false discovery rate (FDR) and 
considered significant if the FDR-corrected P-value was ≤ 0.05. 
4.5.8 Analysis of covariance (ANCOVA) modelling  
An ANCOVA is a general linear model which blends ANOVA and regression. ANCOVA modelling 
was used to identify covariates significantly associated with log IL-1β and TNF- secretion. A base 
model ANCOVA determined the association of log agonist concentration, TLR2 (PAM3CSK4) and 
TLR4 (LPS) stimulation, GI toxicity and the interaction between these covariates, on log IL-1β and 
TNF- secretion using the software program R [104]. All covariates and their interaction terms 
were examined in the ANCOVA model with step-wise removal of the covariate or interaction term 
of least significance until only significant covariates or interaction terms remained in the model. 
The covariates or interaction terms remaining in the model were identified as significantly 
associated with log IL-1β and/or TNF- secretion.  
Additionally, the association of participant clinical data such as sex, 5-FU-based regimen, cancer 
type, age, number of treatment cycles and; TLR2 rs3804100, TLR4 rs4986790 and rs4986791, 
IL1B rs16944, rs1143634 and rs1143627, TNF rs1800629, CASP1 rs580253 and CASP5 
rs554344 genotypes, were also examined in an ANCOVA model. Firstly, participant clinical data 
or genotype considered individually associated with log IL-1β or TNF- secretion were identified 
using a likelihood ratio test (FDR corrected P-values ≤ 0.05). These were included in the ANCOVA 
model using a step-up approach starting with the covariate with the lowest FDR-corrected P-value. 
If the clinical data and/or SNPs improved the ANCOVA model, it was retained in the model. If they 
did not improve the ANCOVA model, it was removed.  
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4.6 Results  
4.6.1 Participant clinical data 
Participant clinical data is provided in Table 4.1. 32 participants were recruited to the study with 19 
classified as non-toxic and 13 as toxic following 5-FU-based therapy. There were no significant 
differences in clinical data between the two participant groups (P > 0.05) (Table 4.1). All genotypes 
conformed with Hardy-Weinberg equilibrium (P > 0.05). Genotype results for one participant were 
not available. 
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Table 4.1 Participant clinical data presented as n (%) or median (range)a.  
Total Participants 
n = 32 
Non-toxic 
(n = 19) 
Toxic 
 (n = 13) 
P-value 
Sex 
Female 9 (47%) 8 (62%) 
0.430 
Male 10 (53%) 5 (38%) 
Age 
Median (range) 60 (40 – 73) 68 (40 – 73) 0.172 
Cancer type 
Breast 8 (42%) 2 (15%) 
0.227 Colorectal  10 (53%) 9 (70%) 
Upper GI 1 (5%) 2 (15%) 
5-FU-based regimen  
5-FU monotherapy  3 (16%) 3 (23%) 
0.841 5-FU combination 12 (63%) 7 (54%) 
Capecitabine 4 (21%) 3 (23%) 
Number of treatment cycles  
Median (range) 6 (3 – 30) 6 (2 – 16) 0.780 
Months between last treatment cycle and PBMC isolation  
Median (range) 45 (11 – 77) 40 (7 – 90) 0.826 
a 5-FU monotherapy: 5-FU administered with folinic acid; 5-FU combination: 5-FU administered as part of a 
regimen such as DECO (docetaxel, cisplatin, 5-FU), ECF (epirubicin, cisplatin, 5-FU), EOF (epirubicin, 
oxaliplatin, 5-FU), FEC (5-FU, epirubicin, cyclophosphamide) or FOLFOX (5-FU, oxaliplatin, folinic acid); 
Capecitabine: Capecitabine monotherapy or XELOX (capecitabine and oxaliplatin).  
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4.6.2 No significant differences in IL-1 and TNF- secretion were identified between 
non-toxic and toxic participants from univariate analysis 
No significant differences in pre-stimulated log-transformed IL-1β secretion was identified between 
non-toxic and toxic participants (P = 0.833, Table 4.2). No significant differences were also 
identified in pre-stimulated log-transformed TNF-⍺ secretion (P = 0.649, Table 4.2).  
No significant differences in TLR2 (PAM3CSK4) (0.00005, 0.01 and 1 g.mL-1) or TLR4 (LPS) 
(0.00005, 0.1 and 100 g.mL-1) stimulated log-transformed IL-1 and TNF- secretion between 
non-toxic and toxic participants were also identified (P > 0.05, Table 4.2).  
 
   
 
Table 4.2 Natural log-transformed IL-1 and TNF- -secretion (pg.mL-1) at pre-stimulation and post TLR2 (PAM3CSK4) or TLR4 (LPS) stimulation between 
non-toxic (n = 19) and toxic (n = 13) participantsb. 
 Non-toxic 
 








g.mL-1 Mean (range) Mean (range) FDR-corrected P-value 
LPS IL-1β 
Pre-stimulation 2.0 (0.5 – 3.4) 1.8 (0.8 – 3.5) 0.833 
0.00005 2.5 (0.9 – 3.6) 2.1 (1.6 – 3.6) 0.544 
0.1 2.5 (1.5 – 3.9) 1.7 (2.3 – 3.7) 0.438 
100 2.7 (2.4 – 4.0) 1.8 (2.2 – 3.8) 0.160 
PAM IL-1β 
Pre-stimulation 2.0 (0.1 -2.6) 1.8 (1.0 – 3.0) 0.833 
0.00005 2.1 (0.2 – 3.0) 2.1 (1.5 – 3.0) 0.833 
0.01 2.6 (1.4 – 3.1) 2.2 (1.7 – 3.0) 0.350 
1 2.5 (1.9 – 3.1) 2.3 (1.7 – 2.9) 0.160 
LPS TNF-α 
Pre-stimulation 2.4 (1.2 – 3.8) 2.0 (1.4 – 3.8) 0.649 
0.00005 2.6 (0.9 – 3.9) 2.1 (1.4 – 3.3) 0.322 
0.1 2.4 (1.6 – 4.1) 2.5 (1.6 – 3.6) 0.350 
100 2.9 (1.4 – 4.5) 2.5 (2.0 – 3.7) 0.435 
PAM TNF-α 
Pre-stimulation 2.4 (1.0 – 3.7) 2.0 (1.2 – 3.9) 0.649 
0.00005 2.4 (1.0 – 3.7) 2.3 (0.4 – 2.8) 0.322 
0.01 2.5 (1.4 – 3.6) 2.2 (1.5 – 3.1) 0.322 
1 2.6 (1.3 – 3.8) 2.4 (1.6 – 3.0) 0.322 
bLPS IL-1β: TLR4 (LPS) stimulated IL-1β secretion; LPS TNF-α: TLR4 (LPS) stimulated TNF-α secretion; n: number of participants; PAM IL-1β: TLR2 (PAM3CSK4) stimulated IL-1β 
secretion; PAM TNF-α: TLR2 (PAM3CSK4) stimulated TNF-α secretion.  108 
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4.6.3 Significant differences in TLR2 (PAM3CSK4) stimulated IL-1 secretion between CASP1 
and CASP5 genotypes were identified from univariate analysis 
One-way ANOVA determined significant differences in log IL-1 secretion pre- and post-
stimulation with TLR2 (PAM3CSK4) concentration of 0.00005 g.mL-1 between participants with 
homozygous wild-type, heterozygous or homozygous variant genotype for CASP1 rs580253 and 
CASP5 rs554344 (P = 0.031, Table 4.3). The genotype for CASP1 rs580253 and CASP5 rs554344 
was equivalent for each participant. Linkage disequilibrium analysis was not conducted.   
No significant differences in TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated log IL-1 and TNF- 
secretion between carriers of the homozygous wild-type, heterozygous or homozygous variant 




    
 
Table 4.3 Natural log-transformed IL-1 secretion (pg.mL-1) pre- and post-TLR2 (PAM3CSK4) or TLR4 (LPS) stimulation for carriers of the homozygous wild-
type, heterozygous or homozygous variant genotypes for CASP1 rs580253 and CASP5 rs554344. The genotype for CASP1 rs580253 and CASP5 rs554344 
was equivalent for each participantc. 
  WT/WT  
 




(n = 7) 
Var/Var  
 
(n = 2) 
 
 
g.mL-1 Mean (range) Mean (range) Mean (range) FDR-corrected P-value 
LPS IL-1β 
Pre-stimulation 2.0 (0.5 – 3.5) 1.4 (0.7 – 2.5) 2.6 (1.7 – 3.4) 0.254 
0.00005 2.4 (1.2 – 3.5) 1.8 (0.8 – 3.2) 2.6 (2.3 – 2.9) 0.291 
0.1 2.4 (1.5 - 3.9) 2.0 (1.9 – 3.1) 2.7 (2.4 – 3.0) 0.291 
100 2.5 (1.8 – 4.0) 2.4 (2.1 – 3.6) 2.6 (2.3 – 2.8) 0.644 
PAM IL-1β 
Pre-stimulation 2.0 (1.1 – 3.0) 1.1 (0.1 – 1.9) 2.2 (2.0 – 2.4) 0.008* 
0.00005 2.2 (1.6 – 3.0) 1.5 (0.2 – 2.4) 2.2 (2.1 – 2.2) 0.013* 
0.01 2.5 (1.7 – 3.1) 2.1 (1.4 – 2.7) 2.7 (2.4 - 2.9) 0.055 
1 2.5 (1.9 – 3.1) 2.2 (1.7 – 2.5) 2.7 (2.5 – 2.9) 0.055 
c LPS IL-1β: TLR4 (LPS) stimulated IL-1β secretion; n: number of participants; PAM IL-1β: TLR2 (PAM3CSK4) stimulated IL-1β secretion; WT/WT: homozygous wild-type 





4.6.4 The base ANCOVA model identified TLR2 (PAM3CSK4) and TLR4 (LPS) stimulation in 
conjunction with GI toxicity was predictive for log-transformed IL-1β secretion  
The final ANCOVA model identified two covariates significantly associated with log IL-1β secretion 
(P < 2.2 x 10-16, Figure 4.1). The linear equations produced by the base ANCOVA model are below: 
TLR2 (PAM3CSK4) stimulated log IL-1β secretion (toxic participants): y = 0.10𝑥 + 5.45 
TLR2 (PAM3CSK4) stimulated log IL-1β secretion (non-toxic participants): y = 0.16𝑥 + 6.21 
TLR4 (LPS) stimulated log IL-1β secretion (toxic participants): y = 0.05𝑥 + 5.46 
TLR4 (LPS) stimulated log IL-1β secretion (non-toxic participants): y = 0.11𝑥 + 6.21 
Firstly, the model identified stimulation with both TLR2 (PAM3CSK4) and TLR4 (LPS) agonists was 
significantly associated with log IL-1β secretion (Figure 4.1a). For both agonists, there was a 
concentration-dependent increase in log IL-1β secretion with a greater increase over the 
concentrations used for TLR2 (PAM3CSK4) as indicated by the steeper slopes of the association 
(Figure 4.1a).  
The model also identified GI toxicity was significantly associated with log IL-1β secretion 
(Figure 4.1b). TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated log IL-1β secretion was higher in 
non-toxic participants, with a greater increase as indicated by the steeper slope of the association, 
compared to toxic participants (Figure 4.1b).  
The final ANCOVA model identified no significant associations between TLR2 (PAM3CSK4) and 
TLR4 (LPS) stimulation, GI toxicity and the interaction between these covariates with log TNF-α 



















Figure 4.1 Linear regression models of natural log-transformed IL-1β secretion between a) TLR4 
(LPS) and TLR2 (PAM3CSK4) stimulation and, b) non-toxic and toxic participants following TLR4 
(LPS) and TLR2 (PAM3CSK4) stimulation. Blue shaded regions indicate the 95 % 




## Fixed effects: 
##              Estimate Std. Error        df t value Pr(>|t|)     
## (Intercept)   6.44490    0.26056  37.81682  24.735  < 2e-16 *** 
## log_conc      0.06107    0.01111 219.97372   5.499 1.06e-07 *** 
## Txp          -0.55577    0.12488 219.99629  -4.450 1.36e-05 *** 
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
##  
## Correlation of Fixed Effects: 
##          (Intr) lg_cnc 
## log_conc  0.202        
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4.6.5 Addition of CASP1 and CASP5 SNPs improved the base ANCOVA model  
Likelihood ratio tests identified CASP1 rs580253 and CASP5 rs554344 SNPs were associated with 
TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated log IL-1β secretion (P = 0.003, Figure 4.2). 
Following addition of CASP1/CASP5 SNPs into the base ANCOVA model, the model identified 
these SNPs as predictive for TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated log IL-1β secretion. 
An overall P-value and linear equations for this ANCOVA could not be obtained.  
Linear regression identified TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated log IL-1β secretion 
was significantly different between carriers of the homozygous wild-type, heterozygous and 
homozygous variant genotypes (Figure 4.2). Carriers of the heterozygous genotype (Figure 4.2b) 
demonstrated the steepest slope, followed by carriers of the homozygous wild-type genotype 
(Figure 4.2a) and finally, carriers of the homozygous variant genotype (Figures 4.2c). This indicates 
log IL-1β secretion increased at a greater rate over the TLR2 (PAM3CSK4) and TLR4 (LPS) 
concentrations in carriers of the heterozygous genotype compared to a gradual increase in 
secretion in carriers of the homozygous wild-type or homozygous variant genotypes.  
Likelihood ratio tests identified no significant associations with participant clinical data (sex, 
5-FU-based regimen, cancer type, age and number of treatment cycles) or SNPs for TLR2, TLR4, 






Figure 4.2 Linear regression models of natural log-transformed IL-1β secretion following TLR2 
(PAM3CSK4) and TLR4 (LPS) stimulation between carriers of CASP1 and CASP5 a) homozygous 
wild-type (WT/WT), b) heterozygous (WT/Var) or c) homozygous variant (Var/Var) genotypes. Blue 
shaded regions indicate the 95% confidence intervals of the associations.  
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4.7 Discussion  
Severe GI toxicity is a common and debilitating side effect following 5-FU-based therapy leading 
to sub-optimal therapy outcomes and decreased patient quality of life [2, 6]. It is crucial to identify 
predictive markers for severe GI toxicity to allow personalisation of supportive care measures for 
these patients. This retrospective study identified significant differences in TLR2 (PAM3CSK4) and 
TLR4 (LPS) stimulated IL-1β secretion. Firstly, non-toxic participants (participants who developed 
no or mild to moderate GI toxicity) demonstrated increased stimulated IL-1β secretion over the 
concentrations investigated in comparison to toxic participants (participants who developed severe 
GI toxicity). Secondly, homozygous wildtype, heterozygous and homozygous variant genotypes of 
CASP1 and CASP5 demonstrated significantly different stimulated IL-1β secretion patterns 
independent of GI toxicity. As a result, this study identified the IL-1β secretory response as a 
candidate predictive phenotypic marker for severe GI toxicity risk. 
This current study is the first to investigate stimulated IL-1β and TNF-⍺ cytokine secretion 
post-5-FU-based therapy. Previous ex vivo analysis is limited to circulating IL-1β and TNF-⍺ levels 
in plasma pre- and post-5-FU-based therapy and, have not associated circulating proinflammatory 
cytokine levels with the presence of GI toxicity. In patients with breast cancer receiving FEC (5-FU, 
epirubicin and cyclophosphamide), pre- and post-therapy circulating IL-1β and TNF-⍺ levels in 
plasma were not significantly different [114]. Of note, baseline IL-1β and TNF-⍺ levels in plasma 
were only detectable in 21 % and 19 % of patients, respectively [114]. In contrast, a similar study 
reported mean pre-therapy TNF-⍺ plasma levels were significantly increased in an independent 
breast cancer cohort (n = 20) also receiving FEC (P < 0.001) compared to healthy controls [115]. 
However, this result was not compared to post-therapy TNF-⍺ plasma levels [115]. 
It is difficult to compare pre- and post-stimulation levels of IL-1β and TNF-⍺ from PBMCs to pre- 
and post-therapy circulating IL-1β and TNF-⍺ levels in plasma. However, this current study 
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demonstrates measuring IL-1β and TNF-⍺ secretion from pre- and post-stimulated PBMCs is more 
consistent in comparison to measuring circulating IL-1β and TNF-⍺ levels. For example, 
pre-stimulated IL-1β and TNF-⍺ were detectable in all participants in this current study compared 
to a previous study measuring IL-1β and TNF-⍺ levels in plasma serum [114]. Additionally, on 
average, pre-stimulated IL-1β and TNF-⍺ levels were log 1.44 and log 0.67 (pg.mL-1) higher 
compared to the reported pre-therapy circulating IL-1β and TNF-⍺ levels in plasma [115], 
respectively.  
It is not surprising the pre-stimulation results presented were higher than the IL-1β and TNF-⍺ pre-
therapy plasma serum levels as participants in my study were not chemotherapy naïve and, innate 
immune memory may have influenced stimulated IL-1β and TNF-⍺ secretion. Innate immune 
memory can occur following significant innate immune signalling (such as that experienced during 
5-FU-induced mucosal injury) and leads to a change in reactivity in innate immune cells previously 
exposed to stimuli such as DAMPs or PAMPs [111, 116]. Post-exposure to DAMPs and PAMPs, 
innate immune cells such as monocytes and macrophages can become tolerant, resulting in a 
diminished innate immune response on secondary exposure [111, 116]. Innate immune memory 
has been reported in animal models, where challenges with microbial ligands prior to infection with 
Escherichia Coli (3 x 103 to 5.5 x 103 colony forming units) or Pseudomonas aeruginosa (4 x 105 
colony forming units) resulted in diminished proinflammatory cytokine response and protection 
against sepsis and mortality [117-119].  
The results of this present study support the hypothesis that innate immune memory diminishes 
the innate immune response to a greater extent in toxic participants. This is most likely a direct 
result of the increased exposure to DAMPs and PAMPs during their severe 5-FU-induced mucosal 
injury. Linear regression analysis produced a steeper slope for IL-1β secretion for non-toxic 
participants, indicating a higher response rate to stimulation with TLR2 (PAM3CSK4) and TLR4 
(LPS) compared to toxic participants. Similar clinical studies investigating TLR2 (PAM3CSK4) and 
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TLR4 (LPS) stimulated IL-1β secretion from concentrations of 0.00005 to 100 µg.mL-1 between 
patients with chronic pain (another condition with an inflammatory basis) and healthy patients, also 
identified significant differences in TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated IL-1β secretion 
between the two patient groups [112, 120].  
Although stimulated IL-1β secretion was significantly different between non-toxic and toxic 
participants, the degree of IL-1β secretion was also significantly different between TLR2 
(PAM3CSK4) and TLR4 (LPS) stimulation. The response rate to TLR2 (PAM3CSK4) was higher 
than that of TLR4 (LPS), indicated by a steeper slope of association. This finding suggests 
dampening of TLR4 mediated IL-1β secretion may be more prominent than TLR2 mediated IL-1β 
secretion as a result of innate immune memory post-5-FU-based therapy. In comparison to chronic 
inflammatory conditions, such as chronic pain, TLR4 (LPS) stimulated IL-1β secretion has been 
reported to be higher than TLR2 (PAM3CSK4) stimulated IL-1β secretion [112, 120]. This 
comparison suggests TLR2 and TLR4 stimulated IL-1β secretion differs between acute 
inflammatory conditions, such as severe GI toxicity, and chronic inflammatory conditions, such as 
chronic pain, following innate immune memory.  
Following completion of 5-FU-based treatment, GI toxicity symptoms, such as diarrhoea, may not 
be completely resolved. Up to 49 % of patients whom received chemotherapy (not specific to 5-
FU) for colorectal cancer reported frequent and/or ongoing bouts of diarrhoea 4 - 5 years 
post-chemotherapy [121, 122]. This suggests pre- and/or post-stimulation of IL-1β and TNF-⍺ 
secretion following 5-FU-based therapy may also be a predictive phenotypic marker of current GI 
inflammation and may assist in managing ongoing GI symptoms that persist post-5-FU-based 
therapy. However, in this study, it was not reported whether participants were experiencing GI 
symptoms such as diarrhoea post-5-FU-based therapy.  
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A potential association between IL-1β and genotype was also identified, further highlighting the 
importance of IL-1β secretion. The ANCOVA model also identified CASP1 and CASP5 genotypes 
were associated with TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated IL-1 secretion. CASP1 
encodes caspase-1, also known as interleukin-1β-converting enzyme, and is responsible for 
cleaving inactive precursor IL-1β to its active form [123]. CASP5 encodes caspase-5 which plays 
an important role in apoptosis, inflammation and proliferation [124, 125]. CASP1 rs580253 is a 
synonymous G > A mutation whilst CASP5 rs554344 is an upstream gene variant [73]. The 
functional impact of these SNPs and their effect on IL-1β secretion is not reported [73]. 
Homozygous wild-type carriers secreted lower TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated 
IL-1 over the concentration ranges compared to heterozygous and homozygous variant carriers. 
However, no consistent response of TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated IL-1 
secretion was identified as the presence of wild-type alleles decreased. In addition, in this study 
only two participants were homozygous variant carriers for CASP1 rs580253 and CASP5 
rs554344, which is not reflective of the observed minor allele frequency (0.17) in the Caucasian 
population [73]. Therefore, the exact nature of association is unclear and future studies need to be 
conducted with an adequate number of participants with each genotype.  
In comparison to other TIR domain genes of interest, no associations were identified between 
TLR2, TLR4, IL1B and TNF SNPs and stimulated TLR2 (PAM3CSK4) and TLR4 (LPS) IL-1β and 
TNF-⍺ secretion. This is contrary to the hypothesis and despite TLR2 rs384100 and TNF 
rs1800629 SNPs previously being identified as strong predictors for severe GI toxicity [25]. One 
explanation of this unexpected finding could be PBMCs were stimulated with TLR2 (PAM3CSK4) 
and TLR4 (LPS) agonists in place of stimulation of different cell populations that make up PBMCs. 
The PBMC population contains macrophages, monocytes, dendritic, B, T and Natural Killer cells, 
with the number of these cells highly variable across individuals [126, 127]. The secretion profile 
of these cells is also known to differ from one another, with macrophages and monocytes in 
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particular predominately responsible for IL-1β and TNF-⍺ secretion [126, 127]. Therefore, it is 
possible some wells may have had a different population of cells from another, leading to variability 
in TLR2 (PAM3CSK4) and TLR4 (LPS) stimulated IL-1β and TNF-⍺ secretion, limiting the ability 
to detect an impact of genotypes on secretion. This was a key limitation of this study. In future, 
isolating monocytes and macrophages by cell sorting methods such as fluorescence-activated cell 
sorting (FACS) and flow cytometry, similar to other studies [128], and stimulating identical numbers 
of these individual cells types with TLR2 (PAM3CSK4) and TLR4 (LPS) agonists may give a more 
accurate IL-1β and TNF-⍺ secretion profile for each participant.  
Another limitation of this study was the target sample size of 46 participants (n = 23 non-toxic and 
n = 23 toxic) was not reached. This sample size was selected to ensure the study was adequately 
powered to detect a 2-fold change in IL-1β and TNF-α secretion between non-toxic and toxic 
participants. However, only 32 participants (19 non-toxic and 13 toxic) were recruited within the 
time constraints of the study. In addition, ELISA assays on some supernatant samples needed to 
be repeated due to failure of the standard curves (R2 < 0.99). As a result, some supernatant 
samples required multiple freeze-thaws. This meant degradation of IL-1 and TNF- during the 
thawing process may have occurred and on repeat ELISA analysis, a lower concentration of IL-1 
and TNF- may have been detected in comparison to what was initially present. An optimisation 
experiment was conducted comparing fresh and multiple freeze thaw samples of supernatant 
following stimulation with TLR2 (PAM3CSK4) at 0.00005, 0.01 and 1 g.mL-1 and TLR4 (LPS) at 
0.00005, 0.1 and 100 g.mL-1. It was identified IL-1 and TNF- concentration did decrease, 
though this was only significant after 3 freeze-thaws (P = 0.031) (data not shown). In contrast, 
samples were only freeze-thawed a maximum of twice in this study. Therefore, although IL-1 and 
TNF- may have been decreased following thawing, this was not likely to be significant and impact 
the results.  
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The results of this study need to be validated free of the limitations discussed. Furthermore, 
investigation in a prospective cohort following a similar study design is also required to determine 
when changes in IL-1β and TNF-⍺ secretion occur as a result of innate immune memory 
post-5-FU-based therapy. If these changes are evident following the first cycle of 5-FU-based 
therapy, then pre- and post-stimulated IL-1β and TNF-⍺ secretion may be predictive for severe GI 
toxicity from cycle two of therapy onwards. This would allow patients at most risk of severe GI 
toxicity to be identified and have their supportive care measures personalised from cycle 2 of 
therapy. This may not only decrease their risk of either developing or further developing severe GI 
toxicity but, also improve their quality of life whilst receiving 5-FU-based therapy and their long-term 
therapy outcomes.  
4.8 Conclusion  
To conclude, this retrospective study was the first to identify a significant difference in stimulated 
IL-1 secretion between non-toxic (participants who developed no or mild to moderate GI toxicity) 
and toxic (participants who developed severe GI toxicity) participants post-5-FU-based therapy. 
This indicates the IL-1 secretory response may be a potential predictive phenotypic marker for 
severe GI toxicity risk and highlights the importance of long-term changes in IL-1β secretion linked 





Chapter 5: 5-FU does not significantly inhibit DNA methylation 
within the TNF promoter region following treatment in vitro 
Chapter 5 is presented as a traditional thesis chapter. As well as genetic variation, epigenetic 
modifications can also influence gene expression within the TIR domain innate immune signalling 
pathway. Therefore, epigenetic modifications may be potential predictive markers for severe GI 
toxicity risk. DNA methylation was selected as the epigenetic modification to be investigated in this 
chapter and tumour necrosis factor (TNF) was selected as the gene of interest. The reasoning 
behind this selection will be discussed in the chapter.  
5.1 Introduction  
Severe gastrointestinal (GI) toxicity, graded as  3 on the National Cancer Institute’s Common 
Terminology for Adverse Effects (NCI CTCAE v 4.03 and v 5.0) [10], is a debilitating adverse effect 
of 5-FU-based therapy, with patients requiring dose reductions, treatment delays, early treatment 
cessation and/or hospitalisation to help manage and relieve symptoms [2, 30]. Not only does this 
compromise optimal therapy outcomes but, more importantly, decreases patient quality life whilst 
receiving therapy [6].  
Proinflammatory cytokine tumour necrosis factor alpha (TNF-), encoded by the gene TNF, is 
known to play a significant role in the development of severe GI toxicity following 5-FU-based 
therapy [5, 24]. 5-FU is an antimetabolite drug most commonly used for the treatment of solid 
tumours in the breast, oesophagus and colon [1, 41]. Administration of 5-FU initiates an innate 
immune response [2, 110], mediated by the Toll-like Receptor/Interleukin-1 (TIR) domain innate 
immune signalling pathway [22, 53, 58], subsequently leading to the production of TNF-⍺ from 
peripheral monocytes and tissue macrophages [63, 64]. Secretion of TNF- mediates an 




signalling and further stimulating injury and death in cells of the epithelium and sub-mucosa, 
particularly in the vulnerable GI tract [2]. Cell injury and death throughout the GI tract can result in 
the manifestation of severe GI toxicity symptoms such as nausea, vomiting, mucositis and 
diarrhoea [2].  
Increasing levels of TNF- in the peripheral blood of patients receiving 5-FU-based therapy has 
been associated with the severity of GI toxicity [2, 24]. A single nucleotide polymorphism (SNP) in 
the TNF gene, rs1800629, has been identified as being predictive of severe GI toxicity symptoms 
(diarrhoea, mucositis, nausea and vomiting) in patients following 5-FU-based therapy [25]. 
Additionally, a TNF SNP, rs1799964, was also associated with the occurrence of severe stomatitis 
(also referred to as oral mucositis), also in patients receiving 5-FU-based therapies [95].  
A study by Huizinga et al in whole blood cultures identified a relationship between 
lipopolysaccharide (LPS)-stimulated TNF- secretion and a TNF SNP, rs361525, at a low LPS 
concentration (10 ng.mL-1) in healthy participants (P < 0.05) [99]. However, at a high LPS 
concentration (1000 ng.mL-1), no significant associations were identified between LPS-stimulated 
TNF- secretion and the TNF SNPs rs1800629, 1800750 and rs361525 (P > 0.05) [99]. de Jong 
et al also identified in healthy individuals no associations between LPS-stimulated (1000 ng.mL-1) 
TNF- secretion and the TNF SNPs rs1800629, 1800750, rs361525 and rs80267959 (P > 0.05) 
[98]. The in vitro and ex vivo effect of these TNF SNPs on gene expression and TNF-⍺ secretion 
has been discussed in Chapter 2 [106]. 
These results and, those previously discussed in Chapters 2 [106], 3 and 4 of my thesis, 
demonstrate genetic variation within TNF is not necessarily the only factor responsible for the 
change in TNF-⍺ secretion observed during GI toxicity.  
The increase in TNF-⍺ secretion observed following 5-FU-based therapy may possibly be 




sequence [129]. DNA methylation is a well-known epigenetic modification characterised by the 
addition of a methyl group by a family of enzymes known as DNA methyltransferases (DNMT), 
from S-adenosine methionine (SAM) to the 5-position of the cytosine ring [129]. DNA methylation 
predominately occurs at CpG dinucleotides, many of which are present throughout the promoter 
region of genes, including TNF [130]. Hypermethylated DNA results in inactive chromatin, leading 
to a decrease in gene transcription and subsequent decline in gene expression [129]. DNA 
methylation is reversible and can be easily influenced by an array of exogenous factors [129]. 
Inhibition of thymidylate synthase (TS) by 5-FU also simultaneously prevents the production of a 
key folinic acid derivative required for DNA methylation [1, 35]. Therefore, DNA methylation was 
selected as the epigenetic modification to be investigated in this thesis chapter.  
5-FU is an uracil analogue [35]. The principal active metabolite of 5-FU, fluorodeoxyuridine 
monophosphate (FdUMP) forms a covalent complex with TS, a critical enzyme necessary for 
precursor deoxyribonucleotide synthesis cycle [1, 35]. TS also plays an important role in the folate 
cycle [1, 35]. Inhibition of TS by FdUTP prevents the conversion of dUMP to dTMP and blocks the 
simultaneous conversion of 5, 10-methylene tetrahydrofolate to dihydrofolate, a key folinic acid 
derivative [1, 35]. Dihydrofolate recycles methyl groups and is the source of carbon donors required 
for methionine synthesis used for SAM generation [129]. SAM is the primary methyl donor required 
by DNMT1 and DNMT3A for DNA methylation [129]. With inhibition of TS and consequently, no 
production of dihydrofolate, intracellular levels of methionine and SAM are depleted [131]. Depleted 
levels of methionine and SAM can result in decreased DNA methylation which can subsequently 
upregulate gene transcription and overall gene expression [131].  
In vitro, 5-FU has been identified to influence DNA methyltransferase activity [132, 133]. In a human 
lung cancer cell line, DNMT1 and DNMT3A protein as well as DNMT1 and DNMT3A mRNA 
expression was decreased following 5-FU treatment (2 - 200 μM). However, this was restored when 




hybridisation chain reaction to determine activity of methyltransferase (M.ssl MTase, isolated from 
E.coli), Xu et al identified 5-FU (0 - 400 μM) inhibited M.ssl MTase and, inhibition was proportional 
to the logarithmic value of M.ssl MTase concentration [133]. These results demonstrate the ability 
of 5-FU to inhibit DNA methylation.  
The effect of 5-FU on DNA methylation throughout the TNF promoter gene region is unknown. 
However, differences in methylation at CpG sites throughout the TNF promoter gene region have 
been identified in conditions with a similar underlying inflammatory basis as GI toxicity. Stephens 
et al identified at CpG sites -350, -344 and -342 (also referred to as -169, -163 and -161, 
respectively, upstream of the TNF transcription start site), DNA methylation was increased in 
patients with mild breast pain following breast cancer surgery compared to patients with no breast 
pain following surgery (P < 0.05) [134]. Logistic regression also analysed breast cancer pain with 
multiple covariates (such as DNA methylation, SNPs (including TNF rs1800610), pain group, 
presence of preoperative pain, genomic estimates of self-reported race/ethnicity and mastectomy 
six months post-surgery). The model determined DNA methylation at CpG sites -350 (-169) 
and -344 (-163) was significantly associated with mild breast pain following breast cancer surgery 
compared to other covariates (P = 0.024 and P = 0.033, respectively) [134]. Similarly, dental 
patients with periodontitis showed increased DNA methylation at CpG sites -163 and -161 
compared to patients with no periodontitis (P = 0.02 and P = 0.04, respectively) [135]. An inverse 
correlation between DNA methylation at CpG site -163 and TNF mRNA expression was also 
identified (R2 = 0.16, P = 0.018) [135]. The findings of Stephens et al. and Zhang at al. support the 
concept that DNA methylation within the TNF promoter region may differ between patients who 
develop severe GI toxicity (grade ≥ 3 on the NCI CTCAE v 4.03 and v 5.0) compared to patients 
who develop no (grade 0) or, moderate to mild GI toxicity (grade 1 or 2 on the NCI CTCAE v 4.03 




A decrease in DNA methylation has been identified to increase TNF transcriptional expression 
in vivo, suggesting administration of potential DNA methylation inhibitor 5-FU, will increase TNF 
transcriptional expression. In addition to associating DNA methylation of selected TNF CpG sites 
with the presence of periodontitis, Zhang at al. [135] also investigated the effect of DNA methylation 
inhibitor 5-Aza-2’-deoxycytidine (5-Aza-dc) on TNF transcriptional expression in the monocytic-like 
THP-1 cell line. At 24 h post-5-Aza-dc treatment, messenger RNA level of TNF was 1.6-fold higher 
(P = 0.03) and, 3-fold higher 96 h post-5-Aza-dc treatment (P = 0.003) in comparison to mock 
treated cells [135]. This finding implies that although inflammatory conditions such as breast pain 
and periodontitis have been associated with increased DNA methylation at selected TNF CpG 
sites, during severe GI toxicity induced by 5-FU, DNA methylation at these CpG sites may be 
reduced. Therefore, increasing TNF transcriptional activity, TNF mRNA expression and TNF-⍺ 
secretion. 
The results discussed above led to the hypothesis 5-FU administration may reduce DNA 
methylation throughout the TNF promoter gene region and potentially increase TNF gene 
transcription. This in turn may increase TNF-⍺ secretion and therefore, increase the risk of severe 
GI toxicity. TNF was selected as the gene of interest for this thesis chapter as it has been 
consistently implicated with severe GI toxicity [25, 95] and, contains multiple CpG sites within the 
promoter region prone to DNA methylation [136]. In comparison, other TIR domain innate immune 
signalling pathway genes such as TLR2, TLR4 and IL1B do not have multiple CpG sites throughout 
their promoter regions [136]. Therefore, DNA methylation would not be significant within the 
promoter region to influence gene expression. This current study was designed to investigate the 
concept that 5-FU can inhibit DNA methyltransferase mRNA expression and therefore, reduce DNA 




5.2 Hypotheses and aims  
This study hypothesised:  
1. 5-FU reduces mRNA expression of DNMT1 and DNMT3A therefore, inhibits DNA 
methylation across CpG sites -244, -238, -169, -163, -161, -149, -119, -72, -49 and -38 
upstream of the TNF transcription start site in U937 cells in vitro.  
Aims  
1. To optimise 5-FU and 5-Aza-2’-deoxycytidine (5-Aza-dc) concentration in the U937 cell 
line to determine a treatment dose that would not only induce cell injury and death but, 
result in a viable cell count that would allow adequate DNA and RNA extraction.  
2. To determine changes in mRNA expression of TNF, DNMT1 and DNMT3A following 
treatment with 5-FU and/or methylation inhibitor 5-Aza-dc in U937 cells in vitro using 
real-time polymerase chain reaction (RT-PCR). 
3. To determine changes in DNA methylation at CpG sites -244, -238, -169, -163, -161, -149, 
-119, -72, -49 and -38 upstream of the TNF transcription start site following treatment with 
5-FU and/or methylation inhibitor 5-Aza-dc in U937 cells in vitro using methylation specific 
high-resolution melt (MS-HRM). 
Chapter 5 is the only non-clinical study presented in my thesis. This novel study was conducted in 
vitro and, designed to investigate the concept that 5-FU can inhibit DNMT mRNA expression and 
therefore, reduce DNA methylation across selected CpG sites throughout the TNF promoter region. 
DNA methylation is an epigenetic modification that can be influenced by 5-FU. Differences in DNA 
methylation within genes such as TNF following 5-FU administration may lead to increased TNF-⍺ 
and potentially, increase the risk of mucosal injury and the development of GI toxicity. Therefore, 




on the results of this chapter, future research may be conducted ex vivo using peripheral blood 
mononuclear cells (PBMCs) isolated from participants.  
In addition, although there are 22 CpG sites throughout the TNF promoter region, CpG 
sites -244, -238, -169, -163, -161, -149, -119, -72, -49 and -38 were selected for analysis in this 
thesis chapter. All these sites have previously been investigated and alterations in DNA methylation 
at these CpG sites have previously been reported [134, 135].  
5.3 Methods 
5.3.1 Reagents  
RPMI + L-glutamine cell culture media, foetal bovine serum (FBS), penicillin streptomycin 
(Pen Strep), Dulbecco’s phosphate buffer solution (DPBS), SYTO9™️ green fluorescent nucleic 
acid stain and trypan blue stain were obtained from Thermo Fisher Scientific (MA, USA). Dimethyl 
sulfoxide (DMSO), 5-Aza-2’-deoxycytidine (5-Aza-dc), sterile distilled H2O (Milli-Q®), 100 % 
methylated DNA and 100 % unmethylated DNA were obtained from Merck (Darmstadt, Germany). 
5-FU was obtained from Hospira (IL, USA). Quantitect SYBR® green polymerase chain reaction 
(PCR) master mix, 10 X PCR buffer, RNase-free water, magnesium chloride (MgCl) and 
HotStarTaq™️ DNA polymerase were obtained from QIAGEN (CA, USA). Deoxyribonucleotide 
(dNTP) solution mix was obtained from New England Biolabs (MA, USA). Enriched media was 
prepared using RPMI + L-glutamine, 10 % FBS and 1 % Pen Strep.  
5.3.2 Culture of U937 cells  
5.3.2.1 Establishing cell culture  
Cells of the human myeloid cell line U937 were obtained from the European Collection of 
Authenticated Cell Culture (ECACC 85011440). U937 cells were selected for this study as they 




therefore, it was essential the cell line selected for this study exhibited monocytic-like properties. 
To establish cell culture, cells were removed from liquid nitrogen and rapidly thawed in a water 
bath at 36 C. Once thawed, cells were transferred to a 15 mL Falcon® tube containing 4 mL of 
pre-warmed enriched media. Cells were centrifuged at 300 x g for 5 min and supernatant was 
removed and discarded. The cell pellet was resuspended in 4 mL of DPBS and cells were 
centrifuged again at 300 x g for 5 min to remove residual cryoprotectant. Supernatant was removed 
and discarded, and cells resuspended in 10 mL of pre-warmed enriched media. Viable cell count 
was determined using trypan blue staining. Briefly, 10 µL of cells were mixed thoroughly with 10 
µL of trypan blue in a 96-well plate. 10 µL of the 1:1 mixture was loaded into a counting slide and 
placed in a T20 automated cell counter (Bio-Rad Laboratories Inc., CA, USA). The total cell count 
was 4.96 x 104 with 92 % cell viability. Cells were subsequently seeded in a Corning® T25 vented 
flask (Corning Incorporated, NY, USA) and placed in a humified incubator (Sanyo, Japan) at 37 C 
and 5 % CO2. Cell growth was assessed daily using trypan blue staining as well as under a phase 
contrast microscope (Nikon, Japan). After 72 h, cells were confluent with a total cell count was 
1.37 x 106 and 87 % cell viability. Cells were centrifuged at 300 x g for 5 min and supernatant was 
removed and discarded. The cell pellet was resuspended in 2 mL of pre-warmed enriched media 
and cells were split, with 1 mL of cells added to two 50 mL Falcon® tubes containing 24 mL of 
pre-warmed enriched media. Cells were mixed by inversion and seeded in two Corning® T75 
vented flasks (Corning Incorporated, NY, USA) and incubated at 37 C and 5 % CO2.  
5.3.2.2 Maintaining cell culture  
U937 cells were grown and maintained at a cell count of 1 x 106 cells in 25 mL. Cells were checked 
every 48 h. Firstly, viable cell count was determined using trypan blue staining as previously 
described. When viable cell count was less than 1 x 106 cells, cells were centrifuged at 300 x g for 
5 min, supernatant was removed and the cell pellet was resuspended in 25 mL of pre-warmed 




C and 5 % CO2 for a further 48 h. When viable cell count was greater than 1 x 106 cells, cells were 
split or cryopreserved. To split cells, cells were transferred to a 50 mL Falcon® tube and centrifuged 
at 300 x g for 5 min. Supernatant was removed and the cell pellet was resuspended in 2 mL of 
pre-warmed enriched media. 1 mL of cells were added to two 50 mL Falcon® tubes each containing 
24 mL of pre-warmed enriched media. Cells were mixed by inversion, seeded in new Corning® 
T75 vented flasks and incubated at 37 C and 5 % CO2 for 48 h. For cryopreservation, cells were 
centrifuged at 300 x g for 5 min and supernatant was removed. The cell pellet was resuspended in 
7.5 mL of RPMI + L-glutamine supplemented with 20 % DMSO and 10 % FBS and cryovials were 
filled with 1.5 mL of resuspended cells. Cryovials were cooled slowly overnight at -80 C using a 
CoolCell® (Biocision, CA, USA) and then transferred to liquid nitrogen storage the following day. 
The above procedures were repeated until cells reached passage 10, at which time they were used 
for treatment 5-Aza-dc, 5-FU or 5-Aza-dc in combination with 5-FU.  
5.3.3 5-FU and 5-Aza-dc optimisation 
5-Aza-dc is a cytidine analogue and potent methylation inhibitor irreversibly binding DNMT1, 
leading to a decrease in global DNA methylation during DNA replication [138]. 5-Aza-dc was 
included in treatment as a positive control. Based on previous literature using a THP-1 cell line, a 
monocyte-like cell line with similar properties to U937, it was determined cells would be treated 
with 5-Aza-dc at a concentration of 5 µM [135]. As the combined effect of 5-Aza-dc and 5-FU was 
unknown, 5-FU concentration needed to be optimised. This was to ensure 5-FU would induce cell 
death in combination with 5-Aza-dc and, cell viability following treatment would be adequate to 
extract DNA and RNA from cells.  
Prior to drug treatment, cells were serum starved for 24 h to induce cell cycle arrest in the G1 
phase. As both 5-FU and 5-Aza-dc are antimetabolites, adding these drugs to cells in G1 arrest 




Briefly, cells were centrifuged at 300 x g for 5 min and supernatant was removed and replaced with 
RPMI + L-glutamine supplemented with 1 % Pen Strep. Cells were incubated at 37 C and 5 % 
CO2 for 24 h. Following serum starvation, viable cell count was determined using trypan blue 
staining. Cells were centrifuged at 300 x g for 5 min and supernatant was removed and replaced 
with pre-warmed enriched media, diluting the cells to a working viable cell count of 2 x 105 cells.  
In a Corning® 24-well plate, 1.2 mL of 2 x 105 viable cells were plated and 5-FU was added in 
triplicate to give a final concentration of 0, 10, 30, 40 and 50 µM in combination with 5 µM 5-Aza-dc. 
50 mg 5-Aza-dc was dissolved in 1 mL of Milli-Q® prior to treatment and diluted to a working 
concentration of 50 µM using Milli-Q®. Aliquots were stored at -80 C. 5-FU was supplied at a 
concentration of 1 g in 10 mL sterile water and was diluted to working concentrations prior to 
treatment using Milli-Q®. Working drug concentrations were made 10-fold higher than the desired 
concentration to reflect the 1/10 dilution that occurred when added to cell medium. Cells were 
treated with 5-FU and 5-Aza-dc at 0, 24 and 48 h and, cell viability was measured using trypan 
blue staining prior to each treatment time point. Total cell count and live cell count were averaged 
between the replicates and percentage cell viability was calculated for each 5-FU concentration 
by: average live cell count/average total cell count x 100. Optimisation was repeated twice over a 
two-week period. The optimisation results are presented in Figure 5.1 and will be discussed in the 
results.  
5.3.4 5-FU and 5-Aza-dc treatment  
From the optimisation experiments (Figure 5.1), it was determined cells would be treated in 
triplicate on six separate occasions to produce six biological replicates and six sets of independent 
results as follows: vehicle control (Milli-Q®), 5 µM 5-Aza-dc, 40 µM 5-FU or, 5 µM 5-Aza-dc in 
combination with 40 µM 5-FU. Cells were treated at 0 and 24 h time points, with cell viability 




working viable cell count of 2 x 105 as described previously. At 48 h, well contents were collected, 
pooled for each treatment group and percentage cell viability was calculated for each treatment 
group by: average live cell count/average total cell count x 100. Well contents were then stored at 
-20 C until RNA or DNA isolation. Cells were treated in triplicate on six separate occasions to 
produce six biological replicates and six sets of independent results.   
5.3.5 Gene expression of TNF, DNMT1 and DNMT3A using Real-Time Polymerase Chain 
Reaction (RT-PCR) 
5.3.5.1 RNA isolation  
Total RNA was isolated from 2 mL of cells at a minimum concentration of 2 x 105 cells using the 
NucleoSpin® RNA Isolation Kit as per the manufacturer’s instructions (Macherey-Nagel, 
Germany). Cells were centrifuged at 15,000 x g for 2 min and supernatant was discarded. To lyse 
cells, the cell pellet was resuspended in 350 µL of RA1 buffer and 3.5 µL of -mercaptoethanol 
was added and vortexed vigorously. Following vortexing, 350 µL of 70 % ethanol was added, the 
sample was again vortexed and loaded into a NucloSpin RNA column placed in a 2 mL collection 
tube. To bind RNA to the silica membrane, the column was centrifuged at 11,000 x g for 30 sec 
and flow-through was discarded from the collection tube. To desalt the silica membrane, 350 µL 
of membrane desalting buffer was added and the column was centrifuged at 11,000 x g for 1 min. 
To remove genomic DNA, 95 µL of rDNase reaction mixture was added to the matrix of the column 
and incubated at room temperature for 15 min. Following incubation, 200 µL of buffer RAW2 was 
added and the column was centrifuged at 11,000 x g for 30 sec. The column was placed in a new 
2 mL collection tube and 600 µL of buffer RA3 was added to the column and centrifuged again at 
11,000 x g for 30 sec. The flow through was discarded and 250 µL of buffer RA3 was added to the 
column and centrifuged at 11,000 x g for 30 sec. The column was placed in a 1.5 mL 




at 11,000 x g for 1 min. RNA was quantified using the Synergy™️ Mx Microplate Reader (BioTek 
Instruments, VT, USA) and was stored at -20 C until cDNA conversion.  
5.3.5.2 cDNA synthesis  
Isolated RNA was converted to cDNA using the iScript cDNA synthesis kit as per manufacturer’s 
instructions (Bio-Rad Laboratories Inc). Briefly, 4 µL of 5 x iScript and 1 µL of iScript reverse 
transcriptase was added to 15 µL of RNA in a 0.65 mL PCR tube. The following incubation was 
run on an FTS320 Thermal Sequencer (Corbett Research, NSW, Australia): 25 C for 5 min, 46 C 
for 20 min, 95 C for 1 min. Following incubation, cDNA was quantified using the Synergy Mx 
Microplate Reader. cDNA was immediately diluted to 100 ng/µL using RNase-free water and 
stored at -20 C until RT-PCR analysis.  
5.3.5.3 RT-PCR  
Primers used for RT-PCR were designed using Primer3 [139] and purchased from Integrated DNA 
Technologies (IA, USA) (Table 5.1). Gene expression was normalised to the housekeeping gene 
GAPDH. GAPDH has previously been used as a housekeeper gene in RT-PCR following 5-FU 
treatment [132, 140, 141]. RT-PCR reactions contained 1 µL cDNA sample (100 ng.µL-1), 5 µL 
Quantitect SYBR® Green PCR Master Mix, 0.5 µL of each forward and reverse primer (50 µM) 
and 3 µL RNase-free water to make a total volume of 10 µL. All samples were run in triplicate and 
all assay runs contained a non-template control. Using the Rotor-Gene Q (QIAGEN), each PCR 
consisted of a hold at 95 C for 15 min followed by 40 cycles of 95 C for 15 sec, 55 C for 30 sec 
and 72 C for 30 sec. Cycle threshold (Ct) values were calculated and Ct cut-off was set while 
viewing fluorescent readings in log scale. Melt curve analysis was conducted to ensure no 




Table 5.1 a) RT-PCR and b) MS-HRM primers.  










Forward: 5’-AATCAGTCAGTGGCCCAGAAG-3’ 57 
95 
Reverse: 3’-AAAGTTGGGGACACACAAGC-5’ 56 
DNMT1 
Forward: 5’-ACTGCTGGGTTTCAAATGCC-3’ 56 
78 
Reverse: 3’-TGAAACACCAAGGCACCAAG-5’ 56 
DNMT3A 
Forward: 5’-TTTGCTTGACAGTGGTTGCG-3’ 57 
83 
Reverse: 3’-TGCAGCGGCTTTTCTATAGC-5’ 56 
GAPDH 
Forward: 5’-CTCTCTGCTCCTCCTGTTCGAC-3’ 59 
69 
Reverse: 3’-TGAGCGATCTGGCTCGGCT-5’ 61 
 
b MS-HRM primers  
CpG sites included 
within the primer region 





Forward: 5’-TAGGTTTTGAGGGGTATGGG-3’ 54 
Reverse: 5’-TCAAAAATACCCCTCACACTCC-3’ 55 
-169, -163, -161 
Forward: 5’-GAGTGTGAGGGGTATTTTTGATG-3’ 54 
Reverse: 5’-GCAACCATAATAAACCCTACACCTTC-3’ 56 
-149, -119 
Forward: 5’-GCAACCATAATAAACCCTACACCTTC-3’ 54 
Reverse: 5’-CAACCAACCAAAAACTTCCTTAAT-3’ 52 
-72, -49, -38 
Forward: 5’-GAGGGGTATTTTTGATGTTTGTGT-3’ 54 




5.3.6 DNA methylation analysis of the TNF gene using methylation-specific high-resolution 
melt (MS-HRM) 
5.3.6.1 DNA isolation 
DNA was isolated from 2 mL of cells at a minimum concentration of 2 x 105 cells using the 
DNeasy Blood and Tissue Kit (QIAGEN). Cells were centrifuged at 15,000 x g for 2 min and 
supernatant was discarded. To lyse cells, the cell pellet was resuspended in 200 µL DPBS and, 
20 µL of protein kinase K and 200 µL of Buffer AL was added. The sample was vortexed vigorously 
and incubated at 56 C for 10 min. Following incubation, 200 µL of 100 % ethanol was added, the 
sample was vortexed and loaded into a DNeasy Mini spin column placed in a 2 mL collection 
tube. The column was centrifuged at 6,000 x g for 1 min and transferred to a new 2 mL collection 
tube. 500 µL of Buffer AW1 was added and the column was centrifuged at 6,000 x g for 1 min. The 
flow through was discarded and 500 µL of Buffer AW2 was added. The column was centrifuged 
for at 15,000 x g for 3 min and transferred to a new 1.5 mL microcentrifuge tube. DNA was eluted 
by adding 200 µL Buffer AE to the matrix of the column membrane, incubating the column for 1 
min at room temperature and centrifuged at 6000 x g for 1 min. DNA concentration was quantified 
using the Synergy Mx Microplate Reader and stored at 4 C until bisulfite modification.  
5.3.6.2 Bisulfite modification of DNA  
Isolated DNA was diluted to 300 ng.µL-1 using RNase-free water and bisulfite modified using the 
EZ DNA Methylation-Gold Kit (Zymo Research, CA, USA). In addition, 300 ng.µL-1 of 100 % 
methylated DNA and 100 % unmethylated DNA were also bisulfite modified using the 
beforementioned kit. 100 % methylated DNA and 100 % unmethylated DNA were used as positive 
and negative controls, respectively, in MS-HRM. 130 µL of CT conversion reagent was added to 
20 µL of diluted DNA in a 0.65 mL PCR tube and mixed by vortexing. The following incubation was 




incubation, the sample was loaded into a Zymo-SpinTM IC Column containing 600 µL of M-Binding 
Buffer placed in a collection tube. The sample was mixed in the column by inversion, and the 
column was centrifuged at 10,000 x g for 30 sec. The flow through was discarded and 100 µL of 
M-Wash Buffer was loaded into the column. The column was centrifuged again at 10,000 x g for 
30 sec and flow through was discarded. 200 µL of M-Desulphonation Buffer was loaded onto the 
matrix of the column and incubated at room temperature for 20 min. Following incubation, the 
column was centrifuged at 10,000 x g for 30 sec. 200 µL of M-Wash Buffer was added to the 
column and centrifuged again at 10,000 x g for 30 sec. This step was repeated twice. Bisulfite 
modified DNA was eluted by placing the column in a new 1.5 mL microcentrifuge tube, adding 10 
µL of M-Elution Buffer directly to the column matrix and centrifuged at 10,000 x g for 30 sec. The 
concentration of bisulfite modified DNA was quantified using the Synergy Mx Microplate Reader. 
Bisulfite modified DNA was immediately diluted to 100 ng.µL-1 and stored at -20C until MS-HRM 
analysis.  
5.3.6.3 MS-HRM 
Primers used for MS-HRM were from previous literature and purchased from Integrated DNA 
technologies (IA, USA) (Table 5.1) [135]. Each primer set included a number of CpG sites (Table 
5.1). MS-HRM reactions contained 1 µL bisulfite modified DNA (100 ng.µL-1), 2.5 µL 10 x PCR 
buffer, 1.5 µL MgCl (25 mM), 2 µL dNTP solution mix (2.5 mM), 1.5 µL of each forward and reverse 
primer (50 µM), 0.75 µL SYTO 9, 0.25 µL HotStarTaq DNA Polymerase and 9 µL RNase-
free water to make a total volume of 20 µL. All samples were run in duplicate and for each primer 
pair, a reaction containing bisulfite modified 100 % methylated and 100 % unmethylated DNA was 
included as a positive and negative control, respectively. Using the Rotor-Gene 600 (Corbett 
Research, NSW, Australia) each MS-HRM consisted of a hold at 95 C for 15 min followed by 50 




for 30 sec occurred before HRM was run for 1 cycle of 0.1 C temperature increases every 12 sec 
rising from 65 C to 95 C. Fluorescence values were calculated by Rotor-Gene Q analysis 
software (Version 2.3, QIAGEN).  
5.3.7 Statistical Analysis  
Data was tested for normality using the D’Agostino & Pearson test. In the optimisation experiment, 
data was normally distributed therefore, differences in cell viability between 5-FU concentrations 
was determined using t-tests. Correlation analysis was performed using Pearson correlation 
between 5-FU concentration alone or in combination with 5-Aza-dc and percentage cell viability. 
Differences in viability between cells treated with vehicle control, 5-Aza-dc, 5-FU or 5-Aza-dc in 
combination with 5-FU was determined using either the Friedman or Wilcoxon test with Dunn’s 
multiple comparison test as data was not normally distributed. For RT-PCR analysis, Ct values 
were analysed using the Ct method [142] to calculate relative expression. Relative expression 
was then compared between cells treated with vehicle control, 5-Aza-dc, 5-FU or 5-Aza-dc in 
combination with 5-FU using the Friedman test and Dunn’s multiple comparison test as data was 
not normally distributed. For MS-HRM analysis, fluorescence values for the four treatment groups 
(vehicle control, 5-Aza-dc, 5-FU or 5-Aza-dc in combination with 5-FU) as well as for the 100 % 
methylated DNA positive control, were normalised to the 100 % unmethylated DNA negative 
control. Normalisation corresponded to the percentage of DNA methylation for each sample and 
this was then compared between cells from each treatment group using the Friedman test and 





5.4.1 Optimisation of 5-FU and 5-Aza-dc in U937 cells  
Percentage cell viability was highly correlated with 5-FU concentration alone (R2 = 0.939, 
P = 0.007) and, 5 μM 5-Aza-dc in combination with 5-FU concentration (R2 = 0.924, P = 0.009) 
following 48 h exposure (Figure 5.1).  
5-FU at concentrations of 30 μM (P = 0.024), 40 μM (P = 0.019) and 50 μM (P = 0.002) induced 
significant cell death compared to untreated cells (Figure 5.1). 5 μM 5-Aza-dc alone did not induce 
significant cell death compared to untreated cells (P = 0.051) (Figure 5.1). However, 5 μM 5-Aza-
dc treated in combination with 5-FU at either 30 μM (P < 0.001), 40 μM (P < 0.001) or 50 μM 
(P < 0.001) induced significant cell death compared to untreated cells (Figure 5.1).  
When comparing 5-FU treated alone or in combination with 5 μM 5-Aza-dc, only a significant 
difference in cell viability between cells treated with 40 μM 5-FU alone or 5 μM 5-Aza-dc in 
combination with 40 μM 5-FU was determined (P < 0.001). No significant differences between cells 
treated with i) 10 μM 5-FU alone or 5 μM 5-Aza-dc in combination with 10 μM 5-FU (P = 0.068), 
ii) 30 μM 5-FU alone or 5 μM 5-Aza-dc in combination with 30 μM 5-FU (P = 0.213) and iii) 50 μM 
5-FU alone or 5 μM 5-Aza-dc in combination with 50 μM 5-FU (P = 0.051) were identified.  
From the optimisation experiment, it was determined cells would be treated with 5 µM 5-Aza-dc, 
40 µM 5-FU or 5 µM 5-Aza-dc in combination with 40 µM 5-FU. Median cell viability for cells 
treated with 40 µM 5-FU alone or with 5 µM 5-Aza-dc in combination with 40 µM 5-FU was 68 % 
and 56 %, respectively (Figure 5.1). This confirmed the concentration of 40 µM 5-FU was sufficient 
to induce DNA damage and cell death as well as, result in adequate cell viability necessary for 















Figure 5.1 Optimisation of 5-FU and 5-Aza-dc in U937 cells to determine a treatment dose that will not only induce cell injury and death but, result in a viable cell 





5.4.2 5-FU and 5-Aza-dc induce cell death  
At 24 h following treatment, median viability of cells treated with 5-FU was 77 % (P = 0.044) and those 
treated with 5-Aza-dc in combination with 5-FU was 73 % (P = 0.007), significantly decreased 
compared to cells treated with vehicle control at 91 % median cell viability (Figure 5.2a). At 48 h (48 h 
post-first treatment and 24 h post-second treatment), median viability of cells treated with 5-FU was 
70 % (P = 0.022) and those treated with 5-Aza-dc in combination with 5-FU was 57 % (P < 0.001), 
which was also significantly decreased compared to cells treated with vehicle control at 93 % median 
cell viability (Figure 5.2b). No significant differences in median cell viability were identified between 
cells treated with vehicle control and 5-Aza-dc at 24 h and 48 h (P = 0.202 and P > 0.999, respectively). 
The significant cell death observed in cells treated with 5-FU or 5-Aza-dc in combination with 5-FU, 
compared to untreated cells at 48 h, is consistent with the results of the optimisation experiment 
(Section 5.4.1).  
Wilcoxon tests determined there were no significance differences in median cell viability between 24 
and 48 h (48 h post-first treatment and 24 h post-second treatment) for cells treated with vehicle control 
(P = 0.875), 5-Aza-dc (P = 0.656), 5-FU (P = 0.219) and 5-Aza-dc in combination with 5-FU 
(P = 0.563).  
Images of cells were taken at 24 and 48 h (48 h post-first treatment and 24 h post-second treatment) 
following treatment under a phase contrast microscope at 50 x magnification (Figure 5.3). 
Morphological changes were obvious following treatment with 5-Aza-dc, 5-FU and 5-Aza-dc in 
combination with 5-FU. A clear decrease in cell number was observed, cells lost their spherical shape 
















Figure 5.2 U937 cell viability at a) 24 and b) 48 h following treatment with vehicle control (Milli-Q®), 
5 µM 5-Aza-dc, 40 µM 5-FU or, 5 µM 5-Aza-dc in combination with 40 µM 5-FU. Line indicates median 














































































































Figure 5.3 Morphological characteristics of U937 cells at 24 and 48 h following treatment with a and 
b) vehicle control (Milli-Q®), c and d) 5 µM 5-Aza-dc, e and f) 40 µM 5-FU or, g and h) 5 µM 5-Aza-dc 
in combination with 40 µM 5-FU. Images were taken under a phase contrast microscope at 50 x 
magnification.  








5.4.3 Gene expression of TNF is significantly increased following treatment with 5-FU and 5-FU in 
combination with 5-Aza-dc 
Cells treated with vehicle control had significantly lower relative expression of TNF compared to cells 
treated with 5-FU or 5-Aza-dc in combination with 5-FU (Figure 5.4a). The median expression ratio of 
TNF in cells treated with 5-FU was 0.187 compared to 0.070 in cells treated with vehicle control 
(P = 0.005). Likewise, the median expression ratio of TNF for cells treated with 5-Aza-dc in 
combination with 5-FU was 0.171 compared to vehicle control (P = 0.044). There were no significant 
differences in relative expression of TNF between cells treated with 5-Aza-dc and cells treated with 
vehicle control (P = 0.265).  
Cells treated with 5-Aza-dc had significantly lower relative expression of DNMT1 compared to cells 
treated with vehicle control, with the median expression ratio of DNMT1 in cells treated with 5-Aza-dc 
being 0.075 compared to 0.500 in cells treated with vehicle control (P < 0.001) (Figure 5.4b). There 
were no significant differences in relative expression of DNMT1 between cells treated with 5-FU or 
5-Aza-dc in combination with 5-FU and cells treated with vehicle control (P > 0.999 and P = 0.152, 
respectively). 
There were no significant differences in relative expression of DNMT3A between cells treated with 
















Figure 5.4 Relative gene expression of a) TNF, b) DNMT1 and c) DNMT3A in U937 cells treated with vehicle control (Milli-Q®), 5 µM 5-Aza-dc, 40 µM 5-FU or, 
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5.4.4 DNA Methylation at TNF CpG Sites 
Across CpG sites -244 and -238, DNA methylation was significantly lower in cells treated with 
5-Aza-dc and 5-Aza-dc in combination with 5-FU compared to cells treated with vehicle control 
(Figure 5.5a). Median DNA methylation of -244 and -238 in cells treated with 5-Aza-dc was 53 % 
compared to 78 % in cells treated with vehicle control (P = 0.0005). Median DNA methylation 
across these CpG sites in cells treated with 5-Aza-dc in combination with 5-FU was 55 % compared 
to cells treated with vehicle control (P = 0.031). There were no significant differences in DNA 
methylation across CpG sites -244 and -238 between cells treated with i) 5-FU and vehicle control 
(P > 0.999), ii) 5-FU and 5-Aza-dc (P = 0.061), iii) 5-FU and 5-Aza-dc in combination with 5-FU 
(P = 0.877) and, iv) 5-Aza-dc and 5-Aza-dc in combination with 5-FU (P > 0.999).  
Across CpG sites -169, -163 and -161, DNA methylation was also significantly lower in cells treated 
with 5-Aza-dc and 5-Aza-dc in combination with 5-FU compared to cells treated with vehicle control 
(Figure 5.5b). Median DNA methylation of -169, -163 and -161 in cells treated with 5-Aza-dc was 
54 % compared to 84 % in cells treated with vehicle control (P = 0.044). Median DNA methylation 
across these CpG sites in cells treated with 5-Aza-dc in combination with 5-FU was 43 % compared 
to cells treated with vehicle control (P < 0.001). There were no significant differences in DNA 
methylation across CpG sites 169, -163 and -161 between cells treated with i) 5-FU and vehicle 
control (P > 0.999), ii) 5-FU and 5-Aza-dc (P > 0.999), iii) 5-FU and 5-Aza-dc in combination with 
5-FU (P = 0.054) and, iv) 5-Aza-dc and 5-Aza-dc in combination with 5-FU (P > 0.999).  
MS-HRM primers amplifying CpG sites -149 and -119, and -72, -49 and -38 upstream of the TNF 
transcription start site were not analysed as these primers amplified non-specific products and 
could provide any results (data not shown). Therefore, DNA methylation across these CpG sites 
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Figure 5.5 DNA methylation was compared in U937 cells treated with vehicle control (Milli-Q®), 5 
µM 5-Aza-dc, 40 µM 5-FU or, 5 µM 5-Aza-dc in combination with 40 µM 5-FU across CpG sites 
a) -244 and -238 and, b) -169, -163 and -161 upstream of the TNF transcription start site. Line 
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5.5 Discussion  
The findings of this study indicate 5-FU does not inhibit DNA methyltransferase activity in 
monocytic-like cells and does not reduce DNA methylation at CpG sites throughout the TNF 
promoter region. The aim of this study was to investigate if 5-FU could inhibit mRNA expression of 
DNMT1 and DNMT3A and therefore, reduce DNA methylation across CpG sites -244, -238, 
169, -163, -161, -149, -119, -72, -49 and -38 upstream of the TNF transcription start site in U937 
cells. It was identified only treatment with DNA methylation inhibitor 5-Aza-dc was able to 
significantly decrease DNMT1 mRNA expression and reduce DNA methylation across CpG sites 
-244, -238, -169, -163 and -161. This demonstrates 5-FU is not a potent DNA methylation inhibitor 
and therefore, may not increase TNF gene expression and subsequent TNF-⍺ secretion that is 
characteristic of mucosal injury experienced during severe GI toxicity.  
This was one of the first studies investigating the effect of 5-FU in combination with 5-Aza-dc on 
mRNA expression and DNA methylation within the TNF gene in the U937 cell line. It was 
determined treatment with 5 μM 5-Aza-dc did not significantly decrease cell viability in U937 cells, 
suggesting the antimetabolite action of 5-Aza-dc as a cytidine analogue [138] and, its effect as a 
potent DNA methylation inhibitor [143], did not induce significant cell death in the U937 cell line. 
Significant cell death was determined to be a direct consequence of 5-FU, with median cell viability 
inversely proportional to 5-FU concentration. Following treatment with 5-Aza-dc and/or 5-FU at 24 
and 48 h, cell viability was significantly different between cells treated with 5-FU and 5-Aza-dc in 
combination with 5-FU compared to cells treated with vehicle control. This decrease in cell viability 
was expected based on the results of the optimisation experiment.  
DNA methylation is mediated by DNMT1 and DNMT3A which both catalyse the transfer of methyl 
groups to CpG sites within the DNA sequence. To determine if 5-FU inhibits DNA methylation, it 
was investigated if treatment with 5-FU inhibited mRNA expression of DNMT1 and DNMT3A. No 
such inhibition of DNMT1 and DNMT3A was observed following treatment with 5-FU, with a 
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significant decrease in DNMT1 only observed following treatment with 5-Aza-dc alone. These 
results are contradictory to previous literature which demonstrated 5-FU (2 – 200 μM) in vitro 
significantly decreased DNMT1, DNMT3A and overall methyltransferase expression [132]. Ham et 
al. investigated the effect of 5-FU on DNMT1 and DNMT3A expression in a human lung cancer cell 
line (A549) [132] compared to the monocytic-like U937 cell line used in this study. Cancer cells are 
highly methylated in comparison to monocytes and as a result, the degree of inhibition of 
expression of DNMT1 and DNMT3A following the addition of a DNA methylation inhibitor or drug 
that inhibits DNA methylation, may differ between the two cell types. Cancer cells may have a 
greater degree of DNA methylation inhibition due to their already highly methylated state, 
explaining why Ham et al identified significant differences in DNMT1 and DNMT3A expression 
following 5-FU treatment whereas, no significant differences in DNMT1 and DNMT3A following 
5-FU treatment were identified in this study. This suggests 5-FU may not inhibit DNA methylation 
in monocytic-like cells to the same degree as cancer cell types.  
To determine if inhibition of DNA methylation increases TNF expression, TNF mRNA expression 
was also investigated in this study. TNF mRNA expression was significantly increased only in cells 
treated with 5-FU alone or with 5-FU in combination with 5-Aza-dc. This result is in agreement with 
previous preclinical research demonstrating increased TNF expression and TNF-⍺ serum levels 
following 5-FU treatment [110]. However, TNF mRNA expression was not significantly different 
following treatment with 5-Aza-dc, contrary to the hypothesis that cells treated with 5-Aza-dc would 
show a significant increase in TNF mRNA expression. This demonstrated DNA methylation did not 
influence TNF mRNA expression, contradictory to the hypothesis for this current study which was 
based on previous results by Zhang et el. [135] who identified THP-1 cells treated with 5 μM 
5-Aza-dc exhibited an increase in TNF expression. Zhang et al. [135] investigated DNA methylation 
in the THP-1 cell line, a human monocytic leukaemia cell line [144], with similar properties to the 
U937 human myeloid leukaemia cell line [137] used in this current study. However, a possible 
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explanation for the discrepancy in results between this current study and the study by Zhang et al. 
is that TNF mRNA expression for cells treated with 5-Aza-dc was determined at 48 h in this study 
compared to 24 h in the study by Zhang et al. [135]. Although cell culture media was replaced and 
cells were re-treated at 24 h, ideally TNF mRNA expression should have also been investigated at 
the 24 h time point (24 h following first treatment) in order to confirm cell death did not significantly 
impact the TNF mRNA expression. When 5-Aza-dc and 5-FU were first administered, cells were in 
cell cycle arrest at the G1 phase. This was to increase the likelihood of these antimetabolites 
becoming incorporated in newly synthesised DNA. When re-treated with 5-Aza-dc and 5-FU at 24 
h, cells were not necessarily in the same cell cycle phase and cell death was prominent, particularly 
in cells already treated with 5-Aza-dc, 5-FU, and 5-Aza-dc in combination with 5-FU. Therefore, 
the inhibitory effect of 5-FU on DNMT1 and DNMT3A mRNA expression as well as the effect of 
5-Aza-dc on TNF mRNA expression may have been significant at 24 h but, lost significance at 48 
h due to cell death and variation in cell cycle phases.  
The effect of 5-FU on DNA methylation within the TNF gene, particularly at CpG sites -244 
and -238, and -169, -163 and -161 upstream of the TNF transcription start site, was also 
determined. Treatment with 5-Aza-dc or 5-Aza-dc in combination with 5-FU significantly decreased 
DNA methylation across these CpG sites, while there was no impact of 5-FU. This is contradictory 
to previous research identifying differences in DNA methylation across these CpG sites in other 
inflammatory-based conditions [134, 135]. These studies investigated DNA methylation in gingival 
tissue, containing a range of cell types including fibroblasts, macrophages, osteoblasts and 
inflammatory cells (such as neutrophils and eosinophils) [135] and; DNA methylation in DNA 
isolated from peripheral blood mononuclear cells, comprised of lymphocytes, monocytes and 
dendritic cells [134]. In my study, as DNA methylation was solely investigated in monocytic-like 
U937 cells, this further suggests DNA methylation varies across cell types. 
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MS-HRM primers amplifying CpG sites -149 and -119, and -72, -49 and -38 upstream of the TNF 
promoter region were not included in analysis and, DNA methylation could not be investigated at 
these sites. Following multiple MS-HRM runs, these primers consistently amplified non-specific 
regions (determined from melt curve analysis following each MS-HRM run) and PCR products 
could not be detected using agarose gel electrophoresis (data not shown). These primers were 
used previously in THP-1 cells [135], a cell line with similar properties to U937 cells [137]. However, 
it is possible in U937 cells, the regions of interest for these primers may contain a low frequency of 
DNA methylated sites. Consequently, as the primers were specific to methylated regions it is 
possible they would not amplify the region containing the CpG sites of interest due to low DNA 
methylation frequency. Additionally, with the consistent amplification of non-specific products, there 
may have been high background within the regions of interest, making it difficult to distinguish 
changes in DNA methylation across the selected CpG sites.  
A key limitation of this study was TLR agonists such as lipopolysaccharide (LPS) were not included 
in treatment with 5-Aza-dc and/or 5-FU. As discussed in Chapter 2, TLRs mediate an innate 
immune response via the TIR domain signalling pathway, leading to the secretion of 
proinflammatory cytokines such as TNF-⍺, which is characteristic of 5-FU-induced GI toxicity. The 
inclusion of LPS or a similar TLR agonist would have investigated an alternate hypothesis; namely 
the inflammatory response induced by 5-FU is responsible for inhibition of DNA methylation of the 
TNF gene, rather than 5-FU itself. This could have possibly explained why DNA methylation was 
not significantly different throughout the TNF promoter region in this study following 5-FU 
treatment.  
As this was a pilot study aimed to investigate the concept that 5-FU reduces DNA methylation 
within the TNF gene promoter region, MS-HRM was selected to detect DNA methylation over 
pyrosequencing. Pyrosequencing is a high-cost, outsourced DNA methylation detection assay 
which determines the exact DNA methylation percentage at individual CpG sites. In comparison, 
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although MS-HRM is low cost and provides fast and sensitive detection of DNA methylation, it does 
so across multiple selected CpG sites which is its biggest pitfall. As a result, the methylation of 
combined CpG sites may hide the fact that methylation at one CpG site may have been significantly 
different after treatments. In addition, with missing data from CpG sites -149 and -119, and -72, -49 
and -38 upstream of the TNF promoter region, it was not determined if 5-FU was able to 
significantly reduce DNA methylation at these CpG sites. 
5.6 Conclusion  
In conclusion, 5-FU did not reduce mRNA expression of DNMT1 and DNMT3A or, reduce DNA 
methylation across TNF promoter CpG sites -244 and -238, and -169, -163 and -161. Although the 
hypothesis was not supported, the limitations of this study prevent a concrete conclusion that DNA 
methylation within the TNF gene following 5-FU-based therapy is not a potential predictive marker 
for severe GI toxicity. This study needs to be repeated addressing the limitations discussed, 
notably, treating not only U937 cells but a cancer cell line as a positive control with a variety of 
5-FU and/or 5-Aza-dc concentrations in addition to TLR agonists such as LPS. Once the predictive 
potential of DNA methylation within the TNF promoter gene region is identified following 5-FU 
treatment, ex vivo analysis can then occur in isolated PBMCs to determine if the results are 
clinically translatable and DNA methylation of the TNF gene is viable predictive marker for severe 
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Chapter 6: Thesis discussion 
This thesis presents results of studies investigating the potential of the TIR domain innate immune 
signalling pathway to predict severe GI toxicity risk following 5-FU-based therapy. The major 
findings of this thesis are divided into retrospective clinical, ex vivo and in vitro observations. It 
must be noted the design and conduct of each study was independent from other studies.  
In Chapter 3, multivariate logistic regression built a final risk prediction model which identified 
5-FU-based regimen to be predictive for severe GI toxicity risk in participants classified as non-toxic 
(no or moderate to mild GI toxicity) and toxic (severe GI toxicity) to 5-FU. This was the first time 
logistic regression modelling has demonstrated 5-FU-based regimen to be predictive for severe GI 
toxicity risk. This result is contradictory to the pilot study [25], which identified TLR2 rs384100 and 
TNF rs1800629 SNPs in conjunction with cancer type (colorectal and upper GI) to be predictive for 
severe GI toxicity risk.  
Throughout this current study as the demographic, clinical and genetic composition of the 
participant cohort changed, so did the predictive nature of demographic, clinical and genetic 
variables as identified by risk prediction modelling. This was most evident when the interim risk 
prediction model identified SNPs within IL1B (rs16944 and rs1143434), in conjunction with cancer 
type (colorectal and upper GI), to be predictive for severe GI toxicity risk. However, these identified 
predictors lost their predictive nature in the final risk prediction model.  
Risk prediction models are becoming increasingly prominent in clinical practice and therefore, 
consistent with similar research examining patients receiving chemotherapy and/or radiotherapy 
for advanced cancers [145-147], multivariate logistic regression modelling was chosen for 
statistical analysis. However, due to the small and highly variable clinical make-up of the participant 
cohorts, Bayesian Networking (BN), another form of risk prediction modelling, may have been a 
more appropriate modelling method. BN has also been used extensively in patient cohorts 
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receiving chemotherapy and/or radiotherapy [148, 149]. Compared to the multivariate logistic 
regression method used for statistical analysis in Chapter 3 (discussed in Section 3.4.4), BN can 
outperform multivariate logistic regression models as less data is required to reach peak model 
performance [150]. Additionally, BN determines the relationship between the covariates included 
in the model and their dependency on each other, depicted by a directed acyclic graph [150]. 
Therefore, BN may provide a more informative risk prediction model for severe GI toxicity following 
5-FU-based therapy. Multivariate logistic regression and BN models have been compared within 
clinical patient cohorts previously but, one has not consistently been identified as more reliable or 
predictive than the other [151, 152]. Due to time constraints, BN was not modelled with the final 
participant cohort and compared to the final risk prediction model built using the multivariate logistic 
regression method. Nonetheless, the sensitivity and specificity of a risk prediction model to 
accurately identify patients at most risk of severe GI toxicity would be greatly improved with the 
addition of a phenotypic marker. However, there is a lack of phenotypic marker for severe GI 
toxicity. This led to the ex vivo study in Chapter 4.  
In Chapter 4, investigation of an ex vivo phenotypic marker for severe GI toxicity in a subset of 
participants recruited from Chapter 3 was undertaken. It was determined stimulated IL-1β secretion 
post-5-FU-based therapy was significantly increased in participants classified as having a non-
toxic response to 5-FU at the time of therapy. Additionally, CASP1 rs580253 and CASP5 rs554344 
genotypes were also associated with stimulated IL-1β secretion post-5-FU-based therapy however, 
there was no consistent change in secretion of stimulated IL-1β secretion with the increasing 
presence of the variant allele. The association between CASP1 rs580253 and CASP5 rs554344 
genotypes and stimulated IL-1β secretion was independent of GI toxicity risk. To the best of my 
knowledge, this was the first study investigating stimulated TIR domain innate immune response 
in participants post-5-FU-based therapy. 
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Overall, no three-way association with GI toxicity, genotype or stimulated IL-1β secretion was 
identified. This suggests IL-1β as a phenotypic marker for severe GI toxicity risk is not dependent 
on genotype. This is consistent with previous research which has identified many SNPs in IL1B are 
in linkage disequilibrium therefore, those with opposing effects on gene functioning and IL-1β 
secretion [94] may ‘cancel’ one another out, which could explain why no relationship between 
stimulated IL-1β secretion and SNPs within IL1B was not identified in my study. The results of 
Chapter 4 indicate differences in stimulated IL-1β secretion post-5-FU-based therapy and, 
potentially general IL-1β secretion, may not be heavily influenced by genotype but more so, the 
innate immune cells, such as monocytes and macrophages, from which IL-1β is secreted. 
Additionally, no significant associations were determined between stimulated TNF-⍺ secretion and 
GI toxicity, suggesting any potential differences in TNF-⍺ secretion between the two toxicity groups 
may only occur during treatment with 5-FU itself and not following TLR2 or TLR4 stimulation. Future 
studies could examine proinflammatory cytokine responses in PBMCs collected from participants 
prior to receiving 5-FU-based therapy to determine when changes in IL-1β and TNF-⍺ secretion 
occur as a result of innate immune memory induced by 5-FU-based therapy.  
The results of the interim predictive risk model in Chapter 3 and, secretion results from Chapter 4, 
implicated IL1B genotype and stimulated IL-1β secretion, respectively, with GI toxicity in 
participants recruited to both study cohorts. However, due to the limitations of both studies, it is 
difficult to conclude if SNPs within IL1B, stimulated IL-1β secretion and SNPs within CASP1 and 
CASP5 genes (CASP1 and CASP5 are both responsible for cleaving inactive IL-1β to its active 
form) are potential genetic and phenotypic predictive markers for severe GI toxicity risk. The MAF 
of SNPs within IL1B in participants recruited in Chapter 3 was not reflective of the Caucasian 
population and, as more participants were added to the study cohort, IL1B rs16944 and rs1143634 
were no longer identified to be predictive for severe GI toxicity risk in the final risk prediction model. 
In Chapter 4, whilst stimulated IL-1β secretion was significantly different between non-toxic and 
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toxic participants, secretion was observed in PBMCs isolated from participants post-5-FU-based 
therapy. Consequently, due to the presence of innate immune memory, this secretion may not be 
reflective of the stimulated IL-1β secretion profile observed in PBMCs pre- and throughout 
5-FU-based therapy. Therefore, IL-1β secretion may potentially have no significance as a 
phenotypic marker for severe GI toxicity risk pre- and throughout 5-FU-based therapy. Additionally, 
although stimulated IL-1β secretion was also significantly different between SNPs within CASP1 
(rs580253) and CASP5 (rs554344), only 2 participants were carriers of the homozygous variant 
genotype for both SNPs. This may explain why no consistent decrease in stimulated IL-1β 
secretion pattern was observed with changes in genotype.  
Neither Chapters 3 or 4 identified a significant relationship between SNPs within TNF and severe 
GI toxicity risk or, stimulated TNF-⍺ secretion post 5-FU-based therapy with GI toxicity risk, 
respectively. This formed the basis for investigating whether DNA methylation induced by 5-FU 
was an alternate genetic modification within TNF that may be predictive for severe GI toxicity in 
Chapter 5. This was the only non-clinical study in my thesis and investigated the effect of 5-FU on 
DNA methylation within the TNF gene. Although 5-FU did increase TNF mRNA expression 
following treatment as expected, treatment with the DNA methylation inhibitor 5-Aza-dc did not 
significantly increase TNF mRNA expression. This demonstrated inhibition of DNA methylation was 
not necessarily responsible for increased TNF mRNA expression. This was contradictory to 
previous research by Zhang et al. upon which the methodology of Chapter 5 was based [135]. 
Furthermore, treatment with 5-FU did not significantly decrease DNMT1 mRNA expression 
compared to 5-Aza-dc, suggesting 5-FU is not a potent DNA methylation inhibitor. At the selected 
CpG sites within the TNF gene promoter region, treatment with 5-FU also did not significantly 
reduce DNA methylation compared to untreated cells and cells treated with 5-Aza-dc. This further 
supports the suggestion 5-FU does not reduce DNA methylation within the TNF gene in a 
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monocytic-like cell line. But, further research is needed in PBMCs isolated from participants pre- 
and throughout 5-FU-based therapy to more closely resemble clinic.  
It is difficult to compare the results of Chapter 5 to previous research as to my knowledge, this is 
the first study to investigate the influence of 5-FU treatment on DNA methylation within TNF in vitro. 
The hypotheses for this study was based upon an additional inhibitory effect of 5-FU on the enzyme 
thymidylate synthase (TS). As well as inhibiting DNA synthesis, 5-FU also prevents the conversion 
of a key precursor folinic acid derivative required for DNA methylation. The results in Chapter 5 
suggest this inhibitory effect is not sufficient to prevent DNA methylation of the TNF gene therefore, 
this mechanism cannot explain increased TNF mRNA expression following 5-FU treatment. 
However, the results of this study must be considered in the context of its limitations, which 
prevents a concrete conclusion to be made. Most notably, missing data for 5 of the 10 CpG sites 
selected for analysis and, not treating cells with a variety of 5-FU and 5-Aza-dc concentrations. In 
future, DNA methylation investigations could occur simultaneously in a study like that presented in 
Chapter 4. The results would potentially carry greater clinical relevance as analysis would occur in 
PBMCs isolated from participants who received 5-FU-based therapy.  
Future directions  
The research conducted in Chapters 3 and 4 was retrospective in nature. However, to counteract 
the limitations discussed and identify clinically translatable genetic, phenotypic and epigenetic 
predictors for severe GI toxicity risk, prospective studies would need to occur. Retrospective 
analysis allowed identification of 2185 potential participants who were treated with 5-FU-based 
therapy from 2012 to 2018. However, even with these 2185 potential participants, it stil l took over 
3½ years to recruit the target sample size of 150 participants. Prospective analysis was unable to 
occur due to high expense of conducting such a study, funding that was not able to be obtained 
during my PhD.  
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Prospective analysis would allow accurate collection of GI toxicity data and selection of participants 
based on genotype to ensure the MAF of the cohort is reflective of the Caucasian population. For 
ex vivo analysis, a prospective study would allow pre- and post-5-FU-based stimulation of PBMCs 
to determine changes in the IL-1β and TNF-⍺ secretory response that may occur during 
5-FU-based therapy. Simultaneously, DNA methylation analysis could also occur on PBMCs 
isolated from participants directly after receiving 5-FU. However, as severe GI toxicity risk is an 
under represented area of medical oncology, the best chance of investigating severe GI toxicity in 
a prospective cohort would be to conduct research in combination with a clinical trial.  
Significance of results 
Although severe GI toxicity is mediated by the TIR domain innate immune signalling pathway, the 
development of severe GI toxicity is multifaceted. Therefore, the more information included in a 
risk prediction model for severe GI toxicity, such as demographics, clinical data, genotype, 
proinflammatory secretory response and DNA methylation percentage, the greater the chance of 
accurately identifying patients at risk of severe GI toxicity.  
As discussed throughout this thesis, predictive risk modelling gives the most accurate method of 
correctly identifying patients at risk of severe GI toxicity prior to receiving 5-FU-based therapy. 
However, the logistics of translating a predictive risk model for severe GI toxicity into clinic is not 
straight forward. Evidently, statisticians would be required to input patient data, run the risk 
prediction model as well as, report and translate the results of the model to the medical oncologist 
in charge of the patients’ care. More importantly, extra clinical staff would also be required to collect 
the necessary demographic data, clinical data and patient biological samples necessary for the 
model on behalf of already time poor medical oncologists. If assays on patient biological samples 
are required to be undertaken, laboratory staff would also need to be employed. Before translating 
risk prediction models into clinic, it would also need to be considered if the financial cost of 
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employing additional staff at every hospital site to conduct the risk prediction modelling outweighs 
not only the financial benefit on the health care system and for patients receiving 5FU-based 
therapy but, also outweighs improved patient quality of life whilst receiving treatment. This type of 
economic evaluation has not been previously conducted.  
Identifying patients at most risk of severe GI toxicity is imperative to allow the personalisation of 
their supportive care measures to reduce the severity of GI toxicity experienced. Not only would 
this improve patient quality of life during 5-FU-based therapy but, will also positively influence their 
immediate and long term prognosis. Although the observations made throughout this thesis point 
to no concordant predictive marker for severe GI toxicity risk, my thesis has shown that GI toxicity 
can be interrogated by demographic, genetic, phenotypic and epigenetic approaches. Further work 
can be used to model these factors together as well as identify deeper relationships with personal 
characteristics to move to a truly personalised therapy age.  
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Appendix: Chapter 2 
Korver SK, Gibson RJ, Bowen JM & Coller JC (2019) Toll-like receptor/interleukin-1 domain innate 
immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal 
toxicity risk following 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 83: 
217 - 236.  
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Appendix: Chapter 4 
Chapter 4, Appendix Natural log-transformed IL-1 secretion (pg.mL-1) pre- and post- TLR2 
(PAM3CSK4) or TLR4 (LPS) stimulation for carriers of homozygous wild-type, heterozygous or 
homozygous variant genotypes for a) TLR2 rs3804100, b) TLR4 rs4986790 and rs4986791, c) 
IL1B rs16944 and rs1143627, d) IL1B rs1143634 and e) TNF rs1800629.  
 
   




    
a TLR2 rs3804100 
  
WT/WT 
(n = 28) 
WT/Var 
(n = 3) 
 
 




Pre-stimulation  1.9 (0.5 – 3.5)  2.1 (0.8 – 2.1) 0.665 
0.00005 0.4 (0.1 – 2.3) 0.4 (0.2 – 0.4) 0.747 
0.1 2.4 (1.5 – 3.9) 2.4 (2.1 – 2.8) 0.765 
100 2.5 (1.8 – 4.0) 2.3 (2.1 – 2.4) 0.665 
PAM IL-1β 
Pre-stimulation 1.9 (0.1 – 3.0) 1.4 (1.3 – 2.0) 0.747 
0.00005 2.1 (0.2 – 3.0)  2.0 (1.9 – 2.1) 0.747 
0.01 2.4 (1.4 – 3.1) 2.2 (1.9 – 2.4) 0.665 
1 2.5 (1.7 – 3.1) 2.2 (1.9 – 2.2) 0.665 
LPS TNF-α 
Pre-stimulation 2.1 (1.2 – 3.8) 3.4 (1.6 – 3.5) 0.665 
0.00005 2.4 (1.1 – 4.1) 3.2 (2.1 – 3.5) 0.665 
0.1 2.4 (1.6 – 3.8) 3.6 (2.3 – 3.8) 0.665 
100 2.5 (1.4 – 4.0) 3.7 (2.0 – 3.8) 0.747 
PAM TNF-α 
Pre-stimulation 2.0 (0.8 – 3.5) 2.8 (1.2 – 2.9) 0.665 
0.00005 2.3 (1.0 – 3.7) 2.6 (0.4 – 3.1) 0.665 
0.01 2.3 (1.4 – 3.6) 3.1 (2.9 – 3.3) 0.665 
1 2.5 (1.2 – 3.8) 3.0 (2.3 – 3.4) 0.665 
LPS IL-1β: TLR4 (LPS) stimulated IL-1β secretion; n: number of participants; PAM IL-1β: TLR2 (PAM3CSK4) stimulated IL-1β secretion; WT/WT: homozygous wild-type 
genotype; WT/Var: Heterozygous genotype.  
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b TLR4 rs4986790 and rs4986791 WT/WT 
(n = 28) 
WT/Var 
(n = 3) 
 
 




Pre-stimulation 1.9 (0.5 – 3.5)  3.1 (1.7 – 3.1) 0.801 
0.00005 0.4 (0.08-2.5) 0.5 (0.2 – 0.5) 0.966 
0.1 2.4 (1.5 – 3.9)) 3.2 (1.7 – 3.7) 0.801 
100 2.5 (1.9 – 4.0)) 3.3 (1.8 – 3.6) 0.801 
PAM IL-1β 
Pre-stimulation 1.8 (0.1 -3.0) 2.5 (1.6 – 2.6) 0.801 
0.00005 2.1 (0.2 – 3.0)  2.5 (1.7 – 2.5) 0.866 
0.01 2.4 (1.4 – 3.0) 2.9 (1.7 – 3.1) 0.801 
1 2.5 (1.7 – 3.1) 2.8 (2.0 – 3.0) 0.801 
LPS TNF-α 
Pre-stimulation 2.3 (1.2 – 3.8) 1.9 (1.6 – 2.9) 0.801 
0.00005 2.5 (1.1 – 4.1) 2.3 (2.3 – 3.2) 0.966 
0.1 2.4 (1.6 – 3.8) 2.4 (2.3 – 3.2) 0.966 
100 2.6 (1.4 – 4.0) 2.5 (2.3 – 3.2) 0.866 
PAM TNF-α 
Pre-stimulation 2.2 (0.8 – 3.5) 1.7 (1.4 – 2.1) 0.801 
0.00005 2.3 (0.4 – 3.7) 1.8 (1.8 – 2.5) 0.801 
0.01 2.3 (1.4 – 3.6) 1.5 (1.4 – 2.3) 0.400 
1 2.5 (1.2  – 3.8) 2.1 (1.8 – 2.5) 0.801 
LPS IL-1β: TLR4 (LPS) stimulated IL-1β secretion; n: number of participants; PAM IL-1β: TLR2 (PAM3CSK4) stimulated IL-1β secretion; WT/WT: homozygous wild-type 
genotype; WT/Var: Heterozygous genotype.  
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  c IL1B rs16944 and rs1143627 
 
WT/WT 
(n = 13) 
WT/Var 
(n = 15) 
Var/Var 
(n = 3) 
 
 




Pre-stimulation 1.9 (0.5  – 3.4)  2.1 (0.7  – 3.5) 1.8 (11 – 1.8) 0.622 
0.00005 0.4 (0.2 – 0.6) 0.4 (0.08 – 0.6) 0.3 (0.3 – 0.3) 0.547 
0.1 2.4 (1.9 – 3.9) 2.5 (1.5 – 3.7) 2.1 (2.0 – 2.4) 0.622 
100 2.5 (2.1 – 4.0) 2.4 (1.8 – 3.8) 2.1 (2.1 – 2.4) 0.622 
PAM IL-1β 
Pre-stimulation 1.9 (0.11 – 2.6) 2.0 (1.1 – 1.8) 1.4 (0.1 – 1.8) 0.547 
0.00005 2.1 (1.2 – 3.0) 2.1 (0.2 – 3.0) 2.0 (1.9 – 2.1) 0.92 
0.01 2.5 (1.9 – 3.0) 2.4 (1.4 – 3.1) 2.1(2.0 – 3.1) 0.622 
1 2.5 (2.2 – 3.1) 2.4 (1.7 – 3.0) 2.2 (2.0 – 2.4) 0.547 
LPS IL-1β: TLR4 (LPS) stimulated IL-1β secretion; n: number of participants; PAM IL-1β: TLR2 (PAM3CSK4) stimulated IL-1β secretion; WT/WT: homozygous wild-type 
genotype; WT/Var: Heterozygous genotype; Var/Var: Homozygous variant genotype.  
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  d IL1B rs1143634 
 
WT/WT 
(n = 17) 
WT/Var 
(n = 9) 
Var/Var 
(n = 5) 
 
 




Pre-stimulation 1.8 (0.5  –  3.4)  2.1 (0.7 – 3.2) 2.5 (1.7 – 3.5) 0.881 
0.00005 0.4 (0.2 – 0.6) 0.4 (0.08 – 0.5) 0.5 (0.2 – 0.6) 0.881 
0.1 2.5 (2.0 – 4.0) 2.4 (1.5 – 3.3) 2.4 (1.7 – 3.7) 0.881 
100 2.5 (1.9 – 4.0) 2.4 (2.1 – 3.3) 2.8 (1.8 – 3.8) 0.881 
PAM IL-1β 
Pre-stimulation 1.6 (0.1 – 2.6) 2.0 (0.2 – 2.6) 1.8 (1.6 – 3.0) 0.881 
0.00005 2.1 (1.2 – 3.0) 2.1 (0.2 – 2.9) 2.3 (1.7 – 3.0) 0.881 
0.01 2.4 (1.9 – 3.1) 2.4 (1.3 – 2.9) 2.6 (1.7 – 3.0) 0.898 
1 2.4 (1.7 – 3.1) 2.5 (1.9 – 2.9) 2.5 (2.0 – 2.9) 0.881 
LPS IL-1β: TLR4 (LPS) stimulated IL-1β secretion; n: number of participants; PAM IL-1β: TLR2 (PAM3CSK4) stimulated IL-1β secretion; WT/WT: homozygous wild-type 
genotype; WT/Var: Heterozygous genotype; Var/Var: Homozygous variant genotype.  
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  e TNF rs1800629 
 
WT/WT 
(n = 21) 
WT/Var 
(n = 7) 
Var/Var 
(n = 3) 
 
 




Pre-stimulation 2.8 (1.6  – 3.8)  1.8 (1.4  – 3.5) 1.6 (1.2 – 3.5) 0.360 
0.00005 2.6 (1.1 – 4.1) 2.1 (1.5 – 3.5) 2.4 (2.1 – 2.4) 0.513 
0.1 2.8 (1.6 – 3.8) 2.3 (1.5 – 3.8) 2.0 (1.9 – 2.3) 0.400 
100 3.0 (1.4 – 4.0) 2.4 (1.9 – 3.8) 2.3 (2.0 – 2.4) 0.400 
PAM IL-1β 
Pre-stimulation 2.4 (0.8 – 1.3) 1.8 (1.3 – 2.9) 1.5 (1.2 – 1.8) 0.400 
0.00005 2.4 (1.0 – 3.7) 2.4 (2.3 – 3.1) 1.9 (0.3 – 2.2) 0.360 
0.01 2.5 (1.4 – 3.6) 2.3 (1.5 – 3.3) 2.2 (2.2 – 2.3) 0.738 
1 2.6 (1.3 – 3.8) 2.5 (1.6 – 3.4) 2.4 (2.3 – 2.5) 0.739 
LPS IL-1β: TLR4 (LPS) stimulated IL-1β secretion; n: number of participants; PAM IL-1β: TLR2 (PAM3CSK4) stimulated IL-1β secretion; WT/WT: homozygous wild-type 
genotype; WT/Var: Heterozygous genotype; Var/Var: Homozygous variant genotype.  
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